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Abstract 
 
The E6 protein from high-risk Human Papillomaviruses (HPVs) has previously 
been shown to be necessary for the persistence of viral episomes in cells, 
however, the mechanism for this remains unclear. High-risk E6 proteins have 
many activities including the ability to degrade p53 and the ability to bind to and 
degrade PDZ proteins. In this study I aimed to further elucidate the role of E6 in 
the persistence of viral episomes.  
 
I used two HPV16 mutant genomes with mutations in the E6 open-reading 
frame; one that is unable to degrade p53 (16E6p53m), and one that lacks the 
PDZ-binding motif (16E6PDZ). I found that both are unable to persist episomally 
in cells thereby implicating these two activities of E6 in HPV episomal 
persistence.   
 
Upon closer investigation of the two mutant genomes, I found that the 
16E6p53m genome does not replicate as efficiently as the wild-type genome. 
This result suggests a function for p53-degradation in genome replication, and 
consequently in genome persistence. Furthermore, by carrying out a more 
detailed analysis of the relationship between E6 and the PDZ protein hScrib, I 
showed that the wild-type E6 protein is stabilised by virtue of the PDZ-binding 
motif, present on its C-terminus. On the other hand, the mutant E6 protein that 
lacks the PDZ-binding motif (E6PDZ) is more susceptible to proteasomal 
degradation. These findings provide evidence for a previously unknown 
outcome of the E6-PDZ protein interaction, in stabilising wild-type E6 protein. In 
addition to the implications of this stabilisation in the persistence of viral 
episomes, it is also significant when considering the activities and properties of 
E6 that contribute to the development of neoplasia.  
 
Finally, I have also found that wild-type HPV16 genomes cannot persist in cells 
that constitutively express E6 protein, suggesting that the correct regulation of 
E6 expression is crucial.  
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Chapter 1: Introduction 
 
1.1. Introduction to papillomaviruses 
Papillomaviruses (PVs) are small, non-enveloped viruses and consist of a 
circular, double-stranded DNA molecule, within an icosahedral protein capsid. 
PVs are epitheliotropic viruses, infecting both mucosal and cutaneous epithelial 
tissues, and their life-cycle is tightly linked to the differentiation of their host cells 
(Favre et al., 1997). The viruses infect the basal layer of the epithelium and 
production of mature virions at the end of the viral life-cycle is confined to the 
upper, most differentiated layers of the tissue (reviewed in Doorbar, 2006). 
Many PVs have been shown to cause a range of diseases, from benign 
proliferative skin or genital warts to cancer. Human PV types (HPVs) that cause 
benign disease are classified as low-risk viruses, whereas the types that can 
cause cancer, such as HPV types 16 and 18, are classified as high-risk types 
(Favre et al., 1997; Laimins, 1993; Walboomers et al., 1999). 
 
The first PV to be identified in animals was the cottontail rabbit PV (CRPV), 
which was shown to cause cutaneous lesions that sometimes progressed to 
malignancy (Shope & Hurst, 1933). PVs are now known to infect a variety of 
different animal species including ungulates, cetaceans, birds (Bernard et al., 
2010; de Villiers et al., 2004) and more recently, reptiles (Herbst et al., 2009) 
and have been shown to be very species-specific, suggesting that they have 
been co-evolving with their host species through time (Bernard et al., 2006). 
More recently the first PV to naturally infect laboratory mice was identified and 
was shown to be transmissible to both nude and immunocompetent laboratory 
mice (Ingle et al., 2010). This discovery has opened new doors and has 
provided an important tool for the future of PV research. 
 
1.2. Classification of papillomaviruses 
PVs were initially classified under the family of Papoviridae, together with 
polyomaviruses, based on their similarities in structure (non-enveloped capsids) 
and circular, double-stranded DNA genome. However, sequencing of the PV 
genome revealed many differences between PVs and polyomaviruses, such as 
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the size and organisation of their genomes (de Villiers et al., 2004). Another 
difference is that PV transcription is unidirectional that is, all transcripts are 
expressed from one strand of DNA (Amtmann & Sauer, 1982; Danos et al., 
1983). This led to PVs being designated as a separate family, the 
Papillomaviridae.  
 
To date, over 180 PV types have been identified (Bernard et al., 2010). 
Sequencing of PV genomes has led to a phylogenetic analysis based on the 
homology of the L1 open reading frame (ORF) that encodes the major capsid 
protein and is the most conserved PV ORF. PVs are broadly categorised in 
genera, and types within the same genus share more than 60% identity in their 
L1 DNA. Genera can be sub-categorised into species, types, subtypes and 
variants. Types within the same species have 71% - 89% identity to each other 
(de Villiers et al., 2004). 
 
1.3. Human papillomaviruses (HPVs) 
Using the classification system described above, HPVs are found in five out of 
twenty-nine genera (Apha, Beta, Gamma, Mu and Nu) with the animal and bird 
PVs comprising the other twenty-four genera. The genus with the greatest 
medical importance is Alpha, which includes the HPVs associated with genital 
cancers (the high-risk types) such as HPV16 and HPV18. This genus also 
includes the low-risk HPV types causing genital warts, for example HPV11, as 
well as those causing cutaneous, non-genital warts, such as HPV2 (Bernard et 
al., 2010). 
 
Members of the Beta genus, such as HPV5 and 8, infect cutaneous skin. They 
are typically associated with mild skin lesions, but can spread widely in patients 
suffering from a rare hereditary skin condition called Epidermodysplasia 
Verruciformis (EV). In these patients, infections by Beta PVs are associated 
with the development of non-melanoma skin cancer (Harwood & Proby, 2002; 
Pfister, 2003). The Gamma, Mu and Nu PVs generally infect cutaneous sites 
and cause skin lesions such as verrucas (de Villiers et al., 2004).  
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1.4. HPVs and disease 
Detailed studies of different types of HPVs have found a correlation between 
the ability of HPVs to immortalise cells in culture, and the degree of disease 
caused. For example, the high-risk types HPV16, 18, 31 and 33 are able to 
immortalise primary epithelial cells whereas the low-risk types HPV1a, 5, 6b 
and 11 are not (Pecoraro et al., 1989; Schlegel et al., 1988; Woodworth et al., 
1989). Moreover, the HPV E6 and E7 proteins have been shown to be able to 
immortalise cells independently (Band et al., 1991; Halbert et al., 1991), 
although their immortalisation efficiency is increased when both are expressed 
together in cells (Halbert et al., 1991). 
 
1.4.1. Low-risk and cutaneous HPVs 
Low-risk HPVs are infrequently linked to cancer, but can cause a wide-range of 
benign diseases. Anogenital warts are prevalent amongst the sexually active 
population and are most commonly caused by HPV6 and 11 (Greer et al., 
1995). These two low-risk types are also the cause of most benign HPV-related 
oral lesions (Praetorius, 1997). Cutaneous warts are caused by a large number 
of HPV types, including HPV1 (Egawa et al., 1993) and HPV2, which is also 
able to infect mucosal epithelia (Chan et al., 1997; de Villiers et al., 2004).  
 
Although benign to the majority of the population, low-risk and cutaneous HPVs 
are sometimes associated with rare but severe diseases such as EV and 
recurrent respiratory papillomatosis (RRP). As mentioned above, EV patients 
have a higher susceptibility to infections by HPVs from the Beta genus, and 
develop skin lesions that may progress to cancer (Harwood & Proby, 2002; 
Pfister, 2003). RRP is typically caused by the Alpha-PVs HPV6 and HPV11 
(Gissmann et al., 1982; Mounts et al., 1982) and patients develop papillomas in 
their respiratory tracts (particularly the larynx), which lead to obstruction of the 
airway. It is thought that PVs persist in these patients in a latent state, and their 
re-activation causes the recurrent disease (Steinberg et al., 1983).  
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1.4.2. High-risk HPVs 
The best-studied malignancy caused by HPVs is cervical cancer and it is now 
believed that over 99% of cervical cancers are caused by HPVs. HPV16 and 18 
are thought to account for over 60% of these, with other HPV types, including 
31, 33, 39, 45, and 58, accounting for the rest (Bosch et al., 1995; Clifford et al., 
2003; Munoz et al., 2003; Walboomers et al., 1999). Cervical cancer is the 
second most common cancer in women worldwide, with approximately 500,000 
newly diagnosed cases and 250,000 deaths every year (World Health 
Organisation). Most cervical cancers are squamous cell carcinomas, with the 
rest being adenocarcinomas and a small number being small cell 
neuroendocrine tumours. HPV16 is more commonly associated with squamous 
cell carcinomas whereas HPV18 is more commonly associated with 
adenocarcinomas (Clifford et al., 2003). 
 
The majority of cervical cancers are thought to occur in the transformation zone 
of the cervix, which is an area of metaplastic change, from columnar cells to a 
stratified squamous epithelium (Burghardt & Ostor, 1983; Sun et al., 1992). The 
higher susceptibility of the transformation zone may be due to better access of 
the virus to the basal layer of the epithelium, as well as reduced immune 
surveillance compared to other sites of the cervix (Giannini et al., 2002).  
 
Genital HPV infection is a sexually transmitted infection and the highest 
prevalence is seen in women in their late teens or early 20s. However, the 
incidence of cervical cancer is highest in older women. This delay between 
infection and onset of disease suggests that cervical cancer may arise after 
persistent infection. In such persistent infections, disease is thought to ensue 
due to the prolonged expression of the viral oncoproteins (Schiffman & Kjaer, 
2003). 
 
High-risk HPVs can also cause pre-cancerous cervical disease, which can 
precede the development of cancer. These pre-cancerous lesions are 
histologically classified based on their severity, with cervical intraepithelial 
neoplasia (CIN) - 1 exhibiting the lowest form of dysplasia, and CIN-3 exhibiting 
severe dysplasia (Woodman et al., 2007). In addition to accounting for almost 
all cases of cervical cancer, HPVs are thought to cause a variety of other 
Chapter 1: Introduction 
 22 
anogenital cancers such as anal, vulvar and penile cancers, as well as head 
and neck cancers, such as those of the pharynx, larynx and tonsils (zur 
Hausen, 2009).   
 
1.5. The HPV16 genome 
The HPV16 genome is a 7.9 kb circular, double-stranded DNA genome (Fig. 
1.1) and is divided into three regions by two polyadenylation (poly (A)) sites; the 
early region, the late region, and a non-coding region called long-control region 
(LCR) (Zheng & Baker, 2006). The E1, E2, E4, E5, E6 and E7 non-structural 
proteins are the early proteins and are expressed from the early promoter (p97), 
which lies within the LCR. The L1 and L2 capsid proteins are the late proteins 
and are thought to mainly be expressed from the late, differentiation-dependent 
promoter (p670). This promoter lies within the E7 ORF and can also be used to 
express E1, E2, E4 and E5, depending on the differentiation stage of the 
epithelium (Grassmann et al., 1996; Hummel et al., 1992; Smotkin & Wettstein, 
1986). 
 
The LCR of HPV16, which lies upstream of the E6 ORF also contains regulatory 
elements involved in viral transcription. These cis elements include binding sites 
for various cellular transcription factors, including Sp1, AP-1, Oct-1, and YY1, 
which can both positively and negatively regulate transcription. It has further 
been suggested that regulatory sequences in the LCR may play a role in the 
tissue- or cell-specificity of HPVs (Chan et al., 1990; Gloss & Bernard, 1990; 
Lace et al., 2009; Marshall et al., 1989; Morris et al., 1993, Offord et al., 1993). 
For example, the HPV promoter has been shown to be active in keratinocytes 
but not in fibroblasts (Bernard et al., 1989) and this correlates with higher levels 
of the AP-1 transcription factor in keratinocytes compared to early passage 
fibroblasts (Offord et al., 1993).  
 
Moreover, the LCR contains binding sites for the viral protein E2 (Androphy et 
al., 1987), and the HPV16 LCR contains four such E2-binding sites. Binding of 
E2 has been shown to regulate viral gene transcription (Bernard et al., 1989; 
Bouvard et al., 1994; Phelps & Howley, 1987; Romanczuk et al., 1990; Spalholz 
et al., 1985; Spalholz et al., 1987). E2 has been reported to have both positive 
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and negative regulatory effects on transcription and recent studies have 
suggested that this differential transcriptional regulation may be determined by 
the amounts of E2 viral protein present (Steger & Corbach, 1997), or by the 
physical state and conformation of the viral genome in the cells, (Bechtold et al., 
2003; Schmidt et al., 2005).  Moreover, the LCR contains the viral origin of 
replication (Chiang et al., 1992a), and a binding site for the viral replication 
protein E1, a DNA helicase that is recruited to the viral origin of replication by 
E2 (Desaintes & Demeret, 1996), to initiate viral replication. 
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Figure 1.1: The HPV16 genome 
The HPV16 genome is a 7.9 kb, circular, double-stranded DNA genome and 
consists of 8 main ORFs. These encode for 6 non-structural, early proteins, E6, 
E7 (red), E1, E2, E4 and E5 (green) and 2 structural, late proteins, L1 and L2 
(yellow). The 2 main viral promoters p97 and p670 are shown, as are the early 
and late poly (A) sites (PAE and PAL respectively). The early proteins are 
expressed from both promoters, whereas the late proteins are thought to be 
expressed from the late, differentiation-dependent promoter (p670). Three 
recently identified promoters (p3392 at the 5’ of the E4 ORF, p4062/4 at the end 
of the E5 ORF and p-60 in the LCR), which were found to be active in 
differentiating cells, are shown in purple (Milligan et al., 2007). The LCR is a 
non-coding region and contains cis-acting elements involved in viral replication 
and transcription, including binding sites for transcription factors and for the E1 
and E2 proteins, as well as the viral origin of replication. (The figure has been 
modified from Doorbar, 2006). 
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1.6. HPV16 transcription 
The study of different HPV16 mRNA species in cells that harbour HPV 
episomes has been carried out mostly in W12 cells (Doorbar et al., 1990; 
Milligan et al., 2007). This cell line is a cervical keratinocyte line isolated from a 
low-grade cervical lesion and has been shown to contain predominantly 
episomal forms of the HPV16 genome (Stanley et al., 1989). As such it presents 
a better candidate for the study of viral transcripts than the cervical cancer cell 
lines, such as CaSki and SiHa, as these lines contain only integrated copies of 
the viral genomes and do not support the viral life-cycle. 
 
HPV16 transcripts are divided into early and late transcripts and are 
polyadenylated by an early and two late poly (A) sites respectively (Milligan et 
al., 2007). The early promoter, p97, is regulated by the binding of E2 and 
cellular transcription factors to their binding sites in the LCR (Zheng & Baker, 
2006). Regulation of expression from the late promoter, p670, is less well 
understood but studies suggest that it may be activated by differentiation 
signals within the cell and its activation appears to be independent of viral 
genome amplification (Spink & Laimins, 2005). Transcription from the early 
promoter appears constant throughout the life-cycle of the virus, whereas 
transcription from the late promoter, p670, is greatly enhanced upon 
differentiation (Grassmann et al., 1996; Hummel et al., 1992).  
 
HPV16 transcripts have also been identified that initiate at positions other than 
the abovementioned early and late promoters (p97 and p670). This suggests 
the existence of additional promoters on the HPV genome (see Fig. 1.1). One 
such promoter was mapped to the 5’ of the E4 ORF (p3392), another one at the 
end of the E5 ORF (p4062/4) and a third in the LCR (p-60). These were 
described in W12 cells (Milligan et al., 2007). A promoter in the E4 ORF has 
been previously described in HPV31 genomes, as have promoters in the LCR 
(Ozbun & Meyers, 1997; Ozbun & Meyers, 1999), suggesting that these may be 
conserved across different HPV types.   
 
Almost all HPV transcripts are polycistronic and gene expression is regulated by 
alternative splicing, which generates different mRNA products (Zheng & Baker, 
2006). One example is the alternative splicing of the E6/E7 polycistronic or 
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bicistronic transcripts. High-risk E6 ORFs contain an intron sequence, and 
several splice sites and the excision of the intron has been shown to generate 
alternatively spliced E6 products (Zheng & Baker, 2006). In addition to mRNAs 
containing the full-length E6 sequence, at least 2 spliced species have been 
described, E6*I and E6*II, both of which have the same N-terminal sequences 
as full length E6, but lack the intron sequence and have different C-terminal 
truncations (Doorbar et al., 1990; Schneider-Gadicke & Schwarz, 1986; Smotkin 
et al., 1989). It has been suggested that mRNAs carrying the spliced forms of 
E6 (E6*) are more abundant in cervical cancer lines than ones carrying the full-
length E6 form (Smotkin et al., 1989; Zheng & Baker, 2006). Although this 
splicing would prevent the production of full-length E6 protein, it appears that 
the spliced transcripts favour the expression of E7 protein. (Smotkin et al., 
1989; Tang et al., 2006a; Zheng et al., 2004). Earlier studies have also 
identified a protein product thought to be expressed from the spliced E6* 
species (Schneider-Gadicke et al., 1988). More recent studies have attempted 
to elucidate the activities of the E6* protein compared to the full-length E6 
protein (Pim et al., 2009; Storrs & Silverstein, 2007) but its precise function and 
role in the viral life-cycle remains unclear.  
 
Little is known about the regulation of E6 splicing in cells. Interestingly, a recent 
study suggested that in the presence of epidermal growth factor (EGF), full-
length E6 is expressed, whereas the absence of EGF favours the expression of 
E6* and E7 (Rosenberger et al., 2010). This may suggest a mechanism for the 
regulation of this splicing process in the differentiated epithelium, where growth 
factors are depleted.  
 
Another example of splicing of HPV transcripts, is the generation of the E8^E2 
protein, which is derived from 2 viral ORFs. E8 is an ORF found within the E1 
ORF and is spliced with the C-terminus of E2, to generate E8^E2 protein. 
E8^E2 mRNA species have been identified in a variety of HPVs (they are 
sometimes called E2C), including HPV16 (Doorbar et al., 1990; Sherman et al., 
1992), HPV31 (Stubenrauch et al., 2000) and the low-risk type HPV11 
(Rotenberg et al., 1989). HPV16 and 31 E8^E2 proteins are thought to repress 
viral gene transcription and viral replication (Lace et al., 2008; Stubenrauch et 
al., 2000). Moreover, the HPV31 E8^E2 protein was suggested to inhibit 
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episomal persistence of HPV31 genomes (Stubenrauch et al., 2000). In contrast 
HPV16 E8^E2 did not appear to have an inhibitory effect on the persistence of 
HPV16 genomes (Lace et al., 2008).  
 
Alternative splicing is also essential for the expression of late viral proteins from 
late viral transcripts. Splicing of late transcripts takes place in the differentiated 
layers of the epithelium. The levels of splicing factors, such as SR (serine-
arginine-rich) proteins, in the differentiated layers of uninfected epithelia are 
decreased (compared to the levels in undifferentiated cells) (McPhillips et al., 
2004; Mole et al., 2009a). Recent studies have shown that the viral E2 protein 
up-regulates the expression of different SR proteins, one of which being 
SF2/ASF (splicing factor 2/alternative splicing factor) (McPhillips et al., 2004; 
Mole et al., 2009a; Mole et al., 2009b). Furthermore, the expression of these 
proteins increases upon differentiation of HPV-positive cells, suggesting that E2 
may play a role in altering the cellular environment in differentiated cells, to 
facilitate late viral gene expression (McPhillips et al., 2004; Mole et al., 2009a). 
Interestingly, there also appears to be a correlation between the expression of 
SF2/ASF and the severity of cervical disease, suggesting a potential use of this 
protein as a biomarker for disease (Mole et al., 2009a). 
 
1.7. HPV16 viral life-cycle 
Most work on HPVs has been carried out using the high-risk types and in 
particular HPV16, due to their clinical importance. From this work, a general 
pattern of the HPV life-cycle has been elucidated (Fig. 1.2). HPVs are 
exclusively epitheliotropic viruses, and their life-cycle is dependent on the 
differentiation of the epithelium for its completion. As such, the levels and 
pattern of viral gene expression are tightly regulated and change during the 
differentiation of the epithelium. Different stages of the life-cycle are often 
categorised into early and late events. Early events take place in the basal and 
parabasal layers of the epithelium and comprise the viral entry into cells and the 
establishment of the viral episomes in the nucleus. Late events occur in the 
upper, differentiated layers of the epithelium and comprise the amplification of 
the viral genome, the production of the capsid proteins, and the assembly and 
release of new virions (reviewed in Doorbar, 2005).  
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Figure 1.2: The HPV life-cycle 
Papillomaviruses infect the epithelium by gaining entry to the cells in the basal 
layer (BL), where they establish themselves as low copy number 
extrachromosomal episomes in the nucleus of the cell. Early events in the life-
cycle require expression of the E1 and E2 replication proteins, and E6 and E7 
oncoproteins by the early promoter, p97. When infected cells exit the basal 
layer, they remain in cycle through the activities of E6 and E7. In the middle and 
upper layers, the cells differentiate, and expression from the late promoter p670 
is activated. In these layers, E1, E2, E4 and E5 expression increases, leading to 
viral genome amplification. Following amplification, L1 and L2 are expressed, 
the viral DNA is packaged, and new infectious virions are shed from the surface 
of the epithelium. (The figure has been modified from Doorbar, 2006). 
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1.7.1. Site of infection – basal layer of the epithelium  
The site of infection of HPVs is the basal layer of the epithelium. As mentioned 
earlier, neoplasia usually arises in the transformation zone of the cervix, where 
the squamous epithelium tapers down towards the columnar cells. This 
metaplastic change is thought to afford the virus easy access to the basal cells 
to initiate its life-cycle, and also has reduced immune surveillance compared to 
other cervical sites (Giannini et al., 2002).    
 
Basal cells are the only cells in the epithelium that are capable of division and 
are thought to be comprised of epithelial stem cells and transit amplifying (TA) 
cells. Epithelial stem cells are considered to be undifferentiated cells with 
enhanced proliferative capacity. These cells give rise to TA cells but can also 
self-renew and are thought to persist throughout the lifetime of the epithelium. 
TA cells on the other hand have a finite life-span and continue to differentiate 
(Potten & Loeffler, 1990). It has been suggested that for an infection to be 
persistent, an epithelial stem cell must be infected (Egawa, 2003; Schmitt et al., 
1996), although this has not been proven to date.  
 
A model for how PVs gain entry to epithelial cells has recently been proposed 
by Schiller et al., and implicates both L1 and L2 capsid proteins in the process 
(Schiller et al., 2010). This model suggests that L1 first binds to heparan sulfate 
proteoglycans on the basement membrane, once this has been exposed by a 
micro-lesion in the tissue (Johnson et al., 2009; Joyce et al., 1999). This 
interaction brings about a conformational change, which subsequently exposes 
sites on the L2 capsid protein to being cleaved by enzymes, one of which being 
furin (Richards et al., 2006). This is then thought to expose an L1 site that can 
bind to a cell-surface receptor, mediating the attachment of the virion to 
keratinocytes. The cell-surface receptor involved in this process has not yet 
been identified, but studies have implicated alpha-6 integrin (Evander et al., 
1997) in this process. Following attachment to the cell-surface receptor, PVs 
enter cells by endocytosis. However, which pathway is involved in this remains 
unclear as studies have implicated both clathrin- and caveolae-mediated 
pathways. These discrepancies may reflect differences between the various 
HPV types (Bousarghin et al., 2003).   
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1.7.2. Early events 
1.7.2.1. Establishment and maintenance of HPV episomes 
Following infection, HPV genomes establish themselves as episomes in the 
nucleus of the infected basal cell. It is generally believed that for establishment 
to take place, the viral genome first undergoes a transient replication phase, 
whereby its copy numbers are amplified. Following the initial establishment 
phase, genomes are thought to replicate along with the cellular DNA and divide 
equally into the two daughter cells during cell division, thus maintaining a more 
or less constant copy number in the cells of the basal layer (reviewed in Kadaja 
et al., 2009). 
 
1.7.2.2. Early proteins 
Viral transcripts have been detected in the basal cells of epithelia (Stoler & 
Broker, 1986), although which viral proteins are actually expressed in these 
cells remains unclear. It is widely believed that the viral replication proteins E1 
and E2 are expressed in basal cells from the early promoter, p97, and both of 
these proteins are necessary for the persistence of HPV16 viral episomes (Ken 
Raj, unpublished data). The role of these proteins in replication is well 
established. E2 binds to regions near the viral origin of replication and is able to 
recruit the E1 viral helicase, which in turn recruits the cellular replication 
proteins that are necessary for viral replication (reviewed in Kadaja et al., 2009). 
In addition to its role in viral replication, E2 has also been shown to have an 
important role during cell division by anchoring the viral episomes to mitotic 
chromosomes or the mitotic spindle, thus ensuring their correct segregation and 
localisation into the nucleus of daughter cells (Feeney & Parish, 2009). 
Episomal replication and segregation will be discussed in more detail later.  
Interestingly, several HPVs, as well as BPV1, were also found to be able to 
replicate in yeast, a process that was shown to be independent of both E1- and 
E2-expression (Angeletti et al., 2002).  
 
It is not clear which other viral proteins are expressed in the basal layer of the 
epithelium and this is partly due to the low levels of protein expressed, as well 
as to the lack of sensitive detection methods. However, studies in monolayer 
cell cultures have suggested that both the E6 and the E7 proteins are 
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necessary for the episomal persistence of HPV31 genomes in primary cells 
(Thomas et al., 1999), and that E6 but not E7 is necessary for persistence of 
HPV16 episomes in the immortalised cell line, NIKS (Flores et al., 2000; 
Laurson et al., 2010; and Ken Raj, unpublished data).These studies imply that 
both of these proteins are expressed in the basal layer, as the monolayer cell 
culture system is considered to be a good model for the study of the early 
events of the life-cycle (see section 1.8). 
 
1.7.2.3. Cell proliferation 
In the uninfected epithelium basal cells are eventually pushed to the suprabasal 
layers and exit the cell cycle. This would be detrimental to the virus as the virus 
relies on the cell’s replication machinery in order to replicate its own genome. In 
an HPV infected epithelium, the normal differentiation program of the tissue is 
delayed, and cells in the suprabasal layers are pushed to cycle. This is thought 
to be caused by the combined activities of the E6 and E7 proteins, which push 
cells into S-phase (Cheng et al., 1995; Dollard et al., 1992). The activities of E6 
and E7 that are thought to be responsible for driving suprabasal cell 
proliferation have been extensively studied and the most well characterised 
ones are the degradation of tumour suppressors p53 and pRb respectively 
(Boyer et al., 1996; Scheffner et al., 1990).  Moreover, high-risk E6 is able to 
bind to and degrade PDZ proteins, such as hScrib and hDlg, via a PDZ-binding 
motif on its C-terminus. This motif has been linked to the development of 
epidermal hyperproliferation in transgenic mice (Nguyen et al., 2003) and raft 
cultures (Lee & Laimins, 2004).  
 
Both E6 and E7 have several other activities which can contribute to driving 
cells to proliferate and these will be discussed later. 
 
1.7.3. Late events 
In productive HPV infections, the suprabasal cells do eventually enter terminal 
differentiation and this is required for the induction of the late promoter, p670, 
and consequently the expression of the late proteins. It is not yet clear what 
causes the switch from early to late promoter, but it is believed to occur via 
changes in cell signalling. 
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1.7.3.1. Genome amplification 
As the infected cell approches the upper layers of the epithelium, it becomes 
necessary for the viral genome to be amplified in preparation for packaging into 
the new virions. The switch from early to late promoter leads to an increase in 
the expression of the proteins necessary for genome amplification, E1, E2 (for 
replication) (Klumpp & Laimins, 1999), and E4 and E5 (Hummel et al., 1992).  
 
The roles of E4 and E5 in genome amplification are not very clear. E5 has been 
shown to contribute to the maintenance of a replication competent environment 
in the upper epithelial layers, and to facilitate genome amplification and 
transcription from the late promoter (Fehrmann et al., 2003). E4 on the other 
hand has been shown to arrest cells in the G2 phase (Davy et al., 2002). The 
current model suggests that amplificational replication takes place in cells that 
express E4 as well as E7. These cells are thought to be in a pseudo-S phase 
state, where cellular replication proteins are available for viral DNA replication 
but the cells themselves are not dividing (Davy & Doorbar, 2007) 
 
1.7.3.2. Virus assembly and release 
At the end of the viral life-cycle the two capsid proteins, L1 and L2, are 
expressed and localise to the nucleus (Day et al., 1998; Doorbar & Gallimore, 
1987; Florin et al., 2002). This is followed by the encapsidation of the newly 
replicated viral DNA, and studies have suggested that this process may be 
enhanced by E2 (Day et al., 1998; Zhao et al., 2000). As HPVs are not lytic 
viruses the release of progeny virions relies on the natural shedding of dead 
skin cells (Bryan & Brown, 2001). Viral release from cells may be facilitated by 
the E4 protein which has been shown to disrupt the keratin network of the cells 
thereby making the cells more fragile (Doorbar et al., 1991; Wang et al., 2004).  
 
1.7.4. Abortive infections 
Abortive infections arise in situations where the viral life-cycle is not completed 
and if left untreated, these infections can develop into cancer. It is thought that 
abortive infections occur at specific sites where productive PV infections are not 
supported. An example of this is CRPV infections, which can cause productive 
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infections in the virus’s natural host (the cottontail rabbit), but cause abortive 
infections when inoculated in another host, the domestic rabbit. Similarly 
cutaneous HPVs, which usually cause benign skin lesions, occasionally cause 
cancers when they infect a mucosal site. It has been considered that the 
transformation zone of the cervix may be a sub-optimal site for the completion 
of the life-cycle of high-risk HPV types, thereby making it more prone to the 
development of neoplasia (reviewed in Doorbar, 2006).  
 
CIN-1 lesions closely resemble productive infections, as the life-cycle of the 
virus, although delayed, is eventually completed. In CIN-2 and CIN-3 lesions 
however, the tissue shows higher degree of deregulation and CIN-3 lesions 
closely resemble abortive infections. It has been found that the severity of a 
lesion is reflected in the pattern of viral protein expression. As lesions become 
less productive, there is less expression of the late viral proteins (Middleton et 
al., 2003). Of particular importance is the deregulation of the expression of the 
two viral oncoproteins, E6 and E7, seen in abortive infections. This leads to 
cells in the upper-most layers of the epithelium (which would have normally 
exited the cell cycle during a productive infection) being pushed to cycle 
(Middleton et al., 2003). Aberrant expression of E6 and E7 can lead to genomic 
instability. One way in which deregulation of E6 and E7 expression is achieved 
is by the integration of the viral genome into the cellular chromosomes, which is 
frequently observed in cancers (Durst et al., 1985).   
 
1.8. Papillomavirus models  
The dependence of PVs on the stratified epithelium for the completion of their 
life-cycle has made the study of the life-cycle difficult. It is generally accepted 
that monolayer cell cultures of keratinocytes are good models for the study of 
the events that occur in the basal layer of the epithelium. HPV DNA (isolated 
from plantar warts) was first shown to replicate and persist episomally in 
cultured epidermal keratinocytes in 1982 (LaPorta & Taichman, 1982). Since 
then, many studies have used monolayer cell cultures as systems to study the 
early events in the viral life-cycle such as episomal persistence. Different cell 
isolates have been used, including primary foreskin keratinocytes (Thomas et 
al., 1999) as well as immortalised cell lines, such as NIKS (Flores et al., 1999).  
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However, monolayer cell cultures do not provide good models for the study of 
the late events in the viral life-cycle, such as genome amplification and virion 
production. Clinical samples are sometimes used to study HPV infections but 
these are difficult to obtain and may not contain a productive infection, as these 
samples are often isolated from patients with high-grade disease. Another 
hindrance to the study of PVs is the species specificity which makes several 
animal models unsuitable for the study of the human viruses. In addition to this, 
until very recently no PV that naturally infects laboratory mice had been 
isolated, making the most common laboratory animal model unavailable for 
studies. The recent isolation of such PV (Ingle et al., 2010) promises to provide 
an important tool for PV research, with more reagents and more expertise being 
available for the mouse than any other laboratory animal model. 
 
The study of the HPV life-cycle has been aided by the development of the 
organotypic raft culture system, a three-dimensional system in which 
keratinocytes are allowed to differentiate in culture to form a complete stratified 
epithelium, supported by a collagen dermal equivalent. These rafts support the 
viral life-cycle and have been used in studies aimed at characterising the 
different stages of the life-cycle (Flores et al., 1999) as well as identifying 
factors that may affect it (Flores et al., 2000; Lee & Laimins, 2004). Other 
methods that have been used to induce the differentiation of keratinocytes are 
the culturing of cells in medium with high calcium concentration (Hennings et 
al., 1980) or in semi-solid medium such as methylcellulose (Ruesch et al., 
1998).  
 
Raft cultures can also be used for the production of mature infectious viral 
particles (McLaughlin-Drubin et al., 2004). Alternatively virions can be made by 
co-transfecting viral genomes with L1- and L2-expressing plasmids in 
monolayer cultures of 293T cells (Buck et al., 2005). Production of infectious 
viruses to be used for infectivity studies, is still in early stages. Hence most 
studies employ other means for introducing viral genomes into cells, such as 
tranfections.   
 
Chapter 1: Introduction 
 35 
1.9. The E7 protein  
The HPV E7 protein is a small protein (11 kDa for HPV16) and is one of the 
oncoproteins expressed by HPVs. It has been shown to be able to immortalise 
keratinocytes (Halbert et al., 1991), and when expressed together with E6, can 
also transform them (Munger et al., 1989a). Furthermore, HPV16 E7 was found 
to be able to induce hyperplasia when expressed on its own in the skin of 
transgenic mice (Herber et al., 1996). Many studies have shown that E7 can 
interact directly with several cellular proteins and its biological effects are 
thought to be conferred by its protein-protein interactions. Interestingly, the HPV 
E7 protein shares many similarities with the SV40 large T antigen and the 
adenovirus E1A protein (DeCaprio et al., 1988; Massimi et al., 1996; Whyte et 
al., 1988).  
 
In a normal epithelium, the basal cells are the only cells capable of undergoing 
cell division. HPVs are dependent on the cellular replication machinery in order 
to replicate their DNA. Therefore, in an infected epithelium, it is essential that 
the suprabasal cells are kept in cycle, in order to support viral replication. A 
major role of E7 is to delay the terminal differentiation of the suprabasal cells, 
thereby keeping them in cycle (reviewed in McLaughlin-Drubin & Munger, 
2009). The main activities of E7 are outlined below. 
 
1.9.1. Association with retinoblastoma proteins and effects on cell cycle 
regulators 
The best characterised activity of E7 is its ability to bind to the retinoblastoma 
family of proteins. E7 binds to pRb and pRb-related proteins p107 and p130 and 
targets them for proteasomal degradation (Boyer et al., 1996; Davies et al., 
1993; Dyson et al., 1989; Jones & Munger, 1997; Munger et al., 1989b). 
Interactions with pRb appear to be a common feature of tumour virus proteins, 
as the SV40 large T antigen and the adenovirus E1A protein also bind to it 
(DeCaprio et al., 1988; Whyte et al., 1988). E7 preferentially degrades the 
hypophosphorylated form of pRb (Boyer et al., 1996) and this is the form that 
interacts with the E2F transcription factor (Chellappan et al., 1991.) Binding of 
hypophosphorylated pRb to E2F prevents the transactivation activities of E2F 
and when pRb gets phosphorylated, E2F is free to activate the transcription of 
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genes that promote entry into S-phase (reviewed in Donjerkovic & Scott, 2000). 
Targets of E2F include cyclins A and E, the proliferating cell nuclear antigen 
(PCNA), minichromosome maintainance proteins (MCMs) and DNA polymerase 
α (Cheng et al., 1995; Chien et al., 2000; Dyson, 1998; Leone et al., 1998). By 
interacting with pRb, E7 interrupts the pRb-E2F binding, thus causing the 
release of free E2F. As a result, E7 is able to promote S-phase progression in 
suprabasal cells, which would have otherwise exited the cell cycle. This was 
demonstrated in the analysis of wild-type and E7-deficient HPV16 raft cultures 
which demonstrated a clear need for E7 in the induction of PCNA expression 
and DNA synthesis in suprabasal cells (Flores et al., 2000).   
  
The E7 proteins of low-risk viruses interact with pRb with a much lower 
efficiency than the E7 proteins of high-risk viruses and this correlates with their 
lack of transforming ability (Gage et al., 1990; Heck et al., 1992). Despite this, 
low-risk HPVs can also cause hyperproliferative lesions, suggesting that they 
too have a mechanism for causing aberrant entry into S-phase. It has been 
shown that whereas the E7 protein from the high-risk type HPV16 can degrade 
pRb as well as the related p107 and p130 proteins, the E7 protein from the low-
risk type HPV6 can only degrade p130. Interestingly, in the uninfected 
epithelium, p130 is more abundant in differentiating cells, as opposed to pRb 
and p107, which are more abundant in undifferentiated cells (Zhang et al., 
2006). These observations suggest a mechanism by which both the high- and 
low-risk HPVs can promote the replication of their genomes in the 
undifferentiated epithelium.  
 
Furthermore, both high- and low-risk E7 proteins have been shown to augment 
the activities of the cdk2/cyclin A and cdk2/cyclin E complexes, by directly 
binding to them (Arroyo et al., 1993; He et al., 2003; Nguyen & Munger, 2008; 
Tommasino et al., 1993). The cdk2/cyclin E complex controls entry into S-phase 
whereas the cdk2/cyclin A complex controls progression through S-phase, and 
the G2/M transition (reviewed in Sherr, 1993). E7 also affects the activities of 
these complexes indirectly, by abrogating the activities of cyclin-dependent 
kinase inhibitors (CKIs), p21CIP1 and p27KIP1 (Funk et al., 1997; Jones et al., 
1997; Zerfass-Thome et al., 1996).  
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1.9.2. Association with other cellular binding partners  
In addition to the above, E7 interacts with a variety of other cellular proteins, 
many of which have effects on cellular gene transcription. One of these 
interactions is with histone deacetylase 1 (HDAC-1) (Brehm et al., 1999), which 
results in increase of E2F2-mediated transcription in differentiating 
keratinocytes (Longworth et al., 2005).  E7 also binds to AP-1 transcription 
factors, such as c-Jun, and up-regulates their transcriptional activities (Antinore 
et al., 1996). Furthermore, E7 binds to the TATA box binding protein (TBP), 
another activity that it shares with the adenovirus E1A protein (Massimi et al., 
1996). This interaction was shown to inhibit TBP’s ability to bind to DNA 
(Maldonado et al., 2002), suggesting the inhibition of TBP’s transcriptional 
activity, and has also been shown to correlate with E7’s transforming ability 
(Massimi et al., 1997). 
 
1.9.3. Role in episomal persistence  
In addition to its role in maintaining a replication-competent environment in the 
suprabasal layers of the epithelium, E7 has also been implicated in the 
persistence of viral episomes in the basal layer. This was suggested for HPV11 
as well as HPV31, using monolayer cultures of primary cells (Oh et al., 2004; 
Thomas et al., 1999). Interestingly, studies using HPV16 showed that this is not 
true when an immortalised keratinocyte cell line (NIKS) is used instead (Flores 
et al., 2000; Laurson et al., 2010). This suggests that E7 may not have a direct 
role in episomal persistence, but its effect may instead be a consequence of its 
role in cellular immortalisation. 
 
1.10. The E6 protein  
The HPV E6 proteins are small proteins and for HPV16 approximately 18 kDa 
and 151/158 amino acids long (Foster et al., 1994). E6 proteins contain two 
zinc-finger motifs which have been suggested to play a role in protein stability 
and localisation (Kanda et al., 1991) (Fig.1.3). No enzymatic activity of E6 is 
known and, as with E7, most of its activities are thought to occur through 
protein-protein interactions, although E6 has also been shown to have DNA-
binding abilities (Ristriani et al., 2000). Recent studies have demonstrated that 
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E6 can dimerise or oligomerise in vivo, however, whether or not the monomeric 
and oligomeric forms have different functions remains unclear (Garcia-Alai et 
al., 2007; Zanier et al., 2010).  
 
Studies of the E6 protein have been hindered due to the low levels of protein 
thought to be expressed, as well as the lack of sensitive antibodies. However, 
E6 is still one of the best studied HPV proteins and many of its activities have 
been well characterised. Similarly many cellular binding partners of E6 have 
been identified and these include proteins that E6 targets for proteasomal 
degradation. These interactions implicate E6 in a variety of cellular pathways 
the consequences of which include blocking of apoptosis, evasion of immune 
surveillance and chromosomal instability. In fact, HPV16 E6 has been shown to 
be able to induce cancers when expressed alone in the skin of transgenic mice 
(Song et al., 1999) and interestingly, its PDZ-binding motif was found to be 
necessary for this (Nguyen et al., 2003). 
 
Not much is known about the regulation of the levels of E6 in HPV-infected 
cells. The levels of high-risk E6 proteins are regulated by the proteasome, 
however results vary with regards to low-risk E6 proteins (Kehmeier et al., 2002; 
Stewart et al., 2004). Moreover, a recent study has shown that HPV16 and 18 
E6 proteins are stabilised by their interactions with the E6-associated protein 
(E6AP) (Tomaic et al., 2009b). The main activities of E6 are outlined below.   
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Figure 1.3: Sequence of the 158 amino acid product of the HPV16 E6 ORF 
The E6 protein of HPV16 is 151/158 amino acids long, depending on which of 
the two ATG codons is used in translation. The two methionines that could 
potentially represent the first amino acid of E6 are shown in red and are marked 
as amino acids 1 and 8. The 2 zinc-finger motifs are shown in the boxes. The 
PDZ-binding motif at the C-terminus is shown in blue.  
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1.10.1. Binding to E6AP 
E6 proteins from both high- and low-risk HPV types have been shown to bind to 
E6AP, which is a cellular E3 ubiquitin ligase (Brimer et al., 2007; Huibregtse et 
al., 1991). Through its interaction with E6AP, E6 is able to direct the 
degradation of many of its cellular binding partners, for example p53.  
 
More recently, it has been shown that E6-E6AP binding promotes the 
ubiquitination and proteasomal degradation of E6AP (Kao et al., 2000).  As the 
catalytic activity of E6AP was found to be necessary for this, it has been 
suggested that through its interaction with E6, E6AP ubiquitinates itself and 
targets itself for degradation. Contributing further to the understanding of the 
interaction between E6 and E6AP, a recent study found that E6AP is able to 
stabilise E6, in a manner independent of the former’s catalytic activity (Tomaic 
et al., 2009b). Taken together, these results demonstrate the complex 
relationship between E6 and its binding partners, the outcome of which is 
probably influenced by many factors, including signalling, differential protein 
localisation in the cell and differences in the levels of each protein at various 
stages of the viral life-cycle and disease progression. Many cellular proteins 
have been shown to be destabilised by the presence of E6, however, the 
Tomaic et al. paper is the first report of a protein that alters the stability of E6 
itself. This opens new doors for studying possible effects of other cellular 
proteins on E6.    
 
1.10.2. Association with p53  
The best characterised activity of E6 is its ability to bind to p53 (Werness et al., 
1990). p53 is  a transcription factor as well as one of the key signal transducers 
during times of cellular stress. It is usually present at low levels, and kept in an 
inactive state. It is activated when cellular stress is detected, and initiates a 
cascade of events leading to cell cycle arrest, DNA repair and even apoptosis, if 
the damage is too large to repair (reviewed in Gottlieb & Oren, 1996). 
Interaction with p53 appears to be a common feature amongst proteins from 
different DNA tumour viruses, as both the SV40 large T antigen and the 
adenovirus E1B 55 kDa protein have also been shown to bind to this protein 
(Lane & Crawford, 1979; Sarnow et al., 1982). Interestingly though, whereas the 
Chapter 1: Introduction 
 41 
SV40 large T antigen and the adenovirus E1B 55 kDa protein stabilise p53, the 
high-risk HPV E6 proteins degrade it (Oren et al., 1981; Scheffner et al., 1990; 
van den Heuvel et al., 1993).  
 
Due to p53’s essential functions in preventing replication of damaged DNA, it is 
not surprising that over 50% of cancers have mutations in the p53 gene 
(Vogelstein et al., 2000). p53 is also activated when cells inappropriately enter 
the cell cycle. As mentioned earlier, one of the functions of E7 is to push 
suprabasal cells to divide. As this is not a “natural” occurrence, p53 is activated 
in order to prevent it, and it has been shown that cells that express E7 alone 
have higher levels of p53 than control cells (Demers et al., 1994; Laurson et al., 
2010). HPVs therefore need to circumvent this check-point and they do so by 
the E6-mediated degradation of p53. As such, most HPV-induced cancers 
actually harbour wild-type p53 genes (Crook et al., 1991; Scheffner et al., 
1991).  
 
In HPV-negative cells the levels of p53 are kept tightly regulated and the protein 
is degraded by the ubiquitin-proteasome, and via interaction with the cellular E3 
ubiquitin ligase Mdm-2 (Haupt et al., 1997; Honda et al., 1997). Interestingly, in 
HPV-positive cells the degradation of p53 by E6 is mediated though the binding 
of E6 to p53 and E6AP (Huibregtse et al., 1991; Scheffner et al., 1993). E6AP 
does not target p53 in the absence of a high-risk E6 protein (Huibregtse et al., 
1991). By binding to both E6AP and p53, E6 alters the target specificity of 
E6AP, and causes the proteasomal degradation of p53 by a new pathway. 
Although the role of E6AP in E6-mediated p53-degradation by the ubiquitin-
proteasome pathway seems well established, more recent reports suggest that 
E6AP-independent (Massimi et al., 2008) and even ubiquitin-independent 
(Camus et al., 2007), pathways may also be involved.  
 
E6 proteins from high- and low–risk HPVs bind to p53, however, only high-risk 
types degrade p53 (Foster et al., 1994; Scheffner et al., 1990). The difference is 
thought to lie in the specific regions of p53 that interact with E6 and it had been 
suggested that E6 proteins from high- and low-risk types can bind to the C-
terminus of p53, while only high-risk types can bind to its core DNA-binding 
region (Li & Coffino, 1996). A recent study showed that upon expression of low-
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risk HPV11 E6 protein, p53 is predominantly present in the cytoplasm (Sun et 
al., 2008), suggesting that even without inducing the degradation of p53, low-
risk viruses may still have an effect on its function.  
  
High-risk E6 proteins also employ other approaches to inhibit the activities of 
p53, which do not involve its degradation. For example, they interact with 
histone acetyltransferases CBP/p300 and hADA3, the latter of which they also 
degrade, (Kumar et al., 2002; Patel et al., 1999) which are p53 co-activators.  
 
Several studies have used mutants of the E6 protein in an attempt to identify 
the precise region of E6 necessary for the degradation of p53. One such study 
found that most N-terminal mutations of E6, as well as mutations in either of the 
two zinc-fingers, inhibit the degradation of p53, whereas mutations in the C-
terminus of E6 do not. This study also showed that wild-type E6 and E6 mutants 
that retained the ability to degrade p53, showed abrogation of actinomycin D-
induced growth arrest. On the other hand, E6 mutants that were unable to 
degrade p53 responded to actinomycin-D (low levels of which cause DNA 
breaks) by inducing growth arrest (Foster et al., 1994). This highlights the 
importance of p53-degradation by E6 in overcoming cellular stress. 
Interestingly, the truncated form of E6, E6*, has been shown to bind to full-
length E6 and inhibit E6-mediated degradation of p53 (Pim et al., 1997). The 
same authors also reported that exogenous expression of E6* has been shown 
to inhibit proliferation of HPV-positive cells (Pim et al., 1997). These findings 
suggest a dominant negative role for E6* over full-length E6 with rergards to 
p53-degradation and cell proliferation.  
 
1.10.3. Inhibition of apoptosis 
A consequence of E6-mediated p53-degradation is bypass of apoptotic 
signalling and subsequent death of HPV-infected cells. E6 proteins from low-
risk types are unable to degrade p53, however, results from a recent study 
suggest that low-risk E6 proteins may bypass the p53-induced apoptotic 
response by degrading the acetyltransferase TIP60 (Tat-interacting protein 60 
kDa) (Jha et al., 2010). TIP60 has been shown to be necessary for the p53-
dependent activation of the proapoptotic factor Puma (p53 up-regulated 
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modulator of apoptosis) (Tang et al., 2006b) and Jha et al. reported that in the 
presence of high- or low-risk E6 in cells Puma expression was not induced (Jha 
et al., 2010). 
 
E6 is also able to bypass apoptosis by interfering with both the intrinsic and the 
extrinsic apoptotis pathways. The extrinsic apoptotic pathway is activated by 
viral infections, and E6 has been shown to inhibit this signalling cascade by 
interacting with and degrading key components of the pathway, such as the 
Fas-associated death domain (FADD) and procaspase 8 (Filippova et al., 2004; 
Garnett et al., 2006). The intrinsic apoptotic pathway senses signals from within 
the cell, such as from DNA damage and oxidative stress. Activation of the 
intrinsic pathway results in the activation of pro-apoptotic proteins and 
subsequent release of mitochondrial proteins, such as cytochrome c and 
apoptosis-inducing factor (AIF) into the cytosol (reviewed in Elmore, 2007). E6 
proteins from high-risk, low-risk and cutaneous HPVs have been shown to 
induce the proteasomal degradation of Bak, the protein that forms the 
mitochondrial pores during apoptosis (Jackson et al., 2000; Thomas & Banks, 
1998; Thomas & Banks, 1999). As a result of this, there is no disruption of the 
mitochondria, no release of mitochondrial proteins and no activation of the 
effector caspases. By targeting both the intrinsic and extrinsic apoptotic 
pathways, E6 can ensure that the infected cell circumvents any apoptotic 
signals it may receive.  
 
1.10.4. Disruption of cell-cell adhesion and polarity  
The stratified epithelium is made up of many layers of cells, each at a different 
stage of differentiation. Therefore, it is important that the cellular organisation of 
the epithelium is very tightly regulated to ensure that the correct signals for 
proliferation and differentiation reach the correct cells. This involves the 
establishment of correct contacts between neighbouring cells, as well as 
between cells and the extracellular matrix (ECM) and also, the regulation of 
apico-basal polarity of epithelial cells (Bilder, 2004). For example only basal 
cells are attached to the extracellular matrix of the basement membrane and 
receive proliferation signals. Once a cell exits the basal layer, it stops receiving 
proliferation signals, and starts receiving signals for differentiation. As discussed 
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earlier, HPVs have many ways in which to keep suprabasal cells in cycle so that 
the viral DNA is able to keep replicating. Some of these involve the disruption of 
cell adhesion and polarity by E6. 
 
1.10.4.1. The PDZ proteins – hScrib, hDlg and MAGI 
The PDZ-domain containing proteins (PDZ proteins) are a large group of 
cellular proteins that contain one or more of the structural PDZ domains (named 
after PSD95, DlgA and ZO-1 proteins) involved in protein-protein binding. Some 
PDZ proteins have been shown to interact with viral oncoproteins, such as the 
E6 protein of high-risk HPVs, via the PDZ-binding motifs of the latter. Certain 
PDZ proteins have been implicated in the regulation of epithelial polarity or are 
scaffold proteins that are involved in the organisation of multi-protein membrane 
structures (Thomas et al., 2008). These include hScrib, hDlg and MAGI-1, -2 
and -3, which are the best characterised PDZ proteins with respect to their 
interaction with E6 and have been shown to be targeted for proteasomal 
degradation, by way of this interaction (Gardiol et al., 1999; Glaunsinger et al., 
2000; Kiyono et al., 1997; Lee et al., 1997; Nakagawa & Huibregtse, 2000; 
Thomas et al., 2002).  
 
hScrib and hDlg are human homologues of the well studied Drosophila 
melanogaster genes scribble and discs large respectively (Dow et al., 2003; Lue 
et al., 1994). They are members of the Scribble polarity complex, which 
localises to the basolateral membrane and is implicated in the formation of 
adherens junctions (Bilder & Perrimon, 2000; Firestein & Rongo, 2001; Woods 
et al., 1996). As such, they are involved in keeping the ordered structure of the 
epithelium as well as in signal transduction (Humbert et al., 2003). Importantly, 
loss of cell polarity is a common feature in human cancers (Gardiol et al., 2006; 
Javier, 2008) and it is thus not surprising that these polarity proteins have been 
shown to interact with proteins from various oncogenic viruses such as the HPV 
E6 protein, the Human T-lymphotropic virus Type 1 (HTLV-1) Tax protein and 
the Adenovirus 9 E4ORF1 protein (Glaunsinger et al., 2000; Lee et al., 1997).  
 
In addition to their role in polarity, hScrib and hDlg (and their Drosophila 
counterparts) are important in controlling cell proliferation and have been 
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classified as tumour suppressors (Bilder et al., 2000; Dow et al., 2003; Woods & 
Bryant, 1989). Mutations of these proteins in both Drosophila and mammals 
have been shown to cause aberrant growth and loss of tissue morphology and 
differentiation (Bilder et al., 2000; Woods & Bryant, 1989; Zhan et al., 2008). 
Suggested ways in which loss of polarity proteins could affect growth include 
deregulation of signalling pathways and loss of contact inhibition (Bilder et al., 
2000). 
 
hScrib and hDlg are also implicated as tumour suppressors in studies that have 
shown them to bind to the adenomatous polyposis coli (APC) protein, via the 
PDZ-domains of the former and the PDZ-binding motif of the latter (Matsumine 
et al., 1996; Takizawa et al., 2006). APC is a tumour suppressor that regulates 
cell cycle progression (Baeg et al., 1995) and is part of the Wnt pathway, where 
its role is to keep the levels of free β-catenin low in the absence of Wnt signals 
(reviewed in Logan & Nusse, 2004). Binding of both hScrib and hDlg to APC 
has been shown to contribute to the negative regulation of the cell-cycle 
(Ishidate et al., 2000; Nagasaka et al., 2006). Disruption of this interaction by E6 
(Kiyono et al., 1997; Takizawa et al., 2006) would be expected to result in 
deregulated growth.  
 
The recruitment of both hScrib and hDlg to sites of cell-cell contact appears to 
be dependent on E-cadherin (Navarro et al., 2005; Reuver & Garner, 1998). 
Non-membrane forms of hDlg have also been identified, including nuclear and 
cytoplasmic forms (Garcia-Mata et al., 2007; McLaughlin et al., 2002; Roberts et 
al., 2007). These seem to be at least in part regulated by cellular differentiation, 
suggesting different functions of hDlg at different stages of differentiation or 
even a role for hDlg in the differentiation process (Roberts et al., 2007; Watson 
et al., 2002). Moreover, different phosphorylated forms of hDlg have been 
identified (Mantovani et al., 2001; Massimi et al., 2006) some of which exhibit 
differential cellular localisation. For example, hDlg that is phosphorylated 
following osmotic stress localises to sites of cell-cell contact (Massimi et al., 
2006). Interestingly, phosphorylated forms of hDlg were found to be more 
susceptible to degradation by HPV E6 proteins (Massimi et al., 2006; Narayan 
et al., 2009b). Moreover, hDlg was shown to be a substrate for phosphorylation 
by CDKs 1 and 2 (Narayan et al., 2009a) and its localisation appears to change 
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during the cell-cycle with one study showing it to be predominantly on the 
membrane during G1, and on the mitotic spindle in mitosis (Narayan et al., 
2009a). Together these studies suggest the existence of distinct cellular pools 
of hDlg, with different modifications and functions and hint at the complexity of 
this multifunctional protein.  
 
Loss of polarity has been linked to the development of a more invasive 
phenotype (Humbert et al., 2003) and this is supported by observations that 
aggressive cancers harbour lower levels of hDlg (Watson et al., 2002). Studies 
using mutants of Drosophila Scribble or hScrib have shown that its deregulation 
alone is not enough to cause an invasive phenotype, and additional mutations 
in oncogenes, such as Ras or Notch, are thought to be necessary for this 
(Brumby & Richardson, 2003; Dow et al., 2008). One way in which hScrib has 
been shown to regulate cell migration is by blocking the Ras-activated MAPK 
signalling pathway. Loss of hScrib in conjunction with activation of Ras, 
activates this pathway and promotes cell invasion (Dow et al., 2008).  
 
Another group of PDZ proteins that have been shown to interact with E6 are the 
MAGIs (Glaunsinger et al., 2000; Thomas et al., 2002). E6 targets two pools of 
MAGI, a nuclear and a membrane pool, suggesting that both may be 
detrimental for the viral life-cycle (Kranjec & Banks, 2010). Not much is known 
about the nuclear pool of MAGI, however the membrane pool is involved in tight 
junction formation (Ide et al., 1999; Thomas et al., 2008). Tight junctions 
regulate important signalling pathways that are involved in both cell proliferation 
and differentiation (Matter & Balda, 2003). Loss of MAGI in HPV-infected cells 
may thus deregulate these pathways.  
 
Membrane bound MAGI plays a role in the localisation of the tumour suppressor 
protein PTEN, by interacting with it via the PDZ domains of the former and the 
PDZ-binding motif on the latter (Kotelevets et al., 2005; Wu et al., 2000b; Wu et 
al., 2000c). Interestingly, PTEN is also stabilised via its interaction with MAGI 
(Valiente et al., 2005; Wu et al., 2000b). PTEN down-regulates signalling 
pathways that promote cell growth (Marte & Downward, 1997; Stambolic et al., 
1998) and PTEN mutations have been shown to lead to a decrease in apoptosis 
or an increase in cell growth (Stambolic et al., 1998), both of which can result in 
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tumorigenesis. Therefore, the disruption of the interaction between MAGI and 
PTEN is another way in which E6 can promote malignancy. 
 
In addition to the above, other PDZ proteins have also been shown to bind to 
(and sometimes be degraded by) high-risk E6. These include PATJ (Storrs & 
Silverstein, 2007), which is involved in tight junction formation, and MUPP-1 
(Lee et al., 2000), which localises to tight junctions and is involved in signalling. 
Other targets include TIP-1 (Hampson et al., 2004), TIP-2 (Favre-Bonvin et al., 
2005), PTPN3 (Jing et al., 2007), PTPN13 (Spanos et al., 2008), which are 
involved in signalling pathways, and CAL (Jeong et al., 2007), which is involved 
in trafficking of membrane proteins. 
 
1.10.4.2. Degradation of PDZ-proteins by E6  
The high-risk E6 oncoproteins have a class I PDZ-binding motif (X-S/T-X-V/L) at 
their extreme C-terminus (Kiyono et al., 1997; Lee et al., 1997). Several high-
risk HPV E6 proteins have been shown to possess a PDZ-binding motif, and 
binding to PDZ proteins has been implicated in E6’s tumorigenic activities 
(Nguyen et al., 2003). Furthermore, this C-terminal motif is shared by 
oncoproteins of other tumour viruses such as the Adenovirus E4 ORF1 protein 
and the HTLV-1 Tax protein (Lee et al., 1997) as well as by the NS1 proteins of 
influenza viruses (Obenauer et al., 2006). 
 
The low-risk HPV E6 proteins lack a PDZ-binding motif and consequently are 
unable to bind to PDZ proteins (Kiyono et al., 1997; Lee et al., 1997; Nakagawa 
& Huibregtse, 2000). Intriguingly, recent studies have suggested the 
degradation of PDZ proteins by the E6* splice variant of E6 (which lacks the 
PDZ-binding motif) in the absence of full-length E6 (Pim et al., 2009; Storrs & 
Silverstein, 2007). Some controversy exists with respect to whether or not E6* 
can directly bind to the PDZ proteins, however this may be reflective of the 
different PDZ proteins that were investigated in each study.  
 
Different studies have also looked at whether E6AP is involved in the 
degradation of PDZ proteins by E6, and the results vary. One study suggested 
that the E6-E6AP complex is involved in the degradation of hScrib (Nakagawa 
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& Huibregtse, 2000) whilst others suggested that the degradation of hDlg, 
hScrib, MAGI and PATJ may be E6AP-independent (Grm & Banks, 2004; 
Massimi et al., 2008; Pim et al., 2000; Storrs & Silverstein, 2007). It is probable 
that different mechanisms may be involved in the E6-mediated degradation of 
cellular proteins. This is also supported by data showing E6AP-independent 
degradation of p53 (Massimi et al., 2008). E6 may therefore interact with other 
ubiquitin ligases, apart from E6AP and a recent report has identified the 
ubiquitin ligase EDD as a novel cellular binding partner of E6 (Tomaic et al., 
2011).  
 
E6 proteins from different high-risk HPV types have been shown to have 
varying affinities to PDZ proteins. HPV16 E6 preferentially binds to and 
degrades hScrib, with minimal effect on hDlg, whereas the contrary is true for 
HPV18. This is due to the single amino acid variation in the PDZ-binding motifs 
of the two E6 proteins (Thomas et al., 2005). Interestingly MAGI was found to 
be targeted for degradation efficiently by both HPV16 and HPV18 (Kranjec & 
Banks, 2010).  
 
Most studies looking at the effect of high-risk E6 proteins on PDZ proteins have 
been carried out using the E6 proteins from HPV16 or 18. Whether other high-
risk E6 proteins have the same effects, needs to be determined. Moreover, 
most such studies have been carried out in vitro or using over-expression 
systems. Whether endogenous PDZ proteins are targeted for degradation by 
episomally-expressed E6 remains unclear. In fact, a study using HPV31-
transfected keratinocytes, reported that there was no significant difference in 
the levels of PDZ proteins between un-transfected and transfected cells (Lee & 
Laimins, 2004). However, the authors did report lower viral copy numbers and a 
slower growth rate of cells harbouring a PDZ-binding mutant HPV31 genome, 
compared to cells harbouring the wild-type HPV31 genome (Lee & Laimins, 
2004). 
 
Although the potential tumorigenic effects of the interaction between E6 and 
PDZ proteins have been discussed, the role of this interaction in the viral life-
cycle remains unclear. One role however may be in the persistence of viral 
genomes in the basal layer of the epithelium (Lee & Laimins, 2004). 
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1.10.4.3. Interaction with focal adhesion molecules 
In addition to PDZ proteins, E6 from different PVs have been shown to interact 
with paxillin and zyxin, which are focal adhesion proteins and are involved in 
signal transduction (Degenhardt & Silverstein, 2001; Tong & Howley, 1997). 
Binding of E6 to these proteins results in breakdown of the actin cytoskeleton 
and consequently the cell structure, and could contribute to cell transformation.  
 
1.10.5. Induction of telomerase activity 
Expression of high-risk E6 protein can lead to cell immortalisation (Band et al., 
1991) and one of the mechanisms employed is activation of telomerase. 
Telomerase is a ribonucleoprotein whose function is to extend the telomeric 
ends of chromosomes. It is inactive in most cells and the continuous shortening 
of the telomeres with each cell division eventually leads to cell senescence. 
Telomerase is made up of an RNA template (TERC) and a catalytic subunit 
(hTERT). hTERT activity can be detected in the majority of immortalised cells 
and cancers (reviewed in Wai, 2004).  
 
E6 induces telomerase activity in different cells including human keratinocytes 
and this is independent of E6’s ability to degrade p53 (Klingelhutz et al., 1996). 
Telomerase activity is induced by up-regulation of hTERT transcription 
(Veldman et al., 2001) as well as by direct interaction of E6 with telomerase and 
with telomeric DNA sequences (Liu et al., 2009).  
 
It has also been suggested that E6-mediated activation of telomerase may be 
E6AP-dependent (Liu et al., 2005), however, other studies have suggested that 
there may also be an E6AP-independent pathway (Sekaric et al., 2008). 
Moreover, E6 and E6AP have been shown to promote histone acetylation of the 
hTERT promoter, as well as affect many of its activators and repressors (Howie 
et al., 2009; James et al., 2006). 
 
1.10.6. Association with other cellular binding partners  
In addition to its more well-characterised binding partners mentioned above, E6 
also interacts with other cellular proteins. Some of these interactions correlate 
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with the oncogenic potential of the E6 protein, thus suggesting roles in HPV-
mediated cancer progression. One protein that E6 binds to is E6-targeted 
protein 1 (E6TP1), a GTPase-activating protein that E6 has been shown to 
degrade by means of E6AP (Gao et al., 1999; Gao et al., 2002). Only high-risk 
E6 proteins were found to degrade E6TP1 (Gao et al., 1999).  
 
Other interactions of E6 have more defined implications for cancer progression, 
and these include proteins involved in maintaining chromosome stability. One 
such protein is minichromosome maintenance 7 (MCM7), which both high- and 
low-risk E6 proteins have been shown to bind to (Kukimoto et al., 1998) and 
HPV18 E6 has been suggested to degrade (Kuhne & Banks, 1998). MCM7 has 
a role in ensuring that cellular DNA only replicates once per cell cycle (reviewed 
in Chong et al., 1996), thus disruption of this control is thought to contribute to 
genomic instability. Furthermore, E6 interacts with proteins involved in DNA 
repair, such as XRCC1 (Iftner et al., 2002), and O(6)-methylguanine-DNA 
methyl-transferase (MGMT) (Srivenugopal & Ali-Osman, 2002), the latter of 
which E6 also degrades. These activities of E6 have therefore been suggested 
to sensitise HPV-positive cells to DNA damage and consequently promote 
genetic instability. 
 
As mentioned earlier, E6 interferes with the interaction of APC with PDZ 
proteins (Kiyono et al., 1997; Takizawa et al., 2006), and this may in turn affect 
signalling via the Wnt pathway. Interestingly, a recent study has shown that E6 
expression can also affect the Wnt pathway in a manner that is independent of 
APC (Lichtig et al., 2010). Furthermore, E6 has been shown to down-regulate 
the levels of E-cadherin, which can also deregulate the Wnt pathway (Matthews 
et al., 2003).  
 
Although these activities of E6 have potential implications for cancer 
development, their roles in the viral life-cycle remain unclear.  
 
1.10.7. Effects on viral transcription  
In section 1.10.3 I mentioned the E6-mediated degradation of TIP60 (Jha et al., 
2010). TIP60 is involved in cellular transcription, apoptosis and activation of 
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DNA-damage pathways. (Sun et al., 2005; Sykes et al., 2006; Tang et al., 
2006b). Experiments in HeLa cells showed TIP60 to be a repressor of the viral 
early promoter (measured by the levels of E6 mRNA) (Jha et al., 2010). This led 
the authors to suggest that by degrading TIP60, E6 may be able to counteract 
this repression, thus promoting its own expression as well. It is important to note 
however that the viral promoter is regulated differently depending on the 
physical state and conformation of the viral DNA (Bechtold et al., 2003; Schmidt 
et al., 2005). Therefore, these results may be true for cancer cell lines but may 
not hold true for cell lines in which the HPV DNA is episomal.  
 
1.10.8. E6 localisation 
E6 has been shown to have activities in the cytoplasm, such as binding to 
E6AP, as well as in the nucleus, such as binding to transcriptional regulators. 
Several studies have looked at the localisation of E6 in cells however their 
results differ. E6 has been reported to be primarily nuclear, or nuclear and 
membrane-associated, when expressed in COS cells (Kanda et al., 1991; 
Sherman & Schlegel, 1996) or insect cells (Daniels et al., 1998; Grossman et 
al., 1989). In contrast, it has also been shown to be both nuclear and 
cytoplasmic in cervical lesions (Tosi et al., 1993) and perinuclear in the HPV16-
positive cervical cancer line SiHa (Daniels et al., 1998). In yet another study, E6 
was reported to be primarily cytoplasmic in the HPV16- or 18- integrated 
cervical cancer lines HeLa, CaSki and SiHa, where it was shown to co-localise 
with p53 (Liang et al., 1993), but primarily nuclear in transiently transfected 
COS cells, where it was again shown to co-localise with p53 (Lechner et al., 
1992). More recently, Tao et al. identified three nuclear localisation signals 
(NLSs) on the HPV16 E6 protein, which they authors suggest play an active 
role in driving the protein to accumulate in the nucleus (Tao et al., 2003). It is 
not yet clear if the inconsistency between these studies is due to the different 
cell lines or techniques used. 
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1.11. Immune response and infection clearance  
 
1.11.1. Regulation of the immune response   
The HPV life-cycle has some important features that “protect” the virus from 
being cleared by the immune system. One such feature is the lack of 
inflammation following HPV infection. This is because the virus is not lytic, and 
also because the infected keratinocytes are cells that are already destined to 
die. Moreover, there is no viraemia, as both the infection and the shedding of 
the progeny virions takes place away from the blood and lymphatic systems 
(reviewed in Stanley, 2009).  
 
Moreover, HPVs have been shown to interfere with interferon- (IFN) signalling. 
E7 has been shown to interfere with the transcriptional activity of the IFN-
stimulated gene factor 3 complex (Barnard & McMillan, 1999) and to also bind 
to IFN regulatory factor-1 (IRF-1) and abrogate its transcriptional activity (Park 
et al., 2000). E6 has been shown to do the same to IRF-3 (Ronco et al., 1998). 
Microarray analysis of HPV31-positive cells has indicated a significant down-
regulation of IFN-inducible genes, such as Stat-1, compared to HPV-negative 
cells (Chang & Laimins, 2000) and a similar study using HPV16 suggests that 
this may be at least in part due to expression of E6 (Nees et al., 2001). 
Moreover, E6 has been shown to interact with Tyk2 thereby reducing Jak-Stat 
activation by IFN-α (Li et al., 1999) and E6 and E7 inhibit transcription of toll-like 
receptor 9 (TLR9) and consequently abrogate its signalling pathway (Hasan et 
al., 2007).  
 
Furthermore, in HPV-induced lesions there is a decrease in the levels of E-
cadherin, compared to normal epithelium, and this correlates with reduced 
infiltration of antigen-presenting Langerhans cells (Hubert et al., 2005). The 
depletion of E-cadherin by HPV has been attributed to the activities of both E6 
(Matthews et al., 2003) and E7 (Laurson et al., 2010). Interestingly, down-
regulation of E-cadherin is a feature that HPVs share with other tumour viruses, 
such as Epstein-Barr virus (EBV) (Fahraeus et al., 1992), Hepatitis B (Liu et al., 
2006) and Hepatitis C (Iso et al., 2005) viruses (HBV and HCV). Importantly, a 
potential consequence of this is the reduction of the anti-viral immune response.   
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In addition to E6 and E7, E5 is also involved in immune evasion, as it has been 
shown to decrease the levels of MHC I molecules on the surface of W12 cells. 
As a result, antigen presentation is inhibited, and cell recognition by the immune 
system is reduced (Campo et al., 2010).  
 
1.11.2. Infection clearance 
HPV infections are thought to occur very frequently, seen in as much as 80% of 
some adolescent populations (Brown et al., 2005), yet the incidence of high-
grade disease is considerably lower. It is thought that neoplasias of even the 
highest grade (CIN-3) can naturally regress, however the probability that a 
lesion progresses to cancer increases with the severity of the neoplasia. It has 
been suggested that, if not treated, 40% of CIN-3 lesions may eventually 
develop into cancer (Peto et al., 2004). 
 
Despite the abovementioned methods that HPVs use to evade immune 
responses, it is widely thought that most HPV infections are naturally cleared. 
This is believed to occur either via the self-limiting nature of the viral life-cycle, 
or via the mounting of an immune response (Schiffman & Kjaer, 2003). The role 
of the immune system in infection clearance is also highlighted by the higher 
incidence of infection and disease progression in immunocompromised 
individuals, such as HIV patients and organ transplant patients who are given 
immune-supressants (Palefsky et al., 2006).  
 
Histological analyses of genital warts have revealed infiltration of both T cells 
and macrophages into the wart, which undoubtedly contribute to the eventual 
regression of the wart (Coleman et al., 1994). Furthermore, CD4+ T cell 
responses to HPV E2 and E6 have been implicated in viral clearance, and 
these were found to be reduced in patients with high-grade lesions (Welters et 
al., 2003; Welters et al., 2006). Importantly, the L1 capsid protein has been 
found to be very immunogenic, allowing the development of two HPV 
prophylactic vaccines. These make use of L1 virus-like particles (VLPs) to 
generate anti-L1 antibodies, thereby conferring protection to future HPV 
infection (Stanley, 2009). 
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1.12. Persistence 
Despite the successful clearance of most HPV infections, in some cases the 
infection can persist, and there appears to be a correlation between this 
persistence and the development of high-grade disease or cancer (Remmink et 
al., 1995; Schiffman & Kjaer, 2003). This is thought to occur due to the 
prolonged expression of E6 and E7, whose combined activities can lead to the 
accumulation of mutations and genomic instability.  
 
As mentioned earlier, the combined activities of E6 and E7 cause aberrant cell 
proliferation and also block several important cell-cycle check-points, all of 
which can promote the accumulation of mutations in the cell. In addition, the 
expression of E6 and E7 has been shown to cause abnormal centrosome and 
mitotic spindle formation in HPV-positive cells thereby promoting genomic 
instability and aneuploidy (Duensing et al., 2000; Duensing et al., 2001; 
Heselmeyer et al., 1996). 
 
Persistence of viral DNA in the tissue may be accompanied by a continuing 
productive infection. Alternatively, viral DNA may persist in the basal layer of the 
epithelium as a latent infection, without any signs of disease (Abramson et al., 
2004; Maglennon et al., 2011). Persistence of viral episomes in the basal layer 
of the epithelium is necessary whether for lasting and symptomatic infections, or 
for latent infections. Several studies have identified the need for the expression 
of specific viral proteins in order for episomes to persist. Both of the replication 
proteins, E1 and E2 have been found to be necessary (Ken Raj, unpublished 
data) and, for E1, it has been suggested that its export from the nucleus may 
also be necessary for this (Fradet-Turcotte et al., 2010). Furthermore, E6 and 
E7 were found to be necessary for the persistence of both low- and high-risk 
HPV episomes (Laurson et al., 2010; Oh et al., 2004; Thomas et al., 1999), 
although it appears that, for E7, this may not be the case in immortalised cells 
(Flores et al., 2000; Laurson et al., 2010). E4 and E5 were found to be 
dispensable for episomal persistence (Fehrmann et al., 2003; Genther et al., 
2003; and Ken Raj, unpublished data). 
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In order for extrachromosomal episomes to persist in dividing cells, they must 
both replicate and actively segregate into the two daughter cells upon cell 
division and subsequently localise to the newly formed nuclei. 
 
1.12.1. Replication 
Apart from expressing E1 and E2, HPVs rely entirely on the cellular replication 
machinery to replicate their DNA. The replication for PVs has been proposed to 
consist of three different phases. In the first phase following infection the PV 
episomes replicate faster than cellular DNA resulting in an increase of viral 
genomes per cell (Lusky & Botchan, 1986). This initial amplification phase is 
often referred to as establishment, and is followed by a maintenance phase, 
during which the viral genomes remain at a more or less constant number per 
cell. Both the establishment and maintenance phases are thought to take place 
in the basal cells. In the upper layers of the epithelium, the cells stop dividing 
and the viral genomes undergo amplificational replication again, where their 
copy numbers increase dramatically. 
 
The initial establishment phase is thought to require the presence of two viral 
proteins, E1 and E2, and the viral origin of replication including the E1- and E2-
binding sites (Chiang et al., 1992b; Del Vecchio et al., 1992; Frattini & Laimins, 
1994; Remm et al., 1992; Sverdrup & Khan, 1994). E2 binds to its binding sites 
in the LCR and recruits E1 to its own binding site within the replication origin. 
Following E1 recruitment, E2 is thought to dissociate from its binding sites 
(Desaintes & Demeret, 1996). The role of E1 in viral replication is varied. It is a 
DNA helicase, so is actively involved in the unwinding of DNA (Hughes & 
Romanos, 1993), and is also involved in the recruitment of members of the 
cellular DNA replication machinery to the viral origin of replication. These 
include replication protein A (Han et al., 1999), topoisomerase (Clower et al., 
2006) and polymerase α-primase (Park et al., 1994). 
 
The maintenance phase of DNA replication is characterised by a relatively 
stable HPV copy number per cell following successive rounds of cell division. 
Some controversy exists in terms of the mechanism employed in this phase, 
with a study suggesting that BPV1 DNA replicates once in every cell cycle 
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(Roberts & Weintraub, 1988), and another suggesting a more random 
replication, with some episomes replicating several times and some not 
replicating at all (Piirsoo et al., 1996). A recent investigation of HPVs however 
reported that the mode of replication varies depending on the cell type as well 
as the HPV type studied (Hoffmann et al., 2006). Interestingly, one study also 
proposed that the E1 protein may not be required for this phase of viral 
replication (Kim & Lambert, 2002) whereas another proposed that neither E1 
nor E2 may be required (Pittayakhajonwut & Angeletti, 2010). Therefore, there 
appear to be different mechanisms that regulate the establishment and 
maintenance phases of DNA replication. In fact, it has also been suggested that 
p53 expression down-regulates establishment replication but not maintenance 
replication, further hinting at two different modes of replication (Ilves et al., 
2003; Lepik et al., 1998). 
 
The last phase of DNA replication is the differentiation-dependent 
amplificational replication, which occurs in the upper layers of the epithelium 
and coincides with an increase in E1 and E2 transcripts, generated from the late 
promoter (Klumpp & Laimins, 1999). E4 expression is also up-regulated in this 
phase, and E4 has been shown to be important for this phase of replication 
(Nakahara et al., 2005; Peh et al., 2004; Wilson et al., 2005; Wilson et al., 2007) 
although this may not be true for all HPV types (Fang et al., 2006).  
 
There appear to be differences between the control of viral replication in 
undifferentiated and differentiated cells. It appears that E7 is not required for the 
establishment and maintenance phases of replication but is required for the 
amplification phase (Flores et al., 2000) and this is reflective of the need for E7 
in the induction of the cellular replication machinery in the suprabasal cells. 
Moreover, it has been suggested that E6 inhibits viral replication in 
undifferentiated cells (Grm et al., 2005), but is necessary for DNA amplification 
in differentiated cells (Wang et al., 2009). Furthermore, HPVs have been shown 
to activate the ATM (ataxia-telangiectasia mutated) DNA damage response 
pathway and this is necessary for DNA amplification in differentiated cells but 
not establishment and maintenance replication (Moody & Laimins, 2009). 
Therefore, it appears that different mechanisms may be at play to promote viral 
replication across the various stages of the life-cycle.  
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Interestingly, the replication of viral DNA is targeted by IFN-signalling and it has 
recently been shown that, for HPV replication, one mechanism of this is the 
binding of p56, an interferon-inducible protein, to E1 (Terenzi et al., 2008).  
 
1.12.2. Segregation of episomes 
Segregation of viral episomes has been studied in different DNA tumour viruses 
and common features have been identified. Segregation is thought to be 
controlled by the tethering of viral episomes to cellular chromosomes before or 
during mitosis. This is mediated via a DNA-binding viral protein, which binds to 
the viral episomes, and a DNA-binding cellular protein, which binds to the 
cellular chromosomes. The viral and cellular proteins interact, thereby tethering 
the viral episomes to cellular chromosomes (Feeney & Parish, 2009). 
 
E2 proteins from a variety of PVs have been shown to associate with cellular 
chromosomes during mitosis (Bastien & McBride, 2000; Ilves et al., 1999; 
Lehman & Botchan, 1998; Oliveira et al., 2006; Skiadopoulos & McBride, 1998) 
or with the mitotic spindle (Van Tine et al., 2004). This proposes a role for E2 in 
ensuring proper segregation of viral episomes, and also suggests that PVs may 
employ different mechanisms for episomal segregation. 
 
Several cellular proteins have been implicated in this process and these include 
Brd4, a member of the bromodomain protein family (Abbate et al., 2006; Baxter 
et al., 2005; You et al., 2004; You et al., 2005) and ChlR1 (Parish et al., 2006a), 
a DNA helicase involved in the cohesion of sister chromatids (Parish et al., 
2006c). More recently, the topoisomerase II-binding protein 1, TopBP1, was 
also suggested as a possible mediator of episomal segregation as it was shown 
to interact with HPV16 E2 in mitosis (Donaldson et al., 2007). The elucidation of 
this process has been made more difficult by the fact that these cellular proteins 
are also known to be involved in other viral processes, such as transcription and 
replication and therefore care must be taken when trying to dissect these roles. 
Moreover, studies suggest that the mechanisms for the segregation of viral 
episomes (McPhillips et al., 2006; Oliveira et al., 2006) may vary between 
different PVs. 
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Studies of other tumour viruses have revealed similar mechanisms for episomal 
persistence. The viral protein involved in tethering of EBV episomes to cellular 
chromosomes was shown to be EBNA1 (EBV nuclear antigen 1) (Petti et al., 
1990), whereas for Kaposi’s sarcoma-associated herpesvirus (KSHV), it was 
found to be LANA (latency-associated nuclear antigen) (Cotter & Robertson, 
1999). Moreover, both histone H1 (Marechal et al., 1999) and EBNA binding 
protein 2 (EBP2) (Wu et al., 2000a) have been proposed as the cellular proteins 
that mediate the binding of EBV episomes to cellular chromosomes, whereas 
for KSHV possible candidates include Brd4 (You et al., 2006) and histones H2A 
and H2B (Barbera et al., 2006).  
 
It is interesting to note the various similarities between these three tumour 
viruses in that E2, EBNA1 and LANA have all been implicated in viral 
replication, viral transcription and tethering of viral episomes for segregation.  
 
1.13. Aims of thesis 
The general aim of this study was to elucidate the role of the viral E6 protein in 
the persistence of HPV episomes in cells. The specific objectives are outlined 
below: 
 
1) To investigate specific activities of E6 that are necessary for the persistence 
of HPV16 episomes; 
 
2) To determine how these activities of E6 may be regulating viral episomal 
persistence; 
 
3) To further characterise the interaction of the E6 protein with PDZ proteins. 
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Chapter 2: Materials and Methods 
 
2.1. Commonly used buffers and reagents 
Table 2.1: Buffers and reagents 
Name Components 
1x Phosphate buffered 
saline (PBS) 
1% NaCl, 0.025% KCl, 0.14% Na2HPO4,  
0.025% KH2PO4 
SDS electrophoresis 
buffer 
25 mM Tris base, 250 mM glycine, 0.1% sodium 
dodecyl sulfate (SDS); pH 8.3 
Luria Broth 1% Bacto-Tryptone, 0.5% Bacto-yeast extract,   
1% NaCl 
Luria Agar LB medium plus 1.5% Difco agar 
SOC medium 2% Bacto-Tryptone, 0.5% Bacto-yeast extract, 
0.06% NaCl, 0.02% KCl, 0.2% MgCl2.6H2O, 
0.25% MgSO4.7H2O, 0.36% Glucose 
Transfer buffer 48 mM Tris, 39 mM Glycine, 20% Methanol 
RIPA protein extraction 
buffer 
150 mM NaCl, 1% Triton X, 0.5% Sodium 
Deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 
0.005 mM EDTA. Protease Inhibitor cocktail was 
added prior to use (3 µl per 1 ml buffer) 
RIPA 6% SDS protein 
extraction buffer 
Same as RIPA Protein Extraction buffer but with 
6% SDS instead of 0.1% SDS. 
Urea protein extraction 
buffer 
8M urea, 0.1M NaH2PO4, 0.01M Tris; pH 7.0 
Trypsin-versene 0.8% NaCl, 0.02% KCl, 0.12% Na2HPO4,  
0.02% KH2PO4, 0.01% EDTA, 0.13% trypsin, 
0.001% phenol red. pH 7.8  
20x SSC 3 M NaCl, 300 mM sodium citrate; pH 7.0 
5x SDS gel-loading 
buffer 
250 mM Tris-Cl (pH 6.8), 500 mM dithiothreitol 
(DTT), 10% SDS, 0.5% bromophenol blue, 50% 
glycerol 
50x Tris acetate  
EDTA (TAE) 
242 g Tris base, 57.1 mL glacial acetic acid,    
18.6 g EDTA 
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2.2. Cell culture methods 
 
2.2.1. Cell lines 
2.2.1.1. J2-3T3 mouse fibroblast cells 
J2-3T3 cells are immortalised mouse fibroblasts, originally isolated from Swiss 
mouse embryos (Todaro & Green, 1963). Irradiated J2-3T3 cells were used as 
a feeder layer for the growth of NIKS cells. 
 
2.2.1.2. Normal Immortalised Keratinocytes (NIKS) 
Most of the experiments described in this study were carried out using NIKS 
cells. NIKS cells are an HPV-negative, spontaneously immortalised keratinocyte 
cell line, which arose from the serial passage of primary cells isolated from 
neonatal foreskin and designated BC-1-EP (Allen-Hoffmann et al., 2000). 
 
2.2.1.3. 293T and HT1080 cells 
293 cells are human embryonic kidney cells that were transformed using 
adenovirus type 5 DNA (Graham et al., 1977). The 293T cell line is a variant of 
the 293 cell line into which the gene for the SV40 T-antigen has been inserted 
(DuBridge et al., 1987). The HT1080 cell line was derived from a biopsy of a 
fibrosarcoma (Rasheed et al., 1974).  
 
2.2.2. Media and supplements 
The media used for the maintenance of the cell lines as well as for the freezing 
of cells for long-term storage are described in Table 2.2. The supplements used 
in cell culture media were prepared as 1000x stocks and filter-sterilised using a 
0.2 µm filter unit. The supplements were frozen at -20 ºC.  
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Table 2.2: Cell culture media and freeze media 
Cell type Medium type  Medium components 
NIKS F-medium  375 ml F12-Ham’s (PAA; E15-817), 125 ml high 
glucose DMEM (PAA; E15-843), 5% (v/v) FBS 
(Hyclone; CH30160.03), 5 ml pen/strep (Sigma; 
P0781), 24 µg/ml adenine (Sigma; A2786),     
8.4 ng/ml cholera toxin (Sigma; C8052), 5 µg/ml 
insulin (Sigma; I4011) and 0.4 µg/ml 
hydrocortisone (Sigma; H0888). Epidermal 
Growth Factor (EGF) was added to the medium 
immediately prior to use at a concentration of   
10 ng/ml (Sigma; E9644) 
NIKS F - freeze 
medium 
80% v/v F-medium, 10% v/v FBS, 10% v/v 
DMSO (Sigma; D2650) 
J2-3T3, 
293T, 
HT1080 
10% DMEM 500 ml high glucose DMEM, 10% v/v FBS and   
5 ml pen/strep  
J2-3T3 3T3 - freeze 
medium 
42% v/v 10% DMEM, 50% v/v FBS and 8% v/v 
DMSO 
293T 293T - freeze 
medium 
40% v/v 10% DMEM, 50% v/v FBS and 10% v/v 
DMSO 
 
2.2.3. Maintenance of monolayer cells 
All cells were cultured at 37 oC and 5% CO2.  
 
2.2.3.1. J2-3T3, 293T, HT1080  
J2-3T3 cells were cultured in 140 mm plates (NUNC; 168381). 293T and 
HT1080 cells were cultured in 90 mm plates (NUNC; 150350). All cell lines were 
split twice a week at a ratio of 1:20 for J2-3T3 and 293T cells and 1:10 for 
HT1080 cells. To harvest, the cells were washed once with trypsin-versene and 
then incubated with trypsin-versene for 1 minute at 37 oC. Medium was then 
added and an aliquot of the cells was transferred to a new plate.  
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2.2.3.2. NIKS 
The NIKS cells (and NIKS containing HPV or NIKS-LXSN cells) were cultured 
on a layer of γ–irradiated J2-3T3 cells (feeder cells). Prior to splitting the NIKS 
cells, J2-3T3 cells were irradiated at a dose of 60 Grays using a Caesium 
source. Feeder cells were plated on 90 mm plates (1.8 x 106 per plate) in 10 ml 
F-medium and left to attach for 1-2 hours at which point the NIKS cells were 
plated over them. The NIKS cells were split 1:5 twice a week. For harvesting, 
NIKS cells were washed twice with trypsin-versene and then incubated in 3 ml 
trypsin-versene at 37 oC for 2 minutes, in order to remove the feeder layer. The 
keratinocytes were then incubated in 3 ml trypsin-versene at 37 oC for 5-10 
minutes. When the cells detached from the plate, 5 ml F-medium was added 
and they were centrifuged at 240 x g for 4 minutes. The cells were re-
suspended in F-medium and an appropriate amount was plated over the feeder 
layer.  
 
2.2.4. Long-term storage of cells 
For long-term storage, a confluent layer of cells was harvested as above, 
pelleted at 240 x g for 4 minutes, re-suspended in 1 ml freeze medium (see 
Table 2.2) and transferred to a cryogenic vial (NUNC; 366656). The vials were 
stored at -80 oC overnight and then transferred to liquid nitrogen.  
 
2.2.5. Transfection of cells 
For transient transfections, the cells were plated 1 day prior to the transfection. 
NIKS cells were harvested as above and plated on 6-well plates (NUNC; 
140675) at a density of 5.5 x 105 per well and over a layer of 1 x 105 feeder 
cells. 293T cells were harvested as above and plated at a density of 6.5 x 105 
per well. Transfections of NIKS cells were carried out using the Effectene® 
Transfection Reagent Kit (QIAGEN; 301425) following the manufacturer’s 
instructions. Cells were transfected with a total of 1 µg of DNA, which was 
purified using the QIAGEN® Plasmid Midi Kit (QIAGEN; 12143) or the QIAGEN® 
Plasmid Maxi Kit (QIAGEN; 12162). For experiments in which the transfection 
efficiency was assessed, the transfection mix was “spiked” with 50 ng of the β-
galactosidase- (β-gal) expressing plasmid, pMV10. The transfection mix was left 
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on the cells for 7 hours. The cells were then washed once and fresh medium 
was applied. Transfections of 293T and HT1080 cells were carried out in the 
same way as described in section 2.5.2 for the Phoenix cells. 
 
2.2.6. Treatment with proteasome inhibitor 
At 46 hours post-transfection, cells were treated with either 40 µM MG-132 
(Sigma; C2211) or DMSO in a total volume of 2 ml of medium for 2 hours. Cells 
were then harvested for protein analysis as described in section 2.9.1. 
 
2.2.7. Treatment with cycloheximide 
At 46 hours post-transfection, cells were treated with either 50 µg/ml 
cycloheximide (Sigma; C4859) or DMSO in a total volume of 2 ml of medium, 
for 60 or 120 minutes. Cells were then harvested for protein analysis as 
described in section 2.9.1. Cells that were not treated with the drug were also 
harvested to serve as the “0 minutes” time-point. 
 
2.3. Persistence assays 
 
2.3.1. Setting-up the population experiments 
For population experiments, NIKS cells were plated on 6-well plates 1 day prior 
to the transfection and at a density of 5 x 105 per well on a layer of 1 x 105 
feeder cells. The transfection was carried out as described in section 2.2.5. The 
cells were transfected with 800 ng of re-circularised HPV16 genome (prepared 
as described in section 2.8.2) and 200 ng pcDNA6 plasmid, which carries a 
blasticidin-resistance gene). The following day, one quarter of the transfected 
cells were plated on a 90 mm plate with 1.8 x 106 feeder cells and the remaining 
three quarters was plated on another plate with 1.8 x 106 blasticidin-resistant 
feeder cells. The following day, DNA was extracted from the one quarter of the 
transfected cells. This was used in a qPCR assay (described in section 2.8.9), 
to determine the number of HPV copies that entered the cells during 
transfection and this was used as a measurement of the transfection efficiency. 
The plate with the three quarters of transfected cells was treated with 8 µg/ml 
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blasticidin antibiotic (Invitrogen; R210-01). A control plate of un-transfected cells 
was also given the same treatment with blasticidin and was used to determine 
the end-point of the antibiotic-treatment. The treatment lasted 3-6 days with a 
change of medium and antibiotics every 2 days. When all control cells were 
dead, the surviving transfected cells were trypsinised and plated onto a new 90 
mm plate with 1.8 x 106 feeder cells. The new plate was labelled “passage 1” 
(p1). 
 
2.3.2. Passing cells for long-term analysis 
After passage 1 the cells were split 1:5 - 1:6 twice a week. When possible, the 
cells were allowed to reach confluence before splitting them. Each time the cells 
were passed to new plates, genomic DNA was extracted from the remaining 
cells using the method described in section 2.8.6. The DNA was always 
extracted fresh on the day the cells were harvested. The cells were passed in 
this way for several passages, depending on the experiment. 
 
2.3.3. Setting-up the clonal experiments 
The plating and transfection of the NIKS cells for clonal experiments is the 
same as for the population experiments described in section 2.3.1. In the clonal 
experiments however, the cells were trypsinised 48 hours post-transfection and 
counted. An equal number of cells from the different transfections, 
approximately one quarter of the total number of cells, was then divided into ten 
90 mm plates each with 1.8 x 106 blasticidin-resistant feeder cells. (i.e. 
approximately one fortieth of the total number of transfected cells was plated in 
each plate). The following day, the cells were treated with blasticidin at a 
concentration of 8 µg/ml. As with the population experiments, this treatment was 
continued until the control cells were dead (3-6 days) with medium changes 
every 2 days. At the end of the antibiotic selection, new medium was added to 
the cells (without blasticidin). One million new feeder cells were also added to 
replenish any feeder cells lost during the selection. The cells were left to grow 
with medium changes every 2 days, until individual clones became visible and 
large enough to pick. This process took 2-3 weeks.   
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2.3.4. Picking individual clones 
When the clones were large enough on the 90 mm plates, they were transferred 
individually into 6-well plates, one clone per well, with 3 x 105 feeder cells. To 
pick the clones, the medium was aspirated off the plate and the plate was 
washed twice with trypsin. The clone was then outlined with the aspirator and 
trypsin was pipetted directly onto the clone. Clones to be picked were chosen 
based on how isolated they were, so as to avoid mixing two or more clones 
together. No more than 7 clones were picked from each 90 mm plate so as to 
avoid the drying of the cells. Figure 2.1 shows a clonal plate that was stained 
with methylene blue solution (1% methylene blue in 50% methanol and 50% 
PBS).  
 
 
 
 
 
 
 
 
Figure 2.1: Methylene blue staining of plate from clonal experiment 
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2.3.5. Growing clones and harvesting for analysis 
When the clones became confluent in the 6-well plates, they were trypsinised 
and passed on to a 90 mm plate (one clone per 90 mm plate) with 1.8 x 106 
feeder cells. The clones were left on the 90 mm plates until they became 
confluent at which point they were harvested and divided into 2 samples. One 
sample was frozen (as described in section 2.2.4) while the other sample was 
used for DNA extraction.  
 
2.4. Transient replication assay 
The method for the transient replication assays was modified from a previously 
described protocol (Taylor & Morgan, 2003). Briefly, NIKS cells (5.5 x 105) were 
seeded onto feeder cells (1 x 105) and transfected the following day with 
equimolar amounts of re-circularised wild-type or mutant HPV16 DNA (1 µg) or 
pET-28 plasmid carrying the E1^E4 cDNA (700 ng, plus 300 ng of pMV11 
plasmid), made by Dr. Pauline McIntosh (NIMR, London) and described in 
McIntosh et al., 2008. Four days post-transfection the cells were trypsinized and 
re-suspended in 0.5 ml PBS at a concentration of 1.8 x 106 cells/ml. Episomal 
DNA was extracted as previously described (Hoffmann et al., 2006). Following 
ethanol precipitation, 3 µl of DNA were digested with Dpn I for 3 hours, and then 
Exonuclease III for 30 minutes, followed by enzyme inactivation at 70 oC for 30 
minutes. Another 3 µl of DNA were treated in the same way, but without any 
enzyme, and these represent the undigested samples. Numbers of E4 copies 
were measured in both Dpn I-digested and undigested samples by qPCR (as 
described in section 2.8.9), using primers against the E4 ORF of HPV16 (Table 
2.8). The former was divided by the latter to give the percentage of replication. 
 
2.5. Retroviral expression system 
A retroviral expression system was used for the stable expression of E6 protein 
or E6 and E7 proteins in NIKS cells, or for the delivery of shRNA constructs. 
This system utilises Phoenix cells, a 293T-based cell line which is capable of 
producing the gag-pol and envelope proteins for amphotropic viruses.   
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2.5.1. Culture of Phoenix cells  
The Phoenix cells were kindly provided by Dr. Garry Nolan (Stanford University, 
Stanford). These cells were cultured in the same way as 293T cells (see section 
2.2.3.1). Phoenix cells were plated in 90 mm plates 1 day prior to transfection at 
a density of 6.5 x 106 cells per plate.  
 
2.5.2. Transfection of Phoenix cells and harvesting of retroviruses 
Phoenix cells were transfected using polyethylinimine (PEI). The medium was 
first removed from the cells and 5 ml of high glucose DMEM without any FBS or 
antibiotics (plain DMEM) was added to the cells. Two mixtures were then 
prepared: A) 655 µl plain DMEM + 45 µl PEI (1 mg/ml) and B) 15 µg plasmid 
DNA (pLXSN  or pRETROSuper plasmids) topped up to 700 µl with plain 
DMEM. Mixtures A and B were combined, vortexed and incubated at room 
temperature for 15-30 minutes. The medium was then removed from the cells, 
3.6 ml of plain DMEM was added to the A + B mixture, and this was added to 
the cells. The transfection mix was left on the cells for 7 hours. The cells were 
then washed once and the medium was replaced with 10 ml 10% DMEM. The 
medium was changed again the following day. At 48 hours post-transfection, 
the medium, which contains retroviruses, was collected and centrifuged at    
240 x g for 4 minutes. The supernatant was collected and 1 ml aliquots were 
either used directly to infect NIKS cells or stored at -80 ºC.  
 
2.5.3. Infection of NIKS and NIKS + HPV16 cells 
NIKS cells were plated 1 day prior to infection, at a density of 5 x 105 per well 
with 1 x 105 feeder cells in 6-well plates. For infection, 1 ml of virus medium was 
mixed with 3 ml plain F12-Ham’s medium (without FBS or antibiotics), with 
supplements in the concentrations described in Table 2.2 for the F-medium. 
Polybrene was also added at a final concentration of 10 µg/ml. The existing 
medium on the cells was replaced with the virus mixture and the cells were 
incubated at 37 ºC for 7 hours, at which point the cells were washed once and 
the medium was replaced with F-medium. The following day the cells were 
passed from the 6-well plates to 90 mm plates with 1.8 x 106 antibiotic-resistant 
feeder cells, and the day after they were treated with neomycin at a 
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concentration of 300 µg/ml (for the infections with LXSN retroviruses) or 
puromycin at a concentration of 1 µg/ml (for the infections with shp53 and 
shScrib retroviruses). This treatment was continued until the control plate 
(uninfected cells) was completely dead (3-6 days), with a medium change every 
2 days.  
 
2.6. Monolayer growth assays  
 
2.6.1. Seeding cells for growth assays 
For the growth assays the cells were plated in 6-well plates. Three wells were 
set up for each cell type and each time-point, in order to obtain triplicate cell 
counts for each time-point. The feeder cells were first plated in each well and 
allowed to attach (3 x 105 per well). The keratinocytes were then trypsinised and 
counted and 1 x 105 cells were plated over the feeder cells. At this point the 
cells were plated in F-medium without any EGF. The day of plating was denoted 
as “day 0”. The following day, the cells were counted for time-point “day 1”. The 
medium was replaced on all the remaining wells with F-medium containing 
EGF. From that point onwards, the medium was changed every 2 days and the 
new medium always contained EGF.   
 
2.6.2. Counting cells for growth assays 
The cells were harvested for counting on days 1, 3, 4, 5 and 7. For harvesting, 
each well was first washed with 2 ml of warm PBS, followed by 1 ml of trypsin. 
To dislodge the feeder cells, 0.5 ml of trypsin was added to each well, and the 
cells were incubated at 37 ºC for 2 minutes. The trypsin was then aspirated and 
the well was washed with PBS to ensure the removal of the feeder cells. To 
remove the keratinocytes, 1 ml of trypsin was added and the cells were 
incubated at 37 ºC for a further 3–5 minutes. To count the cells, 1 ml of medium 
was added to the cells and 0.5 ml of the mix was used for counting on a 
Beckman Coulter Z1 Coulter® Particle Counter.  
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2.7. Generating p53- and hScrib-knockdown cells 
NIKS or NIKS + HPV16 cells were infected with retroviruses carrying shRNA 
constructs against p53, hScrib or a Scrambled sequence (shScramble) as 
described in section 2.5.3.  Following selection with puromycin, the cells were 
passed onto new plates. Once the cells had recovered, they were harvested for 
protein analysis or frozen for future use. Two shRNA constructs were used to 
knock-down hScrib in NIKS cells. These were kindly provided by Dr. Patrick 
Humbert. They are labelled shScrib 1 and 2 in this study and refer to shScrib 
constructs 6 and 7 respectively in Dow et al, 2007 (Dow et al., 2007).  
 
2.8. DNA and RNA techniques 
 
2.8.1. DNA constructs used 
Table 2.3: List of plasmids used in this study 
Name of plasmid Use Reference and/or source 
pSPW12 Plasmid used in 
generating  re-
circularised HPV16 
genomes 
Kindly provided by Dr. 
Margaret Stanley 
(University of Cambridge, 
Cambridge) 
pSPW12E6p53m 
and 
pSPW12E6PDZ 
Plasmids used in 
generating  re-
circularised mutant 
HPV16 genomes 
Made by site-directed 
mutagenesis as described 
in section 2.8.5 
pcDNA6  Used for the expression 
of the blasticidin-
resistance gene 
(Laurson et al., 2010) 
pLXSN, pLXSN-
E6WT and pLXSN-
E6WT/7  
Retrovirus vectors used 
for the stable expression 
of HPV16 E6 and E7 
proteins 
Kindly provided by Dr. 
Denise Galloway (Fred 
Hutchinson Cancer 
Research Center, Seattle) 
(Halbert et al., 1991) 
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pLXSN-E6p53m 
and pLXSN-E6PDZ 
Retrovirus vectors used 
for the stable expression 
of HPV16 E6SAT and 
E6PDZ proteins 
Made by site-directed 
mutagenesis as described 
in section 2.8.5 
pMV11-E6WT, 
pMV11-E6p53m 
and pMV11-E6PDZ 
Used for the transient 
expression of wild-type 
and mutant HPV16 E6 
proteins 
Made by cloning the E6 
ORF in the pMV11 plasmid 
as described in section 
2.8.8 
pRETROSuper-
shScrib 1 and 2 
and 
pRETROSuper-
shScramble 
Used for knocking-down 
hScrib protein 
Kindly provided by Dr. 
Patrick Humbert (Peter 
MacCallum Cancer Centre, 
Melbourne). The shScrib 
constructs 1 and 2 
correspond to shScrib 6 and 
7 respectively (Dow et al., 
2007; Dow et al., 2008) 
pRETROSuper-
shp53 
Used for knocking-down 
p53 protein 
(Brummelkamp et al., 2002) 
pET-28 Used in transient 
replication assay. 
Carries 16E1^E4 cDNA 
Made by Dr. Pauline 
McIntosh (McIntosh et al., 
2008) 
pMV10 Used for the expression 
of β-gal protein 
(Forrester et al., 1992) 
pcDNA-HA-hScrib Used for the transient 
expression of HA-hScrib 
protein 
Kindly provided by Dr. 
Lawrence Banks (ICGEB, 
Trieste) (Thomas et al., 
2005) 
pcDNA-HA-
hScrib∆PDZ 
Used for the transient 
expression of HA-hScrib 
protein that lacks the 
PDZ domains 
Kindly provided by Dr. 
Lawrence Banks (Thomas 
et al., 2005) 
pGWI-HA-Dlg Used for the transient 
expression of HA-Dlg 
protein 
Kindly provided by Dr. 
Lawrence Banks (Gardiol et 
al., 1999) 
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pGWI-HA-11E6 Used for the transient 
expression of HPV11 E6 
Kindly provided by Dr. 
Lawrence Banks 
(Glaunsinger et al., 2000) 
pcDNA-FLAG-
MAGI-1c 
Used for the transient 
expression of FLAG-
MAGI-1c protein 
Kindly provided by Dr. 
Lawrence Banks 
(Glaunsinger et al., 2000) 
pCI-EGFP Used for the expression 
of GFP  
(Tuting et al., 1999) 
 
2.8.2. Preparation of re-circularised DNA 
The HPV16 genome used to transfect cells was obtained by digesting the 
HPV16 DNA out of the pSPW12 plasmid and re-circularising it. The PB, PE and 
EB buffers as well as the QIAprep spin columns mentioned in this section are all 
included in the QIAprep® Spin Miniprep Kit (QIAGEN; 27106). The re-
circularisation was carried out by first digesting 5 µg of pSPW12 plasmid with    
2 µl BamH I enzyme in a total volume of 30 µl for 2.5 hours at 37 oC. The 
enzyme was then deactivated by incubating the mix at 85 oC for 20 minutes. 
The ligation reaction was carried out in a 16 oC water-bath overnight and was 
set up as shown in Table 2.4. To purify and concentrate the re-circularised 
DNA, the ligation reaction was mixed with 10 ml PB buffer and then put through 
a QIAprep spin column. The column was then washed once with 750 µl PE 
solution and the DNA was eluted in 50 µl EB buffer. The quality of the re-
circularised DNA was determined by running 3 µl of the DNA on an agarose gel. 
The re-circularised preps were considered to be of high enough quality if the 
band representing the HPV16 genome was the strongest band on the gel. 
Figure 2.2 shows a picture of one such gel. 
 
Table 2.4: Set-up of the ligation reaction to 
prepare re-circularised HPV16 genomes 
Digested DNA                                               30 µl 
Water                                                        1765 µl 
10x T4 DNA ligase buffer                           200 µl 
T4 DNA Ligase (NEB; MO202S)                    5 µl 
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Figure 2.2: Agarose gel showing quality of re-circularised HPV16 genomes 
The re-circularised and purified DNA was analysed on a 1% agarose gel to 
check its quality. The band representing the re-circularised HPV16 genomes is 
indicated by the arrow. The other bands represent other re-circularised species 
present in the mix, such as re-circularised pSP plasmid (the smallest band) or 
multimeric species (the largest bands). The supercoiled marker is indicated (M) 
and the three lanes (1, 2 and 3) correspond to re-circularised 16WT, 16E6p53m 
and 16E6PDZ genomes respectively, from one such experiment. 
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2.8.3. Transformation of E. coli with DNA 
Plasmid DNA was transformed into competent XL1-Blue cells (grown and made 
competent by Rachel Chung at the NIMR). Plasmid DNA was mixed with 50 µl 
of competent cells and incubated on ice for 30 minutes before heat-pulsing at 
42 oC for 90 seconds. The cells were then cooled on ice and 800 µl of SOC 
medium was added and the cells were incubated at 37 oC for 45 minutes with 
constant shaking. Transformed cells were plated on LB agar plates containing 
ampicillin (100 µg/ml) and incubated overnight at 37 oC.  
 
2.8.4. Plasmid purification 
Three commercial kits were used for plasmid purification, depending on the 
amount of purified plasmid needed. The QIAprep® Spin Miniprep Kit (QIAGEN; 
27106) was used for small-scale preps, from 2–5 ml of bacterial cultures. The 
QIAGEN® Plasmid Midi Kit (QIAGEN; 12143) and the QIAGEN® Plasmid Maxi 
Kit (QIAGEN; 12162) were used for larger-scale preps, from 100 ml and 500 ml 
of bacterial cultures respectively. The purification was carried out according to 
the manufacturer’s instructions. Plasmid DNA was quantified using a Nanodrop 
ND-1000 Spectrophotometer. 
 
2.8.5. Site-directed mutagenesis  
For the purpose of this study, it was necessary to introduce the E6STOP, 
E6p53m and E6PDZ mutations into several plasmids. This was done by site-
directed mutagenesis. The primers used to introduce these mutations are 
shown in Table 2.5.  The mutagenesis reaction was carried out in a total volume 
of 50 µl, by adding 0.2 mM dNTPs, 1x Pfu Ultra Buffer, 0.2 mM of forward or 
reverse primer (individual PCR reactions were set up for each of the two 
primers), 0.15 µg template plasmid and 1 µl Pfu Ultra enzyme (Stratagene; 
600380). The conditions of the PCR reaction are outlined in Table 2.6. The 
template plasmids mutagenised in this way were pSPW12, pLXSN-E6WT and 
pLXSN-E6WT/7. Following the individual PCR reactions, 25µl of each of the 
forward and reverse PCR reactions were combined, 1 µl Pfu Ultra enzyme was 
added and an additional PCR reaction was carried out as shown in Table 2.6 
but with 18 repeats of steps 2–4 instead of 4 repeats. Following this, the 
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template DNA was removed by incubation with 10 U of DpnI (NEB; R0176S) at 
37 oC for 2 hours and 2 µl of this reaction were transformed into XL1-Blue 
bacteria.  
 
Table 2.5: Primers used for site-directed mutagenesis 
E6STOP 
mutation 
Forward: ATGTTTCAGGACCCATAGGAGCGACCCAGAAAG     
Reverse: CTTTCTGGGTCGCTCCTATGGGTCCTGAAACAT 
E6p53m 
mutation 
Forward: 
GCAATGTTTCAGGACCCACAGGAGAGCGCCACAAA 
GTTACCACAGTTATGCACAGAGCTGC 
Reverse: 
GCAGCTCTGTGCATAACTGTGGTAACTTTGTGGCGCT 
CTCCTGTGGGTCCTGAAACATTGC 
E6PDZ 
mutation 
Forward:  
GCAGATCATCAAGAACACGTAGATAAACCCAGCTGTA 
ATCATGCATGG 
Reverse: 
CCATGCATGATTACAGCTGGGTTTATCTACGTGTTCT 
TGATGATCTGC 
 
 
Table 2.6: PCR conditions for site-directed 
mutagenesis 
1) 94oC for 30 seconds 
2) 95oC for 30 seconds 
3) 55oC for 1 minute 
4) 68oC for 18 minutes 
Repeat steps 2–4 four times  
 
2.8.6. Extraction of total genomic DNA 
For the extraction of genomic DNA, cell pellets were first re-suspended in 200 µl 
PBS with 2 mg/ml RNase A (Sigma; R5500) and incubated at 37 oC for 5 
minutes to remove RNA. DNA was then extracted from cells using the QIAamp® 
DNA Mini Kit (QIAGEN; 51306) following the instructions for the Blood and 
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Body Fluid Spin Protocol. Genomic DNA was quantified using a Nanodrop ND-
1000 Spectrophotometer.  
 
2.8.7. Agarose gel electrophoresis 
To check the presence and quality of plasmid DNA, genomic DNA or PCR 
products, the DNA was separated on a 1% agarose gel (1% w/v agarose in 
TAE) containing 0.5 µg/ml Ethidium Bromide.  
 
2.8.8. Cloning of pMV11-E6 plasmids 
For the purpose of this study, the wild-type and mutant E6 ORFs were cloned 
into the pMV11 plasmid, downstream of the cytomegalovirus (CMV) promoter. 
The pSPW12, pSPW12E6p53m and pSPW12E6PDZ plasmids served as 
templates for the amplification of the respective E6 ORFs. The primers used to 
amplify the E6 ORFs are shown in Table 2.7. The forward primer had a BamH I 
restriction site whilst the reverse primers had an EcoR I restriction site. The E6 
ORFs were amplified by PCR, and the PCR products were first purified using 
the QIAquick® PCR Purification kit (QIAGEN; 28104) and then digested over-
night with BamH I and EcoR I restriction enzymes. The pMV11 plasmid was 
also digested with BamH I and EcoR I restriction enzymes. The digestion 
mixtures were then separated on an agarose gel and the bands were excised 
and purified using the QIAquick® Gel Extraction kit (QIAGEN; 28704). For the 
ligation reaction, the vector and inserts were mixed in a ratio of 1:5 and 
incubated with T4 DNA ligase and T4 DNA ligase buffer (NEB; MO202S) in a 
total volume of 10 µl for 6 hours at room temperature and 5 µl of the ligation 
reaction were then transformed into XL1-Blue bacteria as described in section 
2.8.3. 
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Table 2.7: Primers used for the cloning of wild-type and mutant E6 
ORFs into the pMV11 plasmid 
pMV11-
E6WT and 
pMV11-
E6p53m 
Forward: 
GCTGGGATCCATGCACCAAAAGAGAACTGCAATG 
Reverse: 
AGGCGAATTCTTACAGCTGGGTTTCTCTACGTGTTC 
pMV11-
E6PDZ 
Forward: 
GCTGGGATCCATGCACCAAAAGAGAACTGCAATG 
Reverse: 
AGGCGAATTCTTACAGCTGGGTTTATCTACGTGTTC 
 
2.8.9. Quantitative PCR (qPCR) 
Quantitative PCR was carried out on genomic DNA, cDNA or plasmid DNA, 
depending on the assay. When genomic DNA was used as a template, primers 
detecting part of the E4 ORF were used to detect the presence of HPV16 DNA. 
In this case GAPDH was used as a control. When cDNA was used as a 
template, primers that amplify part of the E6 ORF were used to detect the 
presence of E6 transcripts and primers against β-actin were used as a control. 
The E6 primers used will only detect full-length E6 transcripts, and will not 
detect the spliced variants. A list of the primers used in qPCR is shown in Table 
2.8. Figure 2.3 shows the location of the E6 qPCR primers on the E6 ORF.  
 
Table 2.8: Primers used for qPCR 
E4 primers Forward: GACTATCCAGCGACCAAGATCAG  
Reverse: CTGAGTCTCTGTGCAACAACTTAGTG 
GAPDH primers Forward: CGAGATCCCTCCAAAATCAA 
Reverse: CATGAGTCCTTCCACGATACCAA 
E6 primers Forward: AGCGACCCAGAAAGTTACCA 
Reverse: GCATAAATCCCGAAAAGCAA 
β-actin primers 
 
Forward: TGGGCATGGGTCAGAAGGAT 
Reverse: CGGCCAGAGGCGTACAGGGA 
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Figure 2.3: Sequence of HPV16 E6 ORF showing location of qPCR primers 
The DNA sequence of the E6 ORF of HPV16 (GeneBank accession number: 
AF125673, region: 83-559). The forward (FOR) and reverse (REV) qPCR 
primers used to amplify E6 transcripts are indicated, as are the splice donor 
(SD) and splice acceptor (SA) sites.   
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2.8.9.1. Reagent cocktails and cycle parameters  
For qPCR, the ABsolute™ QPCR SYBR® Green ROX mix was used to amplify 
and detect the DNA (ABgene; Ab-1163/a). The samples were first plated in 96-
well plates and these were read using an ABIPrism 7000 Sequence Detection 
System (Applied Biosystems). Prior to each qPCR analysis, a fresh master mix 
was prepared containing 1x SYBRgreen ROX mix and 70 nM of each primer. A 
separate master mix was prepared for each primer set. To set up the reaction,  
75 ng of template (3 µl total) was first pipetted into each well followed by 22 µl 
of the master mix. Each sample was amplified in triplicate for each primer set 
(i.e. 6 wells per sample). The cycle parameters for the qPCR are outlined in 
Table 2.9. The parameters include a dissociation programme at the end of the 
amplification steps. This was set up due to the fact that SYBRgreen can also 
bind to unspecific double stranded DNA, such as primer-dimers, and this 
unspecific binding can interfere with the results. From the dissociation curve 
obtained, the detection of single or multiple products can be determined.    
 
 
 
 
 
2.8.9.2. Standard Curves 
For each set of qPCR primers used in this study, a standard curve was 
generated in order to establish the sensitivity and efficiency of the primers. To 
generate each standard curve, a DNA plasmid containing the sequence that is 
amplified by the primers was chosen as a template. For example, to generate a 
standard curve for the E4 primers, the pSPW12 plasmid was used as a 
Table 2.9a: qPCR cycle parameters 
1) 50oC for 2 minutes                  x1 
2) 95oC for 15 minutes                x1 
3) 95oC for 15 seconds               x40 
    60oC for 1 minutes       
Table 2.9b: Dissociation parameters 
1) 95oC for 15 seconds               x1 
2) 60oC for 20 seconds               x1 
3) 95oC for 95 seconds               x1 
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template. Serial dilutions of the plasmid were prepared, starting from 60 pg/µl 
down to 0.6 fg/µl. These dilutions served as the template for the qPCR reaction 
and 3 µl of the diluted DNA was plated in triplicate wells. To generate the 
standard curves, the amount of DNA in each dilution sample was first converted 
to the number of DNA molecules in that reaction. To use the E4 primers as an 
example, the number of pSPW12 molecules in the dilution samples ranged from 
1.5 x 107, 1.5 x 102. The logs of these values were then plotted on a graph, 
against the Ct value given by the qPCR machine for each sample, and an 
equation was obtained in the form of y = mx + c. The y-value in these equations 
is the Ct value that the qPCR machine measures. The ideal standard curve 
would have a slope of -3.33 as that would represent an increase of 3.33 Cts for 
every 10-fold dilution of sample. The standard curves generated for each primer 
set are shown in Table 2.10 and were prepared in collaboration with Dr. Ken 
Raj. 
 
Table 2.10: Standard curves for primers used for qPCR 
E4 primers y = -3.39x + 37.29 
GAPDH primers y = -3.473x + 35.932 
E6 primers y = -3.387x + 36.577 
β-actin primers  y = -3.387x + 37.204 
 
2.8.9.3. Determination of copy numbers 
To determine the number of E4 copies in each sample, the y-value from the 
equation was replaced by the Ct value and the equation was solved for x. The 
number of copies is the inverse log of x (i.e. 10^x). The samples to be analysed 
by qPCR were always plated in triplicate wells and three Ct values were 
obtained and the standard deviation determined. When standard deviations 
were greater than 0.3, the reactions were repeated.  
 
For this study, a “number of HPV copies per cell” was often calculated. To do 
this, the number of HPV copies per reaction was first calculated (using the E4 
primers) as was the number of GAPDH copies per reaction (using the GAPDH 
primers). The number of GAPDH copies was then divided by 20 to obtain the 
number of cells in the reaction, as previous work in the laboratory (carried out 
Chapter 2: Materials and Methods 
 80 
by Dr. Ken Raj) had determined that the GAPDH primers recognised 20 copies 
per cell. The number of HPV copies was then divided by the number of cells to 
obtain a “number of HPV copies per cell”.  
 
2.8.10. Southern blot analysis 
Southern blot analysis was carried out on the DNA extracted from the 
population and clonal persistence assays in order to determine the physical 
state of the HPV genomes present in the cells. Southern blots were adjusted for 
brightness and contrast using Photoshop, and a white line is sometimes used to 
denote a portion of the gel that has been cropped.  
 
2.8.10.1. Restriction enzyme digestion and gel electrophoresis 
The cellular DNA used for Southern blotting was extracted as described in 
section 2.8.6. Genomic DNA (6–10 µg) was left undigested or was digested with 
Hind III, BamH I or Xba I overnight at 37 oC. The DNA was then separated on a 
1% agarose gel in TAE with 0.5 µg/ml ethidium bromide. The gel was 
electrophoresed at 100 V.  
 
2.8.10.2. Southern blot transfer 
Before transferring, the gel was washed once with distilled water and then 
soaked in denaturation solution (0.5 N NaOH, 1.5 M NaCl) for 30 minutes. The 
gel was then rinsed with distilled water and soaked in neutralisation solution    
(1 M Tris.Cl pH 8, 1.5 M NaCl) for 30 minutes. A capillary transfer stack in 20X 
SSC was used to transfer the DNA from the gel onto a piece of Millipore 
Immobilon™-NY+ Transfer Membrane (Millipore; INYC00010). The transfer was 
carried out overnight at room temperature. The membrane was then washed 
once in 6x SSC and left to dry completely at room temperature before it was UV 
cross-linked at 5000 µJ/cm2.  
 
2.8.10.3. Probe labelling 
The probe used in all Southern blots was undigested pSPW12 plasmid. The 
probe was labelled with 32P-dCTP using the Amersham™ Ready-To-Go™ DNA 
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Labelling Breads (-CTP) (GE Healthcare; 27-9240-01) following the 
manufacturer’s instructions. Following the labelling reaction, the probe was 
cleaned by passing it through a DyeEx™ column (QIAGEN; 63204). It was then 
denatured and applied to the membrane. 
 
2.8.10.4. Pre-hybridisation, hybridisation, washing and exposure 
Following cross-linking, the membrane was re-hydrated with distilled water. It 
was then rolled up and placed in a tube and pre-hybridised in 10 ml 
hybridisation buffer (5x SSPE, 5x Denhardt’s, 100 µg/ml ssDNA, 0.5% SDS) for 
1–2 hours at 68 oC. In the meantime, the probe was prepared (see section 
2.8.10.3). Denatured probe was then mixed with another 10 ml of hybridisation 
buffer. The hybridisation buffer in the tube was discarded, and was replaced 
with the new 10 ml of buffer containing the denatured probe. The membrane 
was left overnight in a rotating oven at 68 oC. The following day, the 
hybridisation buffer was carefully removed and discarded. The membrane was 
washed twice for 5 minutes at room temperature with 2x SSC, 0.1% SDS. This 
was followed by two 15 minute washes at 68 oC with pre-warmed solution of 
0.2x SSC and 0.1% SDS. The membrane was then exposed using a 
Phosphorimager cassette or X-ray film.  
 
2.8.11. Extraction of total RNA 
For extraction of total RNA, cells were harvested and washed once with PBS. 
Pelleted cells were kept on ice at all times. Total RNA extraction was carried out 
using the RNeasy® Minikit (QIAGEN; 74104) and QIAshredder™ kit (QIAGEN; 
79654) following the manufacturers’ protocol. RNA samples were stored at        
-80 oC. 
 
2.8.12. Reverse transcription 
Prior to carrying out reverse transcription, 4 µg of extracted RNA was cleared of 
any genomic DNA using the DNA-free™ kit (Ambion; AM1906) following the 
manufacturer’s instructions. Clean RNA (5 µl) was then added to a tube 
containing 6 µl nuclease-free H2O and 1 µl random primers (Roche; 
11034731001) or 1 µl Oligo(dT)20 primers (Invitrogen; 18418-020). The mixture 
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was incubated at 70 oC for 10 minutes and immediately transferred to ice for 5 
minutes. Reverse transcription was carried out using the SuperScript™ II 
Reverse Transcriptase kit (Invitrogen; 18064-022). The samples were incubated 
at 42 oC for 1 hour followed by 70 oC for 15 minutes. For each RNA sample a  
“+ reverse transcriptase” (+RT) and a “- reverse transcriptase” (-RT) sample 
were prepared. The +RT samples included 1 µl of the reverse transcriptase in 
the reaction whereas the –RT samples included 1 µl of nuclease-free H2O in the 
reaction. The latter were used as a control for the absence of genomic DNA 
from the samples. 
 
2.9. Protein methods 
 
2.9.1. Cell lysis for western blot analysis 
Keratinocytes were first washed with PBS and incubated at 37oC for 5 minutes 
to remove the feeder layer. They were then scraped off the plates using a cell 
scraper (Corning; 3010) and pelleted. When the RIPA 6% SDS or the Urea 
protein extraction buffers were used, 1 µl of Benzonase® Nuclease (Sigma; 
E1014) was first added to each pellet and the pellet was then re-suspended in 
120 µl–150 µl of the protein extraction buffer. The lysates were boiled at 95 oC 
for 7 minutes and centrifuged at 16100 x g for 5 minutes. The supernatant was 
collected and stored at -80oC. When the RIPA extraction buffer (with no 
additional SDS) was used, the pellets were re-suspended in 120 µl–150 µl of 
buffer and incubated on ice for 20 minutes. They were then centrifuged at 
16100 x g for 10 minutes at 4 oC and the supernatant was collected and stored 
at -80oC. 
 
2.9.2. Protein quantification 
For protein quantification, the DC Protein Assay Kit (Bio-Rad; 500-0111) or the 
Bio-Rad Protein Assay Kit (Bio-Rad; 500-0006) were used following the 
manufacturer’s instructions. Bovine γ-Globulin standards (Bio-Rad; 500-0208) 
were used to make a standard curve. 
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2.9.3. SDS-PAGE 
Following protein quantification, equal amounts of protein were prepared in 5x 
SDS gel-loading buffer, containing DTT (final concentration 100 mM). The 
samples were mixed, boiled at 95 oC for 8 minutes and loaded directly on the 
gel.   
 
2.9.3.1. Preparation of gels 
Different percentage gels were prepared depending on the size of the protein to 
be analysed. Table 2.11 shows the composition of the gels used in this study. 
The resolving gels were prepared first (10 ml per gel) and left to set for 
approximately 30 minutes The stacking gels were then prepared and poured 
over the resolving gel (2 ml per gel). The combs were also put in place and the 
gels were left to polymerise for 30 minutes.  
 
For some experiments, the 16% Novex® Tricine gels from Invitrogen were also 
used, following the manufacturer’s instructions. 
 
Table 2.11: Composition of 6% , 10% or 15% Tris-glycine SDS-
polyacrylamide resolving gels and 5% stacking gel 
Resolving Gels (10 ml) 
H2O  5.3 ml or 4 ml or 2.3 ml 
30% acrylamide mix 2 ml or 3.3 ml or 5 ml 
1.5M Tris (pH 8.8) 2.5 ml 
10% SDS 0.1 ml 
10% ammonium persulphate 0.1 ml 
TEMED 8 µl or 4 µl or 4 µl 
Stacking Gel (2 ml) 
H2O  1.4 ml 
30% acrylamide mix 0.33 ml 
1 M Tris (pH 6.8) 0.25 ml 
10% SDS 0.02 ml 
10% ammonium persulphate 0.02 ml 
TEMED 0.002 ml 
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2.9.3.2. Membrane transfer 
All 15% gels were transferred onto 0.2 µm PVDF membranes (Bio-Rad; 162-
0176). All other gels were transferred on to 0.45 µm PVDF membranes 
(Millipore; IPVH00010). Prior to transferring, the membranes were soaked in 
methanol and then left to soak in transfer buffer for at least 30 minutes. The 
transfer was carried out using the Bio-Rad Trans-Blot SD Semi-Dry Transfer 
Cell, at 20 V for 2 hours.   
 
2.9.3.3. Blocking, antibody incubations and washing 
Following transfer, the membranes were rinsed twice with dH2O and then 
blocked in 5% milk in PBS-0.1% Tween for 1 hour at room temperature or 
overnight at 4 oC. In the case of the anti-DYKDDDDK Tag antibody, the 
membrane was blocked in 5% BSA in PBS-0.1% Tween. The membranes were 
then incubated with primary antibody for 1–2 hours at room temperature or 
overnight at 4 oC. The antibodies were diluted in 5 ml of 5% milk in PBS-0.1% 
Tween and are outlined in Table 2.12. The membranes were washed in PBS-
0.1% Tween with several changes of wash buffer. The amount of washing 
depended on the antibody. When the E6 antibody was used, the membranes 
were washed for at least 1.5 hours with a change of wash buffer every 10 
minutes. The membranes were then incubated with secondary antibody diluted, 
as stated in Table 2.13, in 10 ml of 5% milk in PBS-0.1% Tween for 1–2 hours. 
This was followed by a second round of washing. Table 2.14 outlines the 
different anti-E6 primary antibodies that were tested in an attempt to reduce the 
background of the western blots. 
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Table 2.12: Primary antibodies used for western blotting 
Antibody name Dilution Catalogue number 
p53 (DO-1) 1:2000 (2 hours) Santa Cruz; sc-126 
E6 (2E-3F8) - (C-terminus) 1:1000 (overnight) Euromedex; 2E-3F8 
E6 (1E-6F4) - (N-terminus) 1:1000 (overnight) Euromedex; E6-6F4 
Beta-galactosidase (β-gal) 1:2000 (overnight) Abcam; ab616 
HSP-70 (W-27) 1:2500 (1 hour) Santa Cruz; sc-24 
E7 (NM2) 
E7 (716-325) 
(used together, as a cocktail) 
1:500 each 
(overnight) 
Santa Cruz; sc-
65711 and sc-51951  
HA  1:1000 (overnight) Sigma; H6908 
Scrib (C-20) 1:2000 (2 hours) Santa Cruz; sc-
11049 
DYKDDDDK Tag (FLAG tag) 1:1000 (overnight) Cell Signalling; 2368 
(in 5% BSA) 
Histone H2B 1:600 (1 hour) Upstate; 07-371 
HSP-90α/β (H-114) 1:1000 (1 hour) Santa Cruz; sc-7949 
GFP (B-2) 1:750 (overnight) Santa Cruz; sc-9996 
 
 
Table 2.13: Secondary antibodies used for western blotting 
Antibody name Dilution Catalogue # 
Anti-mouse IgG-HRP (from sheep) 1:2500 GE Healthcare; NA931V 
Anti-mouse IgG-HRP (from rabbit)  1:10000 Pierce; 31450 
Anti-rabbit IgG-HRP (from donkey) 1:5000 GE Healthcare; NA934V 
Anti-goat IgG-HRP (from donkey) 1:5000 Santa Cruz; sc-2020 
 
 
Table 2.14: Additional anti-E6 primary antibodies tried  
Antibody name Catalogue number 
HPV16 E6/18 E6 (C1P5) Santa Cruz; sc-460  
HPV16 E6 (N-17) Santa Cruz; sc-1584 
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2.9.3.4. Signal detection 
To detect the proteins, 1 of 3 ECL kits were used, depending on the level of 
sensitivity needed: the Amersham ECL™ Western Blotting Detection kit (GE 
Healthcare; RPN2106) was used for very abundant proteins, the Immobilon 
Western Chemiluminescent HRP Kit (Millipore; WBKLS0500) was used for 
medium sensititivity (such as the detection of E6) and the Amersham™ ECL 
Advance™ kit (GE Healthcare; RPN2135) was used to detect low levels of 
protein. 
 
2.9.4. Detecting E6 expressed from the HPV16 genome 
 
2.9.4.1. Transfection of cells 
For the detection of E6 expressed from the HPV16 genome, NIKS cells were 
plated 1 day prior to transfection, as described in section 2.2.5. Thirty-five wells 
were prepared for each transfection. The 16WT and 16E6PDZ genomes were 
prepared using the method described in section 2.8.2. and the cells were 
transfected with 800 ng of re-circularised genome and 200 ng of pCI-EGFP 
using the method described in section 2.2.5. Master mixes were prepared for 
the transfection of each genome.  
 
2.9.4.2. Harvesting cells 
Forty-eight hours post-transfection the cells were harvested for cell sorting. The 
medium was first removed from the cells and the cells were washed once in 1x 
DPBS (bought as a 10x stock from PAA; H15-011). DPBS was added to the 
cells (2 ml), and the cells were incubated at 37 oC for 4 minutes in order to allow 
the feeder cells to detach. The cells were washed once more with DPBS and 
1.5 ml of Accutase™ solution (Millipore; SCR005) was added to each well. The 
cells were then placed at 37 oC until all the keratinocytes had detached and 
were in a single-cell suspension. Once the cells were in a single-cell 
suspension, the enzyme was deactivated by addition of F-medium, and the cells 
were centrifuged at 240 x g for 4 minutes. They were then washed once in 
buffer (1x DPBS, 0.5% FBS, 5 mM EDTA) and finally re-suspended in buffer to 
be analysed. Immediately prior to the sorting, the cells were passed through a 
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40 µm cell strainer (BD Biosciences; 352340) to ensure that only single cells will 
be analysed.  
 
2.9.4.3. Cell sorting 
The cells were sorted on a Becton Dickinson FACS ARIA II Cell Sorter and the 
sorting was carried out by Graham Preece at the Flow Cytometry Facility at the 
NIMR. An initial sort using cells that had not been transfected with GFP was 
carried out in order to set the gate for the forward- and side-scatter as well as 
the negative gate for FITC. This was followed by a quick sort using the “16WT + 
pCI-EGFP”-transfected cells in order to set-up the positive gate. To avoid 
getting many GFP-negative cells in the GFP-positive sort, the negative and 
positive gates were set so that there was a gap between them. The purity of 
both the GFP-positive and GFP-negative sorted cells was then checked. The 
cells were collected in a small volume of F-medium. Once all the “16WT + pCI-
EGFP”-transfected cells had been sorted, the same was repeated with the 
“16E6PDZ + pCI-EGFP”-transfected cells. Once both cell populations had been 
sorted, the cells were centrifuged at 240 x g for 4 minutes, washed once with 
PBS and the pellets were frozen at -80 oC. For protein analysis, the cells were 
lysed in RIPA 6% SDS protein extraction buffer, as described in section 2.9.1. 
and the lysates were quantified as described in section 2.9.2. 
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Chapter 3: Investigation of E6 activities necessary for 
episomal persistence  
 
3.1. Introduction  
 
The E6 oncoprotein of high-risk HPVs has been shown to interact with multiple 
cellular proteins, such as E6AP (Huibregtse et al., 1991), p53 (Werness et al., 
1990) and several PDZ proteins (Kiyono et al., 1997; Lee et al., 1997; 
Nakagawa & Huibregtse, 2000). Moreover, many of E6’s activities have been 
characterised, including its ability to degrade p53 (Scheffner et al., 1990) and 
PDZ proteins (Gardiol et al., 1999; Nakagawa & Huibregtse, 2000) as well as its 
ability to activate human telomerase (Klingelhutz et al., 1996). These activities 
interfere with important cellular check-points and induce cellular immortalisation 
and aberrant proliferation, all of which contribute to the accumulation of cellular 
mutations and the induction of genomic instability. Although these activities of 
E6 can contribute to the malignant phenotype that sometimes results from a 
prolonged HPV infection, their role in the viral life-cycle is less clear.  
 
Most HPV infections are cleared, either by the natural physiology of the tissue, 
whereby cells from the bottom layer continuously move up towards the surface 
and are sloughed off, or by immune responses mounted by the host against 
HPV-containing cells (Schiffman & Kjaer, 2003). It is the failure to clear an HPV 
infection, therefore permitting persistence of viral episomes and expression of 
viral genes, that is thought to bring about accumulation of mutations, induction 
of genetic instability and eventual development of cancer (Remmink et al., 
1995; Schiffman & Kjaer, 2003). 
  
Ectopically-introduced DNA, such as plasmids, is not known to persist as un-
integrated extrachromosomal DNA in cells upon successive cell divisions. 
Hence it stands to reason that HPV must actively participate in its successful 
persistence as extrachromosomal DNA in the nucleus of its host cell. Numerous 
studies have attempted to elucidate the nature and extend of HPV’s contribution 
in episomal persistence in the basal layer of the epithelium. In these studies, 
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mutant viral genomes were introduced into monolayer cultures of keratinocytes 
(which are taken to represent the basal layer of the epithelium) and the ability of 
the mutant episomes to persist in the population of cells several weeks post-
transfection was assessed using Southern blotting. These studies have indeed 
yielded some unexpected results. The E6 and E7 genes, which were only 
known to possess oncogenic properties, were both found to be necessary for 
persistence of HPV DNA in primary human foreskin keratinocytes (HFK). That 
this was reportedly the case for both the high-risk type HPV31 (Thomas et al., 
1999) as well as the low-risk type HPV11 (Oh et al., 2004) suggested that it was 
the non-oncogenic properties of E6 and E7 that were needed for episomal 
persistence. However, this notion was challenged by observations made by 
Thomas et al. who demonstrated that HPV31 p53-degradation mutant genomes 
were unable to persist in HFKs (Thomas et al., 1999). Another study supporting 
this observation was carried out using hybrid HPV genomes, in which the E6 
ORF of HPV31 was substituted for that of HPV16 (Park & Androphy, 2002). 
Furthermore, a third study investigated the role of the PDZ-binding motif in 
different aspects of the HPV life-cycle, including episomal persistence, using 
mutant HPV31 genomes and primary HFKs (Lee & Laimins, 2004).  
 
However, several unresolved issues need to be highlighted when considering 
the conclusions from these studies. In all of these studies, primary HFKs were 
used in the persistence assay. This point is significant, as mutations within the  
HPV31 E6 or E7 ORF that disrupt the immortalisation activity of the virus will 
produce a negative result for viral episome persistence as the primary cells will 
not survive indefinitely to sustain the persistence of the viral genomes. Indeed 
Thomas et al. pointed out that the HPV31 p53-degradation mutant genomes 
that reportedly failed to persist, were also incapable of immortalising the 
recipient primary HFKs (Thomas et al., 1999). In the study by Park et al., where 
hybrid genomes were used, it is important to consider that such a strategy is 
susceptible to unintentional effects of the E6 ORF substitution, which may 
impinge on the replication/persistence of the viral episomes. For example, it is 
not known if this substitution has inadvertently interfered with the splicing 
pattern of the HPV transcripts, which can in turn affect the quality and quantity 
of viral proteins in the cells. The fact that HPV16 is associated more frequently 
with cancer than HPV31 (Clifford et al., 2003), as well as observations that the 
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HPV16 E6 protein degrades p53 more efficiently than the HPV31 E6 protein 
(Lee & Laimins, 2004), suggest that the two E6 proteins do in fact have different 
quantitative effects. 
 
Interestingly, the need for E7 in episomal persistence was challenged by a 
study that carried out persistence assays in an immortalised cell line, NIKS, 
instead of in primary HFKs (Flores et al., 2000). NIKS are a spontaneously 
immortalised keratinocyte cell line (Allen-Hoffmann et al., 2000) which has been 
shown to support the HPV life-cycle (Flores et al., 1999). In these cells, HPV16 
E7 was found to be dispensable for the episomal persistence of HPV genomes 
(Flores et al., 2000). This suggests that E7 may have been necessary in the 
previous studies only in so far as to immortalise the cells to allow the 
persistence of viral episomes, rather than because it is directly required for 
persistence itself.  
 
As genome persistence is vital for the development of cancer (Remmink et al., 
1995; Schiffman & Kjaer, 2003), it is important to take a closer look at the viral 
requirements that drive this process. Previous work in the laboratory, carried out 
by Dr. Ken Raj, focused on identifying which viral proteins are necessary for the 
episomal persistence of HPV16. HPV16 was chosen as it is the most important 
type from a medical perspective, and no study had looked at how these 
episomes persist in cells in detail before. NIKS cells were chosen so as to be 
able to identify proteins that are necessary for persistence alone, without the 
need for cellular immortalisation interfering with the results. Furthermore, unlike 
primary cells, NIKS provide an isogenic cell background for all the experiments. 
Persistence was measured by the number of HPV-positive clones that could be 
isolated from the transfection of the HPV genomes into the cells, as was 
determined by quantitative PCR (qPCR). This method differs from previous 
studies in two respects: firstly, qPCR is more sensitive than Southern blotting 
and secondly, the cellular cloning method allowed for the analysis of mutations 
that may have otherwise conferred a growth disadvantage to the cells. These 
cells would have potentially been lost from the population, giving the false 
impression that the mutation had a direct effect on episomal persistence. 
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As part of this work, mutant HPV16 genomes were generated, each with a 
STOP codon inserted in a different ORF. The results from this study showed 
that E7 was dispensable for episomal persistence (Laurson et al., 2010), 
thereby confirming the results from the Flores et al. study (Flores et al., 2000), 
as were E4 and E5 (Ken Raj, unpublished data). On the other hand, E1, E2 and 
E6 were found to be necessary for episomal persistence (Laurson et al., 2010; 
and Ken Raj, unpublished data). The need for E1 and E2 was clear, as these 
are the viral replication proteins. However, the role of E6 in episomal 
persistence is less apparent. 
 
The aim of the investigation described in this chapter is to determine which 
activities of the E6 protein are necessary for the persistence of HPV16 
episomes in NIKS cells. Two of the best characterised activities of E6, 1) 
degradation of p53 and 2) binding to PDZ proteins, will be dissected and 
analysed for their role in episomal persistence. I will assess persistence both 
quantitatively by qPCR, as well as qualitatively, using Southern blotting, to 
determine whether the viral genomes persist episomally, are absent or are 
integrated into the host cell’s DNA.       
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3.2. Results 
 
3.2.1. Three different mutations of the E6 ORF are introduced into the 
HPV16 genome 
To investigate the role of the p53-degradation and PDZ-binding activities of E6 
in episomal persistence, I constructed mutants of the HPV16 genome, with 
different mutations in the E6 ORF. Three different mutant genomes were made; 
the first has a one base-pair change which introduces a premature STOP codon 
in the E6 ORF, and was denoted 16E6STOP. The second has a three amino 
acid substitution mutation, which abolishes E6’s ability to degrade p53 (Kiyono 
et al., 1998; Klingelhutz et al., 1996). This mutant was denoted 16E6p53m. The 
third has a four amino acid deletion on the extreme C-terminus of E6, which 
corresponds to the protein’s PDZ-binding motif (Kiyono et al., 1997; Lee et al., 
1997). This mutant was denoted 16E6PDZ. The mutations are shown in the 
context of the E6 ORF in Figure 3.1 and outlined in Table 3.1. 
 
The p53-degradation and PDZ-binding mutations have been previously used in 
the literature and have been well characterised. Table 3.2 lists publications in 
which these two mutants have been used. Most PDZ-binding mutations of E6 in 
the literature have been either six amino acid deletions or single amino acid 
deletions/substitutions. The E6 mutation used in this study is a four amino acid 
deletion, which corresponds to the exact PDZ-binding motif (Kiyono et al., 1997; 
Lee et al., 1997). It should also be noted that most of the available data 
regarding mutations of E6 have been obtained from studies in which E6 was 
over-expressed in cells. Very little information is available with regards to the 
activities of these mutant E6 proteins when they are expressed in the context of 
the whole HPV genome. 
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Figure 3.1: Sequence of HPV16 E6 ORF highlighting introduced mutations 
The DNA sequence of the E6 ORF of HPV16 (GeneBank accession number: 
AF125673, region: 83-559). The regions that have been mutated for this study 
are shown in boxes. The splice donor (SD) and splice acceptor (SA) sites are 
also indicated.   
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Table 3.1: Outline of the base-pair mutations introduced into the E6 
ORF and the resulting amino-acid mutations 
 
Base-pair mutation Amino-acid mutation 
E6STOP cag   to     
tag 
Introduction of STOP 
codon: 
Q to STOP codon 
E6p53m cgacccag   to  
agcgccac 
Three amino acid 
substitution: 
RPR to SAT 
E6PDZ gaaacccagctgtaa   
to  
taaacccagctgtaa 
Four amino acid deletion: 
ETQL to STOP codon 
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Table 3.2: Summary of the information available in the literature about 
the E6 mutants used in this study 
 E6p53m (or E6SAT) E6PDZ 
Degradation of p53? No; (Kiyono et al., 1998; 
Klingelhutz et al., 1996) 
Yes; (Kiyono et al., 
1998; Klingelhutz et 
al., 1996)1 
Binding/degradation 
of PDZ proteins? 
Yes; (Nakagawa & 
Huibregtse, 2000)  
No; (Gardiol et al., 
1999; Glaunsinger et 
al., 2000; Kiyono et 
al., 1997; Nakagawa 
& Huibregtse, 2000)2 
(Lee & Laimins, 
2004)3  
Binding to E6AP? Yes; (Gewin & Galloway, 
2001; Nakagawa & 
Huibregtse, 2000) 
N/A 
Activation of 
telomerase? 
Yes; (Kiyono et al., 1998) 
(for human mammary 
epithelial cells - HMEC) 
(Gewin & Galloway, 2001; 
Klingelhutz et al., 1996) 
(for human foreskin 
keratinocytes – HFKs) 
Yes; (Kiyono et al., 
1998) (for human 
mammary epithelial 
cells - HMEC)1 
(Klingelhutz et al., 
1996) (for human 
foreskin keratinocytes 
– HFKs)1 
 
1
 The mutant in these studies was an HPV16 PDZ-binding E6 mutant protein 
with a six amino acid deletion in the C-terminus.  
2 The mutants in these studies were HPV16 or HPV18 PDZ-binding E6 mutant 
proteins with deletions/substitutions of single amino acids within the PDZ-
binding C-terminal motif.  
3
 The mutant in this study was an HPV31 PDZ-binding E6 mutant protein with 
deletion of the last 4 amino acids of the E6 protein.  
N/A – No information was available for direct binding of a PDZ-binding mutant 
E6 to E6AP. However, this interaction may be inferred by the ability of the 
mutant E6 protein to degrade p53.  
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3.2.2. The 16WT genomes persist in NIKS cells whereas the 16E6STOP 
genomes do not 
Before addressing the persistence of the 16E6p53m and 16E6PDZ mutant 
genomes, it was important to confirm the need for E6-expression in HPV16 
episomal persistence in NIKS cells. To do this, NIKS cells were transfected with 
16WT or 16E6STOP genomes (the latter being unable to make E6 and 
described in Table 3.1). The two genomes were excised from the pSPW12 
plasmid, re-circularised and co-transfected with the pcDNA6 plasmid that 
carries a blasticidin-resistance gene. Following transfection and antibiotic 
selection, the cells were cultured for ten passages and DNA was collected at 
each passage. The DNA was then analysed by qPCR (using primers against 
the E4 region of the HPV genome and against GAPDH as a control) to measure 
the number of HPV copies present per cell (Fig. 3.2A i and ii). It is important to 
note that in these experiments, where a population of cells was analysed, the 
term “HPV copies per cell” actually refers to the mean number of “HPV copies 
per cell” for the cells in the population. 
 
It is clear that the 16WT genomes can persist in NIKS cells, as the number of 
copies per cell remained constant at first and then even increased at later 
passages. The increase in copy numbers is not very surprising as cells 
harbouring the viral genomes may be expected to have a growth advantage. In 
contrast to 16WT genomes, 16E6STOP genomes did not appear to persist and 
the number of copies per cell dropped to zero within three passages. These 
results confirm previous observations (Laurson et al., 2010) and verify that E6 is 
necessary for viral persistence in this system.  
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Figure 3.2: 16WT genomes persist in NIKS cells whereas 16E6STOP and 
16E6p53m genomes do not; 16E6PDZ genomes persist in NIKS cells but 
at lower numbers than 16WT genomes  
In two independent transfection experiments (A and B), NIKS cells were co-
transfected with 16WT, 16E6STOP, 16E6p53m or 16E6PDZ genomes, and the 
pcDNA6 plasmid. Following antibiotic selection, the cells were grown as 
populations for ten passages, and DNA was extracted at each passage. The 
DNA was analysed by qPCR to determine the number of HPV copies per cell. 
The error bars represent the standard deviation of the qPCR triplicates. 
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3.2.3. E6WT and E6PDZ proteins degrade p53 but E6p53m does not 
Although previously characterised in other systems, it was important to confirm 
that the mutant E6 proteins are indeed defective in their respective activities in 
the system used in this study, before assessing their role in episomal 
persistence. Firstly, I wanted to assess the ability of the wild-type and mutant 
proteins to degrade p53. To do this, I used a retroviral expression system to 
express wild-type and mutant E6 proteins in NIKS cells. Briefly, I took a pLXSN 
retroviral vector that has the HPV16 E6 ORF cloned into it (LXSN-E6WT), kindly 
provided by Dr. Denise Galloway, and used it as a template to make LXSN-
E6p53m and LXSN-E6PDZ vectors by site-directed mutagenesis. These 
vectors, along with the empty LXSN vector, were used to make retroviruses 
which were then used to infect NIKS cells. Infected cells would express the E6 
protein from the retroviral promoter and would also be resistant to neomycin. 
 
After infection and antibiotic selection, the cells were lysed and levels of p53 
protein were assessed by western blotting. Figure 3.3 shows one such blot. As 
expected, the wild-type E6 protein and the E6PDZ mutant protein degrade p53, 
although it appears that they do so with different efficiencies. In contrast, the 
E6p53m protein does not degrade p53, and in fact, the levels of p53 appear to 
increase when E6p53m protein is expressed.  
 
3.2.4. The E6WT and E6p53m proteins degrade hScrib but E6PDZ does not 
I next wanted to assess the ability of the wild-type and mutant E6 proteins to 
degrade the PDZ protein hScrib. hScrib was chosen as a target of E6 because 
it has been shown to be preferentially degraded by HPV16 E6. Other PDZ 
proteins such as hDlg on the other hand, were shown to be preferentially 
degraded by HPV18 E6 (Thomas et al., 2005). 
 
To address this, the levels of hScrib protein were analysed in cell lysates from 
the stable E6-expressing cells described in the previous section. The levels of 
hScrib protein in the E6-expressing cells were not lower than in the absence of 
E6 expression (Fig. 3.4A), which is contrary to is expected based on previous 
publications.  
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This result prompted me to have a closer look at the literature. I noticed that the 
available data regarding the degradation of PDZ proteins by HPV E6, were 
obtained either from in vitro degradation assays, from the analysis of cancer cell 
lines, or from experiments in which both E6 and the relevant PDZ proteins were 
over-expressed in cells, from heterologous promoters (Gardiol et al., 1999; 
Kranjec & Banks, 2010; Nakagawa & Huibregtse, 2000; Thomas et al., 2005). I 
therefore decided to use a similar assay to look at the degradation of hScrib by 
the HPV16 E6 protein in this system. 
 
To do so, I sub-cloned the E6WT, E6p53m and E6PDZ ORFs down-stream of 
the immediate early CMV promoter in the pMV11 plasmid. These vectors were 
used to co-express the E6 proteins in NIKS cells, together with an HA-hScrib 
protein expressed from the pcDNA-HA-hScrib plasmid (Thomas et al., 2005), 
kindly provided by Dr. Lawrence Banks. The cells were harvested 48 hours 
post-transfection and lysed for protein analysis. The transfection was carried out 
in triplicate and the levels of HA-hScrib were assessed by western blotting (Fig. 
3.4B and C). The levels of HA-hScrib appear to be lower in the presence of 
E6WT and E6p53m proteins (Fig. 3.4B). However, this was not the case when 
E6PDZ protein was co-expressed instead (Fig. 3.4C), indicating that the E6PDZ 
mutant protein is indeed unable to degrade PDZ proteins.  
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Figure 3.3: Degradation of p53 induced by wild-type and mutant E6 
proteins 
NIKS cells were infected with retroviruses bearing wild-type or mutant E6 
genes. Following antibiotic selection, cell lysates were collected and the levels 
of p53 in the cells were determined by western blotting. HSP70 was used as a 
loading control. The levels of p53 protein were measured using ImageJ 
software and normalised to the loading controls. The bar graph shows the mean 
levels of p53 protein (in arbitrary units) in cells infected with LXSN-E6WT, 
LXSN-E6p53m and LXSN-E6PDZ viruses, normalised to the levels of p53 in 
cells infected with control LXSN viruses for two independent experiments. 
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Figure 3.4: Degradation of hScrib induced by wild-type and mutant E6 
proteins  
A) NIKS cells were infected with retroviruses bearing wild-type or mutant E6 
genes. Following antibiotic selection, cell lysates were collected and the levels 
of hScrib in the cells were determined by western blotting. Actin was used as a 
loading control. B) NIKS cells were transiently co-transfected with pcDNA-HA-
hScrib, and pMV11 control plasmid, pMV11-E6WT or pMV11-E6p53m or C) 
pMV11-E6PDZ. Whole-cell extracts were prepared 48 h post-transfection. The 
western blots show the levels of HA-hScrib. HSP70 was used as a loading 
control. 
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3.2.5. Wild-type E6 protein is able to degrade endogenous hScrib protein 
when expressed from stable clonal cell lines 
Having demonstrated that the E6PDZ mutant protein is indeed deficient in 
degrading hScrib when both are expressed exogenously, I also wanted to 
determine whether the wild-type E6 protein is able to degrade endogenous 
hScrib protein. From the results presented in Figure 3.4A, using stable LXSN-
E6WT cells, it appeared that, at least in these cells, endogenous hScrib protein 
was not degraded by wild-type E6 protein. Interestingly, a study by Lee and 
Laimins showed that the levels of endogenous PDZ proteins (in this case hDlg, 
hScrib and MUPP1) were not significantly different in cells transfected with 
HPV31 genomes compared to un-transfected cells (Lee & Laimins, 2004).  
 
I therefore hypothesised that the levels of E6 present in the population of LXSN-
E6WT cells may not be high enough to cause significant degradation of PDZ 
proteins. To test this, I isolated individual clones of LXSN-E6WT cells with the 
intention of obtaining some that express high levels of the E6 protein. Such 
clones would provide me with the opportunity to test my hypothesis. As a quick 
means of identifying such high E6-expressing clones, I screened clones of 
LXSN-E6WT cells for the p53 protein. The rationale for this approach is based 
on the fact that HPV16 E6 degrades p53 protein (Scheffner et al., 1990), and 
clones with very low p53 levels are likely to express high levels of E6 protein. I 
chose two clones that had very low levels of p53 compared to control cells, and 
western blotting of extracts from these revealed that they were indeed 
expressing readily detectable level of the E6 protein (Fig. 3.5). Assessment of 
the levels of endogenous hScrib by western blotting showed that, when E6 was 
present, the levels of hScrib were clearly decreased (Fig. 3.5). This supports the 
notion that the inability to detect hScrib reduction in a population of E6-
expressing cells was owed to the heterogeneity of E6 expression within the 
cells in the population.  
 
Interestingly, the difference in the levels of p53 protein was much more 
pronounced than the difference observed in the levels of hScrib protein, 
suggesting that more E6 protein may be required to degrade hScrib than to 
degrade p53. Nonetheless, this experiment confirms that wild-type E6 protein is 
able to degrade endogenous hScrib protein.  
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However, the levels of E6 in this experiment are likely to be higher than those 
expressed during a natural HPV infection. This is because protein expression 
from the HPV promoter is kept under tight control by the activities of other viral 
proteins. This control is absent in the LXSN-E6WT cells. Therefore, whether the 
amount of E6 protein expressed in an HPV infection is sufficient to induce the 
degradation of endogenous hScrib protein remains to be established.  
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Figure 3.5: E6WT expressed from stable clonal cell lines can degrade 
endogenous hScrib 
NIKS cells were infected with retroviruses bearing the wild-type E6 gene, and 
the cells were cloned. Cell lysates were collected and the levels of p53, hScrib 
and E6 in two individual clones were determined by western blotting. HSP70 
was used as a loading control.  
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3.2.6. The wild-type and mutant HPV16 genomes have similar transfection 
efficiencies in NIKS cells 
Having characterised the mutant E6 proteins, I next wanted to determine 
whether the mutant genomes are able to persist in NIKS cells. It was first 
important to assess whether the genomes have similar transfection efficiencies 
in NIKS cells, as major differences could potentially affect the results of the 
persistence assays. The transfection efficiencies of the 16WT, 16E6p53m and 
16E6PDZ genomes were assessed in two different ways.  
 
In the first, the cells were co-transfected with the viral genomes and the 
pcDNA6 plasmid (which carries a blasticidin-resistance gene) in the same way 
as they would be for the persistence assays, and DNA was extracted from them 
48 hours post-transfection. The DNA was then analysed by qPCR to determine 
the number of HPV copies per cell. In this assay, the cells were first trypsinised 
and passed onto new plates 24 hours prior to the DNA extraction, to minimise 
the chances of having any Effectene-DNA complexes attached on the outside of 
the cells and interfering with the results. The trypsinisation process of these 
cells involved one quick wash with trypsin-versene, a 2 minute incubation to 
remove the feeder cells and a 5-10 minute incubation to remove the NIKS cells, 
followed by neutralisation of the trypsin and centrifugation of the detached cells. 
The copy numbers for the transfection of the two mutant genomes were 
normalised to those for the transfection of the wild-type genome, for three 
independent experiments (Fig. 3.6A). The transfection efficiencies of the three 
genomes were found to be comparable.  
 
The second method I used to compare the transfection efficiencies of the three 
genomes was to co-transfect the genomes with the pMV10 plasmid that 
expresses β-galactosidase (β-gal). Comparing the protein levels of β-gal in 
these cells confirmed that the transfection efficiency of the 16WT genome was 
not higher than that of the mutant genomes, and therefore would not affect the 
results of the transfection experiments (Fig. 3.6B).  
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Figure 3.6: There are no major differences in the transfection efficiencies 
of the wild-type and mutant HPV16 genomes  
A) NIKS cells were co-transfected with wild-type or mutant HPV16 genomes, 
and pcDNA6 plasmid and the HPV copies per cell were measured by qPCR at 
48 hours post-transfection. The copy numbers for the transfection of the two 
mutant genomes were normalised to those for the wild-type genome. The bar 
graphs show the average of three experiments and the error bars show the 
range. B) NIKS cells were co-transfected with wild-type or mutant HPV16 
genomes and the pMV10 plasmid and lysates were collected at 48 hours post-
transfection. The levels of β-gal were determined by western blotting. HSP70 
was used as a loading control. 
 
 
 
 
Chapter 3: Investigation of E6 activities necessary for episomal persistence 
 109 
3.2.7. 16E6p53m genomes do not persist in NIKS cell populations 
Having confirmed the need for E6 in the persistence of viral DNA in NIKS cells 
(section 3.2.2), I wanted to assess the ability of the E6 mutant genomes to 
persist. The first mutant genome to be analysed was 16E6p53m. As described 
in section 3.2.2. NIKS cells were co-transfected with the viral genomes and the 
pcDNA6 plasmid and treated with blasticidin. Surviving cells were subsequently 
cultured for ten passages, with DNA being collected at each passage. The 
results from two transfection experiments are shown in Figures 3.2A (panels i 
and iii) and Figure 3.2B (panels i and ii).   
 
In both experiments the 16WT genomes were able to persist, as the number of 
HPV copies per cell either stayed more or less constant or even increased at 
later passages. In contrast, the 16E6p53m genomes were unable to persist as 
the HPV copies per cell dropped to zero within four or five passages. Again this 
is consistent in both experiments. I thus conclude that the 16E6p53m genomes 
are unable to persist in NIKS cells.  
 
The persistence profile for the 16WT genomes appears different in the two 
experiments presented in Figure 3.2. As mentioned earlier, an increase in the 
copy number is not surprising, as the presence of viral genomes might be 
expected to give a growth advantage to the cells. This is what seems to be 
happening in the experiment presented in Figure 3.2A. In the experiment 
presented in Figure 3.2B however, the copy number stayed more or less 
constant. This may indicate that an increase in copy number has already 
occurred, prior to the first analysable time-point for this experiment, after which 
the copy number was stabilised. The apparent difference in the persistence 
profiles of the 16WT genome between the two experiments may also be a 
consequence of the heterogeneity that is expected after the transfection and 
culturing of a population of cells, which will be discussed further later on. As 
experimental variations, which may arise from different cell batches or different 
transfection efficiencies were beyond my control, it was imperative that the 
persistence of the 16WT genomes was always assayed in parallel to that of any 
mutant genome, to serve as a positive control. 
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Importantly however, the 16E6p53m genomes were unable to persist in NIKS 
cells in either of the two experiments presented above. This result suggests that 
the region of the E6 protein that was mutated in this genome has a role in viral 
genome persistence. 
 
3.2.8. 16E6PDZ genomes persist in NIKS cell populations 
I next wanted to determine whether the PDZ-binding motif of E6 is necessary 
for viral genome persistence. To do this I transfected NIKS cells with the 
16E6PDZ genomes. This was done as part of the same experiments presented 
in section 3.2.7 and the results are shown in Figures 3.2A (panels i and iv) and 
Figure 3.2B (i and iii).   
 
Unlike the 16E6p53m genomes, these mutant genomes appear to persist in 
NIKS cells. However, the number of HPV copies per cell for the 16E6PDZ 
genomes was lower than for the 16WT genomes and this was consistent in both 
experiments. The 16E6PDZ genomes were in fact present at lower copies than 
the 16WT genomes from passage 1 (p1) and this may be due to a biological 
effect that has already taken place prior to this first analysable time-point. 
Moreover, the copy number of the 16E6PDZ genomes seems to decrease 
initially and then rise again. This is seen in both experiments and is consistent 
with a possible growth advantage for HPV-positive cells in the population. 
 
From the results presented in this section, I conclude that the 16E6PDZ mutant 
genomes can persist in NIKS cells but do so at lower levels than the wild-type 
genomes.  
 
3.2.9. 16E6PDZ genomes do not persist episomally in NIKS cell 
populations 
In the previous section I concluded that the 16E6PDZ genomes can persist in 
NIKS cells, but appear to do so at lower levels compared to wild-type genomes. 
Wild-type HPV16 genomes have been shown before to persist episomally in 
NIKS cells (Lambert et al., 2005; Laurson et al., 2010). I next wanted to 
investigate whether the 16E6PDZ DNA that was detected in the cells by qPCR 
is in fact episomal DNA or whether it has integrated into the cellular genome.  
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To do this, I analysed the DNA collected from the persistence assay described 
in section 3.2.8 by Southern blotting to look at the physical state of the viral 
DNA. The copy numbers of the 16WT and 16E6PDZ genomes (as measured by 
qPCR) were very low in both experiments presented in Figure 3.2. For this 
assay, I analysed the DNA collected from the experiment shown in Figure 3.2A, 
as these samples contained more HPV DNA per cell, thus increasing my 
chances of detecting viral DNA by Southern blotting. 
 
DNA from one passage of the 16WT-transfected cells was digested with Hind III 
in the first instance, which does not cut the HPV16 genome. In all Southern 
blots, an HPV-positive episomal NIKS cell line was used as a positive control 
(Laurson et al., 2010). The positive controls show the three-band pattern 
expected for episomal DNA. The fastest migrating band represents supercoiled 
DNA, the middle band represents linear DNA and the slowest migrating band 
represents open circular DNA. The 16WT genomes appear to have the same 
band pattern as the positive control, which suggests that these genomes 
persisted in a primarily episomal form (Fig. 3.7A). However, the bands were 
difficult to detect due to the low copy number present in these cells. In order to 
confirm the episomal state of the 16WT DNA in the cells, I repeated the 
Southern blot, but digested the DNA with BamH I which cuts the HPV DNA 
once, linearising it. The positive control was also digested with BamH I (Fig. 
3.7B). Single bands of the same size were obtained for the positive control and 
the 16WT sample and represent the linear 8 kb HPV16 genomes. This result 
indicates again that the 16WT genomes were present primarily in an episomal 
form in these cells.   
 
To look at the physical state of the 16E6PDZ DNA, a DNA sample from one 
passage of the 16E6PDZ-transfected cells was again digested with Hind III in 
the first instance (Fig. 3.7C). In this case, the band obtained, although very 
difficult to detect, was of a different size to any of the bands of the positive 
control. This is indicative of integration of the viral genome into cellular DNA. 
This was confirmed by another Southern blot using samples digested with 
BamH I (Fig. 3.7D). Again, the band obtained from the digestion of the 
16E6PDZ sample, although very faint, was shown to be of a different size to 
that of the positive control. This result suggests that the BamH I digestion did 
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not simply linearise the circular 8 kb mutant HPV genome but that an integration 
event has occurred, which brought the HPV DNA in the proximity of cellular 
BamH I sites.  
 
From these experiments, I conclude that, although the 16E6PDZ genome does 
appear to persist in NIKS cells, it does not persist episomally. 
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Figure 3.7: 16WT genomes persist episomally in NIKS cells whereas 
16E6PDZ genomes do not  
DNA extracted from cells from the persistence assay was digested with 
restriction enzymes which either cut or do not cut the HPV genome (BamH I or 
Hind III respectively), and subjected to Southern blotting. DNA from cells 
transfected with 16WT (A and B) or 16E6PDZ (C and D) genomes was 
analysed. The positive control was DNA from an episomal HPV16-positive NIKS 
cell line and the negative control was DNA from HPV-negative NIKS cells. The 
positions of linear (L), open circular (OC) and supercoiled (S) episomal 
genomes are indicated, as is the marker (M) and the position of likely integrated 
DNA (*). The middle portion of each gel was cropped and this is indicated by a 
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3.2.10. 16E6p53m genomes do not persist in NIKS clonal cell lines 
In the experiments described in the previous sections, the DNA analysis was 
carried out on cells that were transfected and grown as a population. An issue 
that arises in these kinds of experiments is that the results represent an 
average of the entire population of cells and may be inordinately influenced by a 
sub-population of cells with growth advantage over the others. Specifically in 
regards to the population experiments above, it is a concern that 16E6p53m 
genomes could induce growth retardation to cells that harbour them. This is 
because, while the mutant E6 protein expressed cannot target p53 for 
degradation, the E7 protein encoded by this HPV16 genome is wild-type, and 
would be capable of increasing the p53 level above that of the basal level 
(Demers et al., 1994; Laurson et al., 2010). In such a scenario, elevation of p21 
levels (transcriptional target of p53) (Stoppler et al., 1998), could confer a 
growth disadvantage to cells that harbour 16E6p53m genomes. In support of 
this, NIKS cells that express only the E7 protein (in the absence of E6) have 
been observed to grow slower than NIKS cells that do not express any HPV 
proteins (Ken Raj, personal communication). Similar concerns apply to the 
16E6PDZ genomes as Lee et al. observed that cells harbouring HPV31 E6 
mutant genomes, incapable of targeting PDZ proteins, grew slower than control 
cells (Lee & Laimins, 2004). Since abrogation of either of these E6 activities 
within the whole HPV16 genome could potentially result in growth disadvantage 
to cells harbouring the mutant genomes, it is important to employ another 
experimental system that addresses these concerns, to verify the results from 
the population studies.  
    
Hence I decided to carry out the persistence assay by analysing individual 
clones of NIKS that were derived from the population of transfected cells.  In 
these experiments, NIKS cells were transfected with HPV16 DNA and pcDNA6, 
and then plated at very low density, followed by selection with antibiotics. This 
experimental design allowed single clones to be easily isolated and cultured 
individually. This eliminates the risk of cells bearing only the pcDNA6 vector and 
devoid of HPV mutant genomes, or cells that may have spontaneously lost the 
viral episomes (Stewart et al., 1994), outgrowing those that harbour the mutant 
viral genomes. Furthermore, some clones would be expected to have a higher 
number of HPV copies per cell, compared to the average of the population, and 
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these could be used to overcome the issue of the very low average HPV copy 
number within the populations that made Southern blotting analysis very 
difficult.  
 
In the first instance, cells were transfected with either 16WT or 16E6p53m 
genomes. Individual clones were isolated and DNA was extracted and analysed 
by qPCR 2-3 weeks post-transfection (Fig. 3.8). As expected, the populations of 
transfected cells were observed to be heterogeneous, with some clones 
harbouring much higher numbers of HPV copies per cell than others. The 
results show that 100% of the 16WT clones and 91% of the 16E6p53m clones 
were positive for HPV DNA. However, the mean number of HPV copies per cell 
of the 16WT clones was 239 whereas that of the 16E6p53m clones was 101. 
The much reduced mean copy number of the 16E6p53m clones (only 42% of 
that of the 16WT clones), supports my previous conclusions about there being a 
difference between these two genomes (section 3.2.7). Table 3.3 gives a 
summary of the results from this experiment. From these, it is clear that both 
genomes (16WT and 16E6p53m) were able to persist in NIKS (albeit with 
different efficiencies) up to this point in the analysis (2-3 weeks post-
transfection). This observation appears to challenge those from the population 
analyses, and supports the idea that the clonal assay has a higher resolution 
than the population assay.  
 
However, the lower average number of HPV copies per cell for the 16E6p53m 
genomes in the clonal cell lines suggests that the mutant HPV genomes in the 
16E6p53m clones may be on the way to being lost and have already dropped in 
numbers. To test this hypothesis, I took one 16WT and one 16E6p53m clone 
and cultured them for several additional passages, extracting DNA at each 
passage. The DNA was then analysed by Southern blotting to determine 
whether the genomes persist during more long-term culturing, and also to 
establish the physical state of the HPV DNA in the cells. The viral DNA in both 
the 16WT (Fig. 3.9A) and the 16E6p53m clone (Fig. 3.9B) appears to be 
episomal, as the bands were of the same size as the episomal positive control. 
Moreover, the 16WT genomes persisted episomally throughout the ten 
passages. In contrast, the 16E6p53m genomes dropped in copy number over 
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time, which is consistent with my hypothesis that the 16E6p53m genomes may 
not be able to persist. 
 
To verify that the eventual loss of 16E6p53m genomes, is not specific to the 
individual NIKS cell clone that was used in the study above, I repeated the 
experiment from the beginning with a fresh transfection and analysed all the cell 
clones at a later time-point; at 4-5 weeks post-transfection instead of 2-3 weeks. 
Figures 3.10A and B show the results from the transfection of the 16WT and 
16E6p53m genomes. In this experiment, 70% of the 16WT clones were positive 
for HPV DNA, compared to the 100% of positive clones in the previous 
experiment. Strikingly, only 24% of the 16E6p53m clones were positive for HPV 
DNA, compared to 91% in the previous experiments. More importantly though, 
the mean number of HPV copies per cell for all the 16E6p53m clones was only 
5% of that of all the 16WT clones (39 copies per cell for the 16WT clones and 2 
copies per cell for the 16E6p53m clones). Taken together with the results from 
the population experiments, these results suggest that the 16E6p53m genomes 
cannot persist in NIKS cells.  
 
3.2.11. 16E6PDZ genomes do not persist in NIKS clonal cell lines 
The clonal experiment was also carried out using the 16E6PDZ mutant 
genomes, with clones being analysed at 4-5 weeks post-transfection and 
compared to the 16WT clones (Fig. 3.10A and C). Strikingly, only 8% of the 
analysed 16E6PDZ clones were found to be positive for HPV DNA (2 out of 26 
clones) and those 2 positive clones were found to have similar numbers of HPV 
copies per cell as some of the 16WT clones. This was very interesting and 
made apparent the lower sensitivity of the population experiments. Table 3.4 
gives a summary of the results from this experiment, for the transfection of the 
16WT, 16E6p53m and 16E6PDZ genomes.  
 
Having observed that the 16E6PDZ genomes integrated into the cellular DNA in 
the population experiment, I was keen to determine the physical state of the two 
HPV-positive 16E6PDZ clones from the experiment described above. To do 
this, I carried out a Southern blot analyses on DNA from two 16WT clones with 
different copy numbers, together with DNA from the two 16E6PDZ-positive 
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clones, as well as an HPV-negative clone from each transfection (as controls) 
(Fig. 3.11). DNA samples from two 16E6p53m clones were also analysed by 
Southern blotting but no HPV DNA was detected, probably due to the low 
number of HPV copies in these cells (as measured by qPCR). For this Southern 
blot, the DNA was digested with Hind III. 
 
Both HPV-positive 16WT clones analysed by Southern blotting were found to 
harbour episomal HPV DNA. In contrast, both HPV-positive 16E6PDZ clones 
were found to harbour integrated HPV DNA as indicated by the HPV DNA 
bands that were of different sizes compared to the positive control. The higher 
copy numbers in these clones allowed me to clearly confirm the integration by 
Southern blotting and these results confirmed those obtained from the 
population assay (section 3.2.9). 
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Figure 3.8: 16WT and 16E6p53m genomes persist in clonal cell lines but at 
different levels 
NIKS cells were co-transfected with 16WT or 16E6p53m genomes, and the 
pcDNA6 plasmid and plated at low density post-transfection. Following antibiotic 
selection and further growth, clones were isolated and grown independently. 
DNA was extracted from individual clones 2-3 weeks post-transfection and was 
analysed by qPCR to determine the number of HPV copies per cell.  
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Table 3.3: Summary of the data from the clonal experiment (analysed 2-3 
weeks post-transfection) 
Mean number of 
HPV copies per cell 
 Percentage of 
HPV +ve 
clones In all clones In +ve clones 
16WT 100% 239 239 
16E6p53m 91% 101 110 
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Figure 3.9: 16WT genomes persist episomally in long-term passaging of 
clonal cell lines, whereas 16E6p53m genomes drop in copy numbers  
Undigested DNA from different passages of A) a 16WT and B) a 16E6p53m 
clone was analysed by Southern blotting. The positive control was DNA from an 
episomal HPV16-positive NIKS cell line and the negative control was DNA from 
HPV-negative NIKS cells. The position of supercoiled (S) episomal genomes is 
indicated, as is the marker (M). The “p” values above each lane indicate the 
passage number of the cells from which DNA was extracted (e.g. p1 indicates 
“passage 1”). The white lines denote portions of the gels that have been 
cropped. 
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(legend on page 122) 
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Figure 3.10: 16WT genomes persist in clonal cell lines whereas 16E6p53m 
and 16E6PDZ genomes do not 
NIKS cells were co-transfected with (A) 16WT, (B) 16E6p53m or (C) 16E6PDZ 
genomes, and the pcDNA6 plasmid and plated at low density post-transfection. 
Following antibiotic selection and further growth, clones were isolated and 
grown independently. DNA was extracted from individual clones 4-5 weeks 
post-transfection and was analysed by qPCR to determine the number of HPV 
copies per cell.  
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Table 3.4: Summary of the data from the clonal experiment (analysed 4-5 
weeks post-transfection) 
Mean number of 
HPV copies per cell 
 Percentage of 
HPV +ve 
clones In all clones In +ve clones 
16WT 70% 39 55 
16E6p53m 24% 2 9 
16E6PDZ 8% 7 95 
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Figure 3.11: 16WT genomes persist episomally in clonal cell lines whereas 
16E6PDZ genomes do not  
DNA from one HPV-negative and two HPV-positive 16WT and 16E6PDZ clones 
was digested with Hind III and analysed by Southern blotting to determine the 
physical state of the HPV DNA. The positive control was DNA from an episomal 
HPV16-positive NIKS cell line and the negative control was DNA from HPV-
negative NIKS cells. The positions of linear (L), open circular (OC) and 
supercoiled (S) episomal genomes are indicated, as is the marker (M). 16WT 
clones 17 and 18 and 16E6PDZ clones 1 and 20 were HPV-positive. 16WT 
clone 19 and 16E6PDZ clone 9 were HPV-negative. 
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3.2.12. 16WT genomes persist episomally in NIKS clonal cell lines in long-
term passaging 
In the previous section I observed that the 16WT genomes were episomal in the 
analysed clones whereas the 16E6PDZ genomes were not. I then wanted to 
confirm that the integration phenotype that I observed with the 16E6PDZ 
genomes was specific to these mutant genomes, and not a result of my 
methodology. To do this, I cultured one of the 16WT clones shown in Figure 
3.11 for a further ten passages, extracting DNA at each passage and analysing 
it by Southern blotting (Fig. 3.12A). The wild-type genomes were observed to be 
episomal irrespective of the time-point analysed. I thus have no reason to 
believe that the loss of the episomal phenotype was a result of my 
methodology, and rather is specific to the 16E6PDZ genomes. To further 
support my results, I also cultured a 16WT clone from an independent 
experiment and analysed its DNA by Southern blotting (Fig. 3.12B). Once 
again, the HPV DNA was found to be episomal and this was consistent over all 
the analysed passages.  
 
I also wanted to verify the integration of the 16E6PDZ genomes analysed in the 
clonal experiment. To do this, I cultured one of the clones shown in Figure 3.11 
for several additional passages, extracted DNA and analysed it by Southern 
blotting (Fig. 3.13A). For this Southern blot, DNA was digested with a different 
enzyme than the one used in the Southern blot in Figure 3.11, to confirm the 
integration event. Xba I, which does not cut HPV16 DNA, was used for the 
digestion. The HPV DNA bands in this clone were again of different size to 
those of the positive control, and in fact appeared as a smear which is indicative 
of multiple integration events. This was consistent for all the analysed 
passages, confirming that it truly represents an integration event. 
 
Intriguingly, the HPV DNA in this clone did not appear to persist even as an 
integrant as the band intensity in the Southern blot decreased over time. This 
suggests that some growth competition may exist within the clone. This would 
be possible if the integration event did not occur in the very first cell from which 
the clone was generated. If this is the case, then the clone would be 
heterogeneous with some cells harbouring integrated copies of the mutant HPV 
genome and some being HPV-negative cells, or even harbouring different 
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integration events. Moreover, it is possible that these cells did not originate from 
a single clone, but maybe from two merged clones that were growing too close 
together. This would again introduce heterogeneity and possible growth 
competition between the cells. It is therefore possible that this specific 
integration event, or the expression of an E6 protein that cannot degrade PDZ 
proteins, may confer a growth disadvantage. However, the precise nature of the 
integration events in these clones, and their effects on the growth of the cells is 
beyond the scope of this study.  
 
Lastly, to confirm that the integration of the 16E6PDZ genome was not specific 
to this experiment, a 16E6PDZ clone from an independent experiment was also 
cultured for several passages and its DNA was analysed by Southern blotting 
(Fig. 3.13B). The HPV DNA from this clone was also found to be integrated into 
the cellular DNA, supporting my previous conclusions that the 16E6PDZ 
genomes cannot persist episomally in NIKS cells.  
 
From these experiments I conclude that neither the 16E6p53m nor the 
16E6PDZ genomes can persist episomally in NIKS cells and this was 
demonstrated by the population as well as the clonal experiments. 
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Figure 3.12: 16WT genomes persist episomally in NIKS cells over several 
passages 
Two 16WT clones (A and B) were cultured for several passages. DNA was 
extracted at each passage, digested with Hind III and analysed by Southern 
blotting. The positive control was DNA from an episomal HPV16-positive NIKS 
cell line and the negative control was DNA from HPV-negative NIKS cells. The 
positions of linear (L), open circular (OC) and supercoiled (S) episomal 
genomes are indicated, as is the marker (M). The “p” values above each lane 
indicate the passage number of the cells from which DNA was extracted (e.g. 
p1 indicates “passage 1”).  
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Figure 3.13: 16E6PDZ genomes do not persist episomally in NIKS cells  
Two 16E6PDZ clones (A and B) were cultured for several passages. DNA was 
extracted at each passage, digested with A) Xba I or (B) Hind III and analysed 
by Southern blotting. The positive control was DNA from an episomal HPV16-
positive NIKS cell line and the negative control was DNA from HPV-negative 
NIKS cells. The positions of linear (L), open circular (OC) and supercoiled (S) 
episomal genomes are indicated, as is the marker (M). The “p” values above 
each lane indicate the passage number of the cells from which DNA was 
extracted (e.g. p1 indicates “passage 1”). The white lines denote portions of the 
gels that have been cropped. 
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3.2.13 Cells expressing mutant E6 do not have a growth disadvantage 
compared to control cells 
 
3.2.13.1. Generation of wild-type and mutant E6/7-expressing cells 
In the experiments described above, I addressed the possibility that the cells 
that carry the E6 mutant genomes may have a growth disadvantage over the 
HPV-negative cells in the population, and may therefore be lost from the 
culture. This potential problem was addressed by carrying out clonal 
experiments, which were aimed at removing the growth competition from the 
population of cells. However, it is possible that the clones themselves may 
eventually become heterogeneous, by spontaneous loss of episomes (Stewart 
et al., 1994), or by un-even segregation of viral genomes. This possibility would 
undoubtedly affect the confidence in my conclusions. Hence, although clonal 
analyses can significantly reduce the influence of potential differential cell 
growth on the outcome of the experiments, it does not eliminate this likelihood 
entirely. 
 
I therefore wanted to determine whether the expression of the mutant E6 
proteins induced a growth disadvantage to cells, compared to control cells that 
express no viral proteins. To do this, I employed a retroviral expression system 
to express E6 proteins in NIKS cells. As the activities of E6 and E7 are closely 
related and often affect each other (for example p53 augmentation by E7 
(Demers et al., 1994; Laurson et al., 2010) and p53-degradation by E6 
(Scheffner et al., 1990)) I considered it important to co-express E6 and E7 in 
these experiments. 
 
To do this, I used a pLXSN retroviral vector that has the HPV16 E6 and E7 
ORFs cloned into it (LXSN-E6WT/7), kindly provided by Dr. Denise Galloway, 
and used it as a template to engineer LXSN-E6p53m/7 and LXSN-E6PDZ/7 
vectors by site-directed mutagenesis. These vectors, along with the empty 
LXSN vector, were then used to make retroviruses with which I infected NIKS 
cells. Infected cells would express the E6 and E7 proteins from the retroviral 
promoter and would also be resistant to neomycin. Following antibiotic selection 
and recovery, the cells were lysed and the lysates were analysed by western 
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blotting which confirmed that the infectants were indeed expressing the HPV16 
E6 and E7 proteins (Fig. 3.14).  
 
 
 
 
 
 
Figure 3.14: Expression of E6 and E7 proteins in LXSN-E6/7 cells 
NIKS cells were infected with retroviruses bearing wild-type or mutant E6 genes 
as well as the E7 gene. Following antibiotic selection, cell lysates were collected 
and the levels of E6 and E7 proteins were determined by western blotting. 
HSP70 was used as a loading control. 
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3.2.13.2. The E6mut/7-expressing cells do not have a growth disadvantage 
compared to the LXSN cells 
To determine whether any of the E6/7-expressing cell populations have a 
growth disadvantage compared to the LXSN cells, a growth assay was 
performed. I considered that by performing a growth assay I would be able to 
observe the consequences of different growth-related variations that may exist 
between the cells. These include differences in the speed of growth and in the 
number of cells that are cycling at any given time, as well as potential 
differences in the levels of cell death. All of these factors would affect the 
number of cells present in each well and would be reflected in the growth curve.  
 
The cells were counted and plated in 6-well plates, so that three wells could be 
counted per sample at various time points. In addition to the 1 x 105 cells 
seeded per well, 3 x 105 feeder cells were plated as well. This is the feeder 
density that the cells have always been grown in, and it was considered 
important to keep this constant, as the speed of growth of the cells may vary at 
different feeder concentrations. The cells were counted at various time-points 
over seven days, when they were at both sub-confluent and confluent stages. 
To ensure that the feeder cells were not counted in this assay, the cells were 
first washed with trypsin-versene and then incubated at 37 oC for 2 minutes to 
allow feeder cells to detach. The cells were then washed with PBS prior to a 
second incubation in trypsin-versene to remove the keratinocytes for counting.  
 
The mean number of cells per sample was plotted on a graph, with error bars 
representing the standard deviation of triplicate wells (Fig. 3.15). The growth 
curves show that neither the LXSN-E6WT/7 cells nor any of the two LXSN-
E6mut/7 cell types grew slower than the control LXSN cells at any stage of the 
assay. This suggests that the expression of the E6p53m or E6PDZ proteins, 
together with E7, does not confer a growth disadvantage to the cells. I thus 
have no reason to think it likely that the lack of persistence of these mutant 
genomes is due to a growth disadvantage of cells harbouring the mutant 
genomes.  
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Figure 3.15: Growth assay of E6/7-expressing cells 
Equal numbers of cells were plated in 6-well plates, and counted in triplicate at 
5 time-points over seven days. The mean number of cells was plotted against 
the time in days. The error bars represent +/- the standard deviation of the 
triplicate counts.    
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3.3. Discussion 
 
In this chapter I presented data that implicate two regions of the HPV16 protein 
in episomal persistence of HPV16 in monolayer cultures of keratinocytes. 
Previous studies have attempted to look at how different activities of E6 may 
affect episomal persistence, by generating E6-mutant genomes (Lee & Laimins, 
2004; Park & Androphy, 2002; Thomas et al., 1999). These studies used 
primary HFKs to study the persistence of either the HPV31 genome (Lee & 
Laimins, 2004; Thomas et al., 1999) or a hybrid HPV31/16 genome (Park & 
Androphy, 2002). In all of these studies, persistence was assessed by the 
detection of HPV DNA by Southern blotting several weeks post-transfection. 
 
Considering that viral persistence in the basal layer of the epithelium is 
considered to be vital for the development of high-grade HPV-related disease 
(Remmink et al., 1995; Schiffman & Kjaer, 2003), I decided that a thorough 
analysis of the requirements for episomal persistence of HPVs would be 
important. To identify factors necessary solely for episomal persistence, without 
any interference from the potential need for cellular immortalisation, I decided to 
study this in NIKS cells instead of primary cells. Furthermore, the HPV16 
genome was chosen for this study, as this is the most significant HPV type with 
respect to cancer development.  
 
The aim of the work presented in this Chapter was to extend the observations 
that the E6 viral protein was necessary for episomal persistence of HPV16 in 
NIKS cells (Laurson et al., 2010), by determining which activities of E6 are 
involved in this function. To this end, two HPV16 mutant genomes were 
constructed, each harbouring a well-characterised mutation in the E6 ORF. The 
first was a p53-degradation mutant genome (16E6p53m) and the second was a 
genome that lacked the PDZ-binding motif of E6 (16E6PDZ).  
 
As part of my studies to characterise these mutations, I showed that the wild-
type E6 protein, when expressed at high levels from a stable clonal cell line, is 
able to degrade endogenous hScrib. More work however is needed in order to 
determine if this degradation also occurs in natural HPV infections, or if this is 
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an effect that is brought about only by abnormally high expression level of the 
E6 protein. 
 
In my assays, the ability of the mutant genomes to persist in NIKS cells was 
always assessed in comparison to that of the wild-type genome (16WT) from 
the same experiment. Two methods for looking at persistence were employed, 
each giving important insight. Firstly, the two genomes were transfected into 
NIKS cells and the cells were grown as a population for several passages. 
Analysis of DNA from these experiments showed that 16E6p53m genomes do 
not persist in NIKS cells whereas 16E6PDZ genomes do persist but not 
episomally. It therefore seems that the p53-degradation activity of E6 may be 
necessary for the persistence of viral DNA in cells and the PDZ-binding activity 
of E6 may be necessary for keeping the episomal state of the genome.  
 
However, these experiments, which resemble the ones carried out by the earlier 
studies mentioned above (Lee & Laimins, 2004; Park & Androphy, 2002; 
Thomas et al., 1999), only give a general idea of what is happening in these 
cells. Therefore, they may be influenced by a small number of atypical 
phenotypes within the population rather than being representative of most cells. 
Even more important however is the fact that some cells in the population may 
carry a growth advantage, which may be unrelated to the ability of the viral 
episomes in those cells to persist. These cells may consequently outgrow the 
others, thus giving a false result with regards to viral DNA persistence.  
 
To avoid such potential problems, I assessed the ability of the mutant genomes 
to persist in individual cell clones instead, which were isolated and grown 
individually so that they would not be subjected to growth competition by other 
cells in the population. An added advantage of this system is the insight gained 
into the degree of heterogeneity that exists within the population of cells. In 
these clonal experiments, the 16E6p53m genomes were again found to be 
unable to persist in cells. Interestingly however, the results from the transfection 
of the 16E6PDZ genomes showed that the phenotype I had observed with the 
population experiments was not the most common across the whole population. 
The analysis of the clones indicated that the 16E6PDZ genomes had in fact 
been lost from the majority of the clones, with a few clones having multi-copy 
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integrations. It should be noted however, that the primers used in the qPCR 
analysis of these clones recognise sequences within the E4 ORF. It is therefore 
possible that other clones may also contain integrated copies of the genome, 
but are not being detected as positive here because their E4 ORF has been 
disrupted. Further analyses with primers to other HPV ORFs can be carried out 
to measure the degree of integration more precisely.    
 
I also considered the possibility that the clones themselves may eventually 
become heterogeneous and therefore decided to directly address the question 
of whether or not the expression of mutant E6 proteins, together with the wild-
type E7 protein, confers a growth disadvantage to the cells. My results indicate 
that cells that express a mutant E6 protein and the E7 protein do not have a 
growth disadvantage compared to control cells, hence conclusively ruling out 
the possible influence of growth competition described earlier.  
 
Taking the results from this chapter together, I conclude that two distinct regions 
of the E6 protein are necessary for the persistence of viral episomes in cells. My 
investigation into episomal persistence went beyond that of previous studies in 
that I have investigated persistence in the absence of the need for cellular 
immortalisation. Furthermore, I have looked at the heterogeneity within 
transfected cells and have taken care to prevent my results from being 
influenced by different growth rates within the cell population. By doing so, I am 
able to conclude that these two regions of E6 are directly involved in episomal 
persistence, and not implicated in it by way of some other function, such as loss 
of HPV-positive cells from the culture.  
 
The two regions of the E6 protein I have been studying were chosen as their 
mutations have been shown to disrupt two key activities of the HPV16 E6 
proteins, the degradation of p53 and the binding to and degradation of PDZ 
proteins. Therefore, the data presented in this chapter would suggest that these 
two activities of E6 are necessary for episomal persistence. However, this has 
not been conclusively proven as the possibility that the introduced mutations 
also disrupt other activities of E6 cannot be dismissed. To determine whether 
degradation of p53 and binding/degradation of PDZ proteins are indeed 
necessary for persistence, it would be necessary to directly interfere with these 
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processes. For example, I could determine whether the 16E6p53m genome is 
able to persist in cells that have constitutively low levels of p53, such as NIKS 
cells that stably express shRNA against p53. Experiments to this end will be 
discussed in Chapter 4. Similar assays could be carried out with the 16E6PDZ 
genomes in NIKS cells in which PDZ proteins have been knocked down. The 
latter however is less straightforward as it is not currently know which specific 
PDZ protein, or combination of proteins, may be implicated in HPV episomal 
persistence.  
 
Intriguingly, my results also indicate that the two mutant genomes I have been 
studying have two different phenotypes with regards to persistence. The 
16E6p53m genomes appear to gradually be lost from the cells, in a similar way 
as the 16E6STOP genomes. On the other hand, the 16E6PDZ genomes are 
either completely lost from the cells, or are occasionally integrated at high copy 
numbers. These observations suggest that the p53-degradation activity and the 
PDZ-binding activity of E6 may affect episomal persistence by different 
mechanisms.   
 
Further work is needed to determine the persistence mechanisms that these 
activities of E6 are involved in. My studies to this end will be the topics of the 
following chapters.  
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Chapter 4: Investigating factors that may affect HPV16 
persistence 
 
4.1. Introduction  
 
As mentioned in Chapter 1, in order for viral episomes to persist in cells, they 
need to be able to replicate as well as segregate correctly into the two daughter 
cells. Both establishment replication and stable maintenance replication are 
necessary for long-term persistence of viral episomes in basal cells. For correct 
segregation, the episomes must segregate equally into the daughter cells, and 
localise to the nucleus of the newly formed cells, in order to be able to undergo 
replication again. The interruption of any of these processes will result in viral 
episome loss. 
 
The mechanisms that regulate the segregation of viral episomes have been 
studied for PVs as well as for some of the other tumour viruses, and common 
features have been highlighted. It is generally thought that viral episomes bind 
to viral proteins which in turn attach the episomes to the cellular chromosomes 
by interacting with a DNA-binding cellular protein (reviewed in Feeney & Parish, 
2009). The only PV-encoded protein that has been identified to play a role in 
this is E2 (Abbate et al., 2006; Bastien & McBride, 2000; Ilves et al., 1999; 
Lehman & Botchan, 1998; Oliveira et al., 2006; Skiadopoulos & McBride, 1998; 
Van Tine et al., 2004). Several cellular proteins, such as Brd4 (Abbate et al., 
2006; Baxter et al., 2005; You et al., 2004; You et al., 2005), Chlr1 (Parish et 
al., 2006a) and TopBP1 (Donaldson et al., 2007), have been suggested to 
mediate the interaction between PV episomes and cellular chromosomes. In 
addition to the cellular chromosomes, E2 has also been reported to tether viral 
episomes to the mitotic spindle to enable segregation (Van Tine et al., 2004) 
and studies suggest that alternative pathways may be used by different PV 
types (McPhillips et al., 2006; Oliveira et al., 2006). Although it is possible that 
other viral proteins, in addition to E2, may also play a role in episomal 
segregation, at this point there is no evidence to suggest a role for E6.  
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On the other hand, a potential role for E6 in viral DNA replication has been 
suggested. p53 binds to members of the cellular DNA replication machinery, 
such as DNA helicases (Sakurai et al., 1994) and replication protein A (RPA), 
the latter of which p53 has been shown to inhibit (Dutta et al., 1993). In addition, 
p53 has been found to localise to sites of viral DNA replication along with 
cellular replication proteins (Wilcock & Lane, 1991).  
 
Moreover, p53 binds to the SV40 large T antigen. This interaction down-
regulates the replication of SV40 DNA (Friedman et al., 1990; Wang et al., 
1989) and it has been shown that p53 prevents the helicase activity of the large 
T antigen (Sturzbecher et al., 1988) and also interferes with its ability to bind to 
DNA polymerase α (Gannon & Lane, 1987).  
 
Importantly, p53 has been implicated in the replication of PVs, having different 
effects at different stages of replication. p53 inhibits the replication of BPV1 as 
well as that of the high-risk HPV type 18 and the low-risk HPV type 11. 
However, this was only found to be true for the amplificational/establishment 
replication that immediately follows infection (Ilves et al., 2003; Lepik et al., 
1998). In contrast, p53 was found to have no effect on the maintenance 
replication of BPV1 that keeps the viral copies at a stable number (Ilves et al., 
2003). These studies provide evidence that establishment replication and 
maintenance replication are regulated by different cellular and viral factors. 
However, it should be noted that in both the Lepik et al. and the Ilves et al. 
studies, p53 was over-expressed in order for it to have an effect on replication. 
Seeing as BPV1 and HPV11 do not encode proteins that have p53-degradation 
activity (unlike HPV16 E6) it is unlikely that physiological levels of p53 would 
inhibit their DNA replication. 
 
Studies have also shown that p53 interacts with the viral replication protein E2 
(Massimi et al., 1999) and that the negative effect of p53 on the replication of 
HPV16 DNA is dependent on this interaction (Brown et al., 2008). These data 
however also hint at a difference between the replication of high- and low-risk 
HPVs. As Brown et al. discuss, HPV11 E2 was unable to bind p53 (Parish et al., 
2006b), and yet p53 has been shown to inhibit HPV11 replication as well (Lepik 
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et al., 1998). This suggests that p53 may down-regulate the replication of high- 
and low-risk HPVs by different pathways.  
 
In this chapter I aim to address possible reasons that may lead to episomal 
loss. I considered that DNA replication was the most obvious to investigate first, 
as cellular targets of E6 (p53) have been directly implicated in it. On the other 
hand, E6 has not been implicated in episomal segregation. 
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4.2. Results 
 
4.2.1. Replication of wild-type and mutant HPV16 genomes   
I first wanted to address the possibility that the failure of the 16E6p53m and 
16E6PDZ mutant genomes to persist in NIKS cells was due to their inability to 
replicate. A previous study has shown that certain mutations in HPV31 E6 
protein rendered genomes unable to replicate in transient assays (Thomas et 
al., 1999). These mutations were in the splice-donor or splice-acceptor sites of 
E6 and their effect on replication could have been due to one of two things: 
firstly, it was possible that expression of the E6* splice variant protein was 
necessary for replication. Secondly, it was also possible that the introduced 
mutation inadvertently affected the expression of E1 and E2, thereby inhibiting 
replication. The latter possibility gains credence from the observation that 
ectopic expression of E1 and E2 in the transfected cells rescued the replication 
of the mutant genomes (Thomas et al., 1999). 
 
It was therefore important to determine whether the mutations I have introduced 
into the E6 ORF of HPV16 genomes affect the ability of the genomes to 
replicate, as this would consequently affect their ability to persist. Previous 
studies that addressed the persistence of HPV genomes in cells assessed their 
ability to replicate by carrying out transient replication assays (Lee & Laimins, 
2004; Lee et al., 2007; Park & Androphy, 2002; Thomas et al., 1999). In these 
assays, viral genomes were transfected into cells, and DNA was extracted five 
days post-transfection. The DNA was digested with Dpn I, which digests the 
methylated (input) DNA, and Southern blotting was used to detect any Dpn I-
resistant DNA, which is DNA that has undergone replication in the transfected 
cells (Peden et al., 1980). In the abovementioned studies, the transient 
replication assays were carried out in SCC13 or C33a cells. These were not the 
same cells in which the persistence assays were carried out in these studies, 
which were primary human foreskin keratinocytes (HFKs). Although not 
specifically pointed out in these reports, the SCC13 and C33a cell lines may 
have been used because they are much more amenable to being transfected 
than HFKs. The results from these transient replication assays would reveal 
whether there is something inherently wrong with the mutant genomes, for 
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example an inadvertent effect on the expression of E1 and E2. However, they 
may not accurately reflect how efficient the replication of each genome is in the 
HFKs. For example, viral replication in HFKs may have a requirement for 
expression of intact E6 protein, which may not be similarly necessary in SCC13 
or C33a cells. 
 
For this study it was important to look at the ability of the 16E6p53m and 
16E6PDZ mutant genomes to replicate in NIKS cells. As the transfection 
efficiency of the NIKS cells is relatively low, I did not expect to obtain enough 
cells that harbour replicated viral DNA, to be able to see the DNA by Southern 
blotting. Even the use of antibiotics to select for cells that harboured viral DNA 
would not generate sufficient number of cells for a Southern blot-based 
transient replication assay in such a short period of time. To bypass this 
problem, I decided to use a qPCR-based transient replication assay instead, 
which is more sensitive than Southern blotting, and therefore requires much 
less starting material. This was modified from a previously described technique 
(Taylor & Morgan, 2003), in which a probe and primers were designed to 
amplify an area of the HPV replication origin. In that study, a Dpn I site was 
introduced into the binding site of the probe, so that non-replicated, methylated 
DNA would be digested and therefore not amplified in the qPCR reaction. Newly 
replicated, un-methylated DNA on the other hand, would be resistant to 
digestion, and would consequently be amplified in the qPCR. Taylor and 
Morgan highlighted the advantages of their qPCR-based assay over the 
Southern blotting method by demonstrating its superior sensitivity in detecting 
small differences in replication (Taylor & Morgan, 2003).  
 
My experimental procedure was different to that described by Taylor and 
Morgan in that I have been working with the entire HPV16 genome and could 
utilise Dpn I sites that exist naturally within the viral genome, to distinguish 
between transfected (input) and newly replicated DNA. A similar qPCR-based 
assay has also been used previously to determine the replication of BPV1 
mutant genomes (Parish et al., 2006a).  
 
In the HPV16 genome, a Dpn I site is present in the E4 ORF and lies within the 
target sequence that is amplified by the set of primers I have been using for 
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qPCR. Hence amplification of this region by qPCR in Dpn I-digested and 
undigested samples would allow the measurement of the magnitude of 
replication of the viral DNA, based on the principles described above.  
 
To test this principle pSPW12 plasmid (which contains the entire wild-type 
HPV16 genome in a pSP64 vector and was grown in bacteria) was digested 
with Dpn I, or left undigested. qPCR was then used to measure the amounts of 
pSPW12 DNA. As a control, the DNA was also digested with Mbo I, an enzyme 
that recognises the same restriction site as Dpn I but would only digest un-
methylated DNA, and would therefore be expected to leave the pSPW12 DNA 
intact. Dpn I digestion significantly decreased the levels of E4 detected 
(p=0.0013), whereas the Mbo I digestion did not (p=0.37) (Fig. 4.1A). However, 
there was still a significant amount of DNA amplification detected in the Dpn I-
digested sample, indicating that the qPCR assay has a high background. The 
Taylor and Morgan study suggested that digesting the DNA with Exonuclease III 
in addition to Dpn I, would help reduce the background (Taylor & Morgan, 
2003). To determine whether this would improve the assay, I compared the 
levels of E4 in samples digested with Dpn I with or without Exonuclease III (Fig. 
4.1B). Digestion with Exonuclease III did reduce the background to almost 
undetectable levels. I therefore decided to use both Dpn I and Exonuclease III 
digestions for the actual experiments.  
 
An unfortunate consequence of Exonuclease III digestion however, is the 
complete removal of all digested DNA, which eliminates the possibility of using 
another viral ORF as template for an internal qPCR control. Such a control 
would be useful to ensure that the amount of template loaded on the qPCR is 
comparable between samples. To bypass this problem, I decided to analyse the 
results from the transient replication assay by measuring the number of E4 
copies in the Dpn I-digested and undigested samples and dividing the former by 
the latter. Apart from the presence of the enzyme, these two samples were 
treated identically. This would ensure that any variation between the samples, 
as a consequence of the cell harvesting or DNA extraction process, would not 
interfere with my results.  
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Figure 4.1: Controls for transient replication assay 
pSPW12 plasmid was digested with A) Dpn I or Mbo I, or left undigested and B) 
Dpn I or Dpn I and Exonuclease III (Exo III), or left undigested. The levels of E4 
were measured by qPCR. The bar charts show the mean E4 copies and the 
standard deviation of three replicates.  
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The controls presented in Figure 4.1 were set up using pure plasmid that was 
isolated from bacteria. I therefore wanted to ensure that the qPCR-based assay 
also works in transient transfections. To do this, I carried out another control in 
which NIKS cells were transfected with either the replication-competent 16WT 
genomes, or a cloning plasmid carrying the E1^E4 cDNA, but no eukaryotic 
promoter or origin of replication (E4 plasmid) (McIntosh et al., 2008). Low 
molecular weight DNA was extracted four days post-transfection, and divided 
into samples that would remain undigested, or would be digested with Dpn I and 
Exonuclease III. The number of E4 copies measured in the digested samples 
was divided by that measured in the undigested samples and multiplied by 100 
to give the percentage of replication. The results are presented in Figure 4.2 
and show that the replication detected in the cells transfected with the 16WT 
genomes was significantly higher that that detected in the cells transfected with 
the replication-deficient E4 plasmid (p=0.048). This indicates that this assay can 
be used to measure DNA that has replicated above background level, as this is 
set by the E4 plasmid.   
 
Having tested the principles of this assay, I set out to determine whether the 
16E6p53m and 16E6PDZ mutant genomes are replication-competent. To do so, 
NIKS cells were transfected with either of the two mutant genomes, the 16WT 
genome or the E4 plasmid. Low-molecular weight DNA was extracted at four 
days post-transfection and samples were either digested with Dpn I and 
Exonuclease III or were left undigested. The transfection was carried out in four 
replicates and Figure 4.3 shows the results.  
 
From these results, I make two important observations. Firstly, the levels of 
replication detected in the cells transfected with any of the three HPV genomes 
were significantly higher than the background level detected with the E4 
plasmid (16WT: p=0.0001, 16E6p53m: p=0.0004 and 16E6PDZ: p=0.017). This 
indicates that, in addition to the 16WT genome, both of the mutant genomes are 
also replication-competent. Secondly, the replication efficiency of the 16E6PDZ 
genomes was found to not be statistically different (p=0.17) to that of the 16WT 
genomes. In contrast, the 16E6p53m genomes were found to replicate less 
efficiently than the 16WT genomes (p=0.0037).     
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In light of these results, I can conclude that although they are not able to persist 
in NIKS cells, both the 16E6p53m and 16E6PDZ mutant genomes are 
nevertheless able to replicate in these cells. However, 16E6p53m genomes 
replicate less efficiently than 16WT genomes and this might be significant in 
terms of the inability of these genomes to persist in NIKS cells.  
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Figure 4.2: Transient replication of 16WT genomes and control plasmid 
NIKS cells were transfected with 16WT genomes or a control plasmid (E4 
plasmid) that has the E4 ORF without any eukaryotic promoter or origin of 
replication. Episomal DNA was extracted at four days post-transfection and the 
number of E4 copies was measured by qPCR in undigested and digested 
samples. The bar chart shows the mean percentage replication and the 
standard deviation of three replicates. 
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Figure 4.3: Transient replication of wild-type and mutant HPV16 genomes 
NIKS cells were transfected with the 16WT, 16E6p53m or 16E6PDZ genomes, 
or the E4 plasmid. Episomal DNA was extracted at four days post-transfection 
and the number of E4 copies was measured by qPCR in undigested and 
digested samples. The bar chart shows the mean percentage replication and 
the standard deviation of four replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Investigating factors that may affect HPV16 persistence 
 148 
4.2.2. HPV DNA cannot persist in E6-expressing cells 
Having ascertained that the 16E6p53m and 16E6PDZ mutant genomes are 
able to replicate in NIKS cells and yet are unable to persist in them, I wondered 
whether this was due to a cis- or a trans-acting effect of these mutations. In the 
case of the 16E6p53m genome for example, which was shown above to 
replicate less efficiently than the 16WT genome, a cis-acting effect could be one 
where the mutation within the E6 ORF reduces the expression of E1 or E2 
genes. A trans-acting effect would be one where the mutant E6 protein is not 
able to carry-out its normal activities in the cell to facilitate persistence.   
 
To investigate this, I wanted to test whether ectopic expression of wild-type E6 
protein in NIKS cells would restore the persistence capabilities of the mutant 
genomes. This could be done by carrying out the persistence assays in NIKS 
cells that constitutively express E6WT (LXSN-E6WT cells, described in Chapter 
3). If the mutant genomes could persist in these cells at levels similar to the 
16WT genomes, that would imply that the E6 mutations had a trans effect on 
persistence. 
 
Before carrying out these persistence assays using the mutant genomes, it was 
necessary to ensure that the 16WT genomes could persist episomally in the 
LXSN-E6WT cells. To do this, I chose two LXSN-E6WT clonal lines that 
express different levels of E6 (Fig. 4.4A), and transfected them with the 16WT 
genomes, and the pcDNA6 plasmid. In accordance to the method described in 
Chapter 3, following antibiotic selection (4 days), the cells were cultured as a 
population for several passages and DNA was collected at each passage. The 
DNA was then analysed by qPCR to determine the number of HPV copies per 
cell. Importantly, HPV-negative LXSN cells were also transfected in parallel to 
act as a positive control. Figure 4.4B shows the number of HPV copies per cell 
measured at each passage. The graph also includes the copy number at 
“passage zero” (p0) which represents the cells that survived antibiotic selection, 
prior to being passed onto a new plate. The HPV copies detected in the 
different transfectants at p0 are at comparable numbers and they all quickly 
drop to much lower levels within one passage. As expected, within an additional 
four passages, the HPV16 DNA in LXSN cells started increasing in numbers 
and continued to increase, with some stabilisation seen at later passages. 
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Unexpectedly however, the copy numbers of HPV16 DNA in both of the E6-
expressing cell lines never recovered and remained very low, through all the 
passages.  
 
To test whether the difference between the persistence of HPV16 DNA in LXSN 
cells and lack of persistence in E6-expressing cells could be due to differences 
in the transfection efficiencies between cells, I repeated the transfection but 
replaced the pcDNA6 plasmid with the pMV10 plasmid that expresses β-
galactosidase (β-gal). The levels of β-gal in each cell type are shown in Figure 
4.5. The two LXSN-E6WT clonal lines were found to have lower transfection 
efficiencies compared to the LXSN cells. Although this could potentially affect 
the results of the persistent assay, as mentioned above, in the experiment 
described in Figure 4.4B I observed that the copy numbers at p0 and p1 were 
similar between the different transfectants. This suggests that the observations 
regarding the persistence of 16WT genomes in these cells are unlikely to be 
due to differences in transfection efficiencies. This will be addressed further 
below.  
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Figure 4.4: 16WT genomes cannot persist in LXSN-E6WT clonal lines 
A) NIKS cells were infected with retroviruses bearing the wild-type E6 gene. 
The cells were selected with antibiotics and cloned. Whole-cell extracts were 
prepared and the levels of E6 in two individual clones were determined by 
western blotting. HSP70 was used as a loading control. B) LXSN cells and two 
LXSN-E6WT clones were co-transfected with 16WT genomes, and the pcDNA6 
plasmid. Following antibiotic selection, the cells were grown as populations and 
DNA was extracted at each passage. The DNA was analysed by qPCR to 
determine the number of HPV copies per cell. The error bars represent +/- the 
standard deviation of the qPCR triplicates.  
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Figure 4.5: Transfection efficiencies of LXSN and LXSN-E6WT clonal lines 
LXSN cells and LXSN-E6WT clones were co-transfected with 16WT genomes 
and the pMV10 plasmid and whole-cell extracts were prepared at 48 h post-
transfection. The levels of β-gal were determined by western blotting. HSP70 
was used as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Investigating factors that may affect HPV16 persistence 
 152 
 
The experiment described above yielded some unexpected but interesting 
results as it suggested that viral genomes (even wild-type ones) cannot persist 
in cells that already express the E6 protein. This could have important 
implications when considering what factors contribute to making a permissible 
cellular environment for HPV infections, as well as when looking at the 
possibility of re-infection of HPV-positive cells. Furthermore, it was intriguing to 
find that a protein that is necessary for episomal persistence is in fact also 
inhibitory to it, if expressed prior to the entry of the viral DNA into the cell.  
 
However, there were some caveats in the previous experiment that needed to 
be addressed prior to making any firm conclusions. The first was that the E6-
expressing cell lines used in the experiment were clones, whereas the LXSN 
cells were not. It was possible that the cloning process may have inadvertently 
selected for some characteristics which were not desirable in this experiment. 
Furthermore, as seen in Figure 4.5, both of these cell lines had somewhat lower 
transfection efficiency than the LXSN cells, and this may have affected the 
ability of the viral genomes to persist in these cells.  
 
To address both of these issues, I made new LXSN and LXSN-E6WT cell 
populations (omitting the cloning step), and used early passages of these cells 
for the persistence assay. I repeated the persistence assay in duplicate for each 
cell population (labelled LXSN (1) and (2) or LXSN-E6WT pop. (1) and (2)), and 
also repeated it in one of the LXSN-E6WT clones (clone 2) used in the previous 
experiment, as an additional control. The levels of E6 are shown in Figure 4.6A. 
The levels of p53 were also determined and, as expected, were much lower in 
the E6-expressing cell population and cell clone (Fig. 4.6A) compared to the 
LXSN cells. The transfection efficiencies of the cells were measured as 
described above (Fig. 4.6B) and the transfection efficiency of the LXSN-E6WT 
clone was again found to be lower than that of the LXSN cells. However, the 
transfection efficiency of the LXSN-E6WT cell population was found to be 
comparable to that of the LXSN cells. 
 
As in the previous experiment, the 16WT genomes persisted in the LXSN cells 
but not in the LXSN-E6WT clone (Fig. 4.7A and B). Interestingly, the 16WT 
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genomes were also unable to persist in the LXSN-E6WT cell population (Fig. 
4.7A and B). I was unfortunately unable to follow the LXSN-E6WT pop. (2) 
transfection further than p6. However, up to that point it closely resembled the 
phenotype observed with the LXSN-E6WT pop. (1), that is, it did not appear to 
support the persistence of 16WT genomes.  
 
The HPV copy numbers for this experiment were also determined at p0. This is 
the time-point when antibiotic selection had stopped (cells were treated with 
antibiotics for six days), but prior to passing the cells onto new plates. At this 
time-point the copy numbers were found to be much higher, and therefore could 
not be presented meaningfully on the same graph as the copy number values of 
the subsequent passages. The data from this time-point alone are presented in 
Figure 4.7C. This shows that high levels of HPV genomes were detected in all 
transfected cell types at this time-point, indicating that the transfections were 
successful. Although there was some variation in the copy numbers in the 
different transfectants, there was no consistency between copy number at p0 
and ability to sustain HPV persistence at later passages. This is indicated by the 
fact that the lowest and one of the highest copy number values measured were 
both found in the two LXSN cell populations which were the only cells that 
supported persistence of the viral DNA.  
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Figure 4.6: Expression of E6 in an LXSN-E6WT cell population and LXSN-
E6WT clone and transfection efficiencies of LXSN and LXSN-E6WT cells 
A) NIKS cells were infected with retroviruses bearing the wild-type E6 gene and 
the cells were grown as a population (LXSN-E6WT pop.). Whole-cell extracts 
were prepared from this cell population as well as from an LXSN-E6WT clone 
and the levels of E6 and p53 were determined by western blotting. HSP70 was 
used as a loading control. B) LXSN and LXSN-E6WT cell populations and an 
LXSN-E6WT clone were co-transfected with 16WT genomes and the pMV10 
plasmid and whole-cell extracts were prepared 48 h post-transfection. The 
levels of β-gal were determined by western blotting. HSP70 was used as a 
loading control. 
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(legend on page 156) 
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Figure 4.7: 16WT genomes cannot persist in LXSN-E6WT cell populations 
LXSN and LXSN-E6WT cell populations and an LXSN-E6WT clone were co-
transfected with 16WT genomes and the pcDNA6 plasmid. Following antibiotic 
selection, the cells were grown as populations and DNA was extracted at each 
passage. The DNA was analysed by qPCR to determine the number of HPV 
copies per cell. The transfection of the LXSN and the LXSN-E6WT cell 
populations was repeated in duplicate. A) The mean number of copies per cell 
between p3 and p10 for all five transfections. B) The mean number of copies 
per cell between p3 and p10 for the transfection of the LXSN-E6WT cell 
populations and LXSN-E6WT clone. C) The mean number of copies per cell 
measured at p0 for all five transfections. The error bars represent the standard 
deviation of the qPCR triplicates. 
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4.2.3. HPV DNA cannot persist in cells that have low levels of p53  
The unexpected inability of even wild-type HPV16 DNA to persist in E6-
expressing cells precludes the use of these cells to test whether 
supplementation of E6 in trans will restore the ability of 16E6p53m and 
16E6PDZ genomes to persist in cells. I would therefore need to adopt an 
alternative approach to answer this question.   
 
As mentioned in Chapter 3, the observation that the 16E6p53m genomes do not 
persist in NIKS cells does not conclusively prove that p53-degradation is 
necessary for persistence, as it is conceivable that this mutant may be unable to 
perform some other activity of E6 which has not yet been attributed to this 
region of the E6 protein. To test this, I wanted to compensate for the loss of this 
activity in 16E6p53m genomes, by constitutively knocking down the levels of 
p53 in NIKS cells. If the 16E6p53m genomes were able to persist in these cells, 
it would prove that p53-degradation is necessary for persistence. Moreover, it 
would prove that the mutation exerted a trans-acting effect instead of an 
unexpected cis effect on the viral genome. 
 
To knock down the levels of p53 in NIKS cells, I used the retroviral expression 
system to stably express an shRNA construct against p53 (NIKS-shp53 cells). 
To obtain homogeneous NIKS-shp53 cell lines, I cloned the retrovirus-infected 
cells. The reduced levels of p53 in three such clones are shown in Figure 4.8A. 
Clone 3 exhibited the highest efficiency in reducing levels of endogenous p53 
protein. 
 
Before using the cells in the intended experiment with 16E6p53m genomes, I 
wanted to ascertain that these cells were competent in supporting wild-type 
HPV16 DNA replication and persistence in the first place. To do this, I co-
transfected NIKS-shp53 (3) cells with the 16WT genomes and the pcDNA6 
plasmid. Following antibiotic selection (4 days), the cells were cultured as a 
population for a few passages and DNA was collected at each passage. The 
DNA was then analysed by qPCR to determine the number of HPV copies per 
cell (Fig. 4.8B). Surprisingly, 16WT genomes failed to persist in NIKS-shp53 
cells.  
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This was truly an unexpected outcome as the current understanding of the 
effect of p53 on HPV replication would not have predicted a detrimental effect of 
reduced levels of p53 on HPV DNA persistence. After all, HPV16 E6 naturally 
reduces the levels of endogenous p53 in the cell. This curious observation 
mirrors that described above regarding the inability of wild-type HPV16 DNA to 
persist when introduced into cells that already express the E6 protein 
constitutively. In combination, it would appear that the inability of the E6-
expressing cells to sustain the persistence of ectopically-introduced HPV DNA 
may be due at least in part to the low levels of p53 in these cells (seen in Fig 
4.6A) at the time of HPV DNA entry. This suggestion is intriguing as it implies a 
positive role for p53 in the early stages of HPV16 persistence. Further 
implications of this will be discussed later, but in regards to my experiments, it is 
clear that I cannot use these cells to address the role of p53-degradation in 
HPV16 DNA persistence in NIKS cells.    
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Figure 4.8: 16WT genomes cannot persist in NIKS-shp53 cells 
A) NIKS cells were infected with retroviruses bearing an shRNA construct 
against p53. The cells were selected with antibiotics and cloned. Cell lysates 
were collected and the levels of p53 in three clones were determined by 
western blotting. Actin was used as a loading control. B) The NIKS-shp53 (3) 
cell line was co-transfected with 16WT genomes and the pcDNA6 plasmid. 
Following antibiotic selection, the cells were grown as populations and DNA 
was extracted at each passage. DNA was analysed by qPCR to determine the 
number of HPV copies per cell. The error bars represent the standard deviation 
of the qPCR triplicates.  
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4.3. Discussion 
 
In this chapter, I aimed to address different factors that could potentially 
contribute to the inability of the 16E6p53m and 16E6PDZ mutant genomes to 
persist in NIKS cells. Previous studies have highlighted the inhibitory effect of 
p53 on the replication of different viruses, including PVs (Brown et al., 2008; 
Ilves et al., 2003; Lepik et al., 1998), suggesting that E6-mediated degradation 
of p53 may be necessary to allow efficient replication of the HPV genomes. This 
effect has been suggested to come about via the interaction of p53 with the viral 
replication protein E2 (Brown et al., 2008). I therefore wanted to determine 
whether the mutant HPV16 genomes were able to replicate in NIKS cells, and if 
so, whether they could replicate with similar efficiency as the wild-type 
genomes.  
 
Data from the qPCR-based transient replication assay is consistent with this 
view as they show that the 16E6p53m genome, which is unable to degrade p53, 
is compromised in replication. Importantly, in my study I investigated replication 
in the context of the entire HPV16 genome, instead of the reporter plasmids 
used in the studies mentioned above, which generally include only the PV origin 
of replication in the presence of ectopically-expressed E1 and E2 proteins. This 
is an important consideration as other viral proteins may have an effect on 
replication by regulating the levels of viral and cellular proteins.  
 
It is important to note however, that in both my study and the ones mentioned 
above, the HPV genomes or reporter plasmids were introduced into the cells by 
transfection and not by infection. Infection with HPV is thought to only introduce 
a small number of genomes into each cell, which are then amplified to 10 - 200 
copies per cell (Doorbar, 2005). When transfection is used to introduce viral 
genomes into cells, a much larger number of genomes is expected to enter 
each cell. It is therefore not known if amplificational/establishment replication 
follows the same mechanism in these transfected cells as it would in cells that 
have been naturally infected. It is worth mentioning however that viral DNA has 
previously been shown to replicate faster than cellular DNA following 
transfection, thus suggesting that amplificational/establishment replication must 
also take place in transfected cells (Lusky & Botchan, 1986). A more detailed 
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analysis would be required to study this in the transfected NIKS cells and to 
determine the timing of the switch between amplificational replication and 
maintenance replication. At this stage it is not clear whether the replication 
levels measured by the qPCR assay solely reflect amplificational replication, or 
if they partly reflect maintenance replication as well. 
 
In any case, my data do show that the 16E6p53m genomes are replication-
competent with reduced efficiency compared to the 16WT genomes. Although 
this difference was found to be statistically significant, this assay cannot tell me 
whether it is also biologically significant and if it is the sole reason for the 
inability of the 16E6p53m genomes to persist in NIKS cells (as observed in 
Chapter 3). The 16E6PDZ mutant genomes are also replication-competent and 
their replication efficiency is not statistically different to that of the 16WT 
genomes.  
 
My transient replication data with regards to the p53-degradation mutant 
genome is consistent with previous studies that also looked at viral genome 
persistence. In the Thomas et al. study, the authors used HPV31 p53-
degradation mutant genomes (with a different mutation than the 16E6p53m 
genomes used in this study) and noted that these do not replicate as efficiently 
as the HPV31 wild-type genomes (Thomas et al., 1999). Moreover, in the Park 
and Androphy study, HPV31/16 E6-mutant hybrid genomes were used that 
carried the same mutation as the 16E6p53m genomes used in this study (Park 
& Androphy, 2002). Like me, these authors concluded that the mutant genomes 
were replication-competent. Although the authors did not comment on this, their 
Southern blot data also suggest that the replication efficiency of the mutant 
genomes was impaired compared to that of the wild-type genomes. This 
observation is again consistent with my results. On the other hand, the data 
available on the transient replication of PDZ-binding mutant genomes are 
different to mine, as reduced replication was observed with HPV31 mutant 
genomes that lack the PDZ-binding motif (Lee & Laimins, 2004). Variations may 
be due to the fact that the abovementioned studies used a different HPV type 
than I did. Moreover, in the earlier studies the replication of the genomes was 
assessed by Southern blotting, which is less sensitive and quantitative than 
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qPCR. A further advantage of my study is that the transient replication assays 
were carried out in the same cell line as the persistence assays, in NIKS cells.      
 
I also wanted to carry out some experiments to determine if the mutations I 
have been working with inhibit persistence in cis or in trans. These yielded 
some very interesting results in that I found that wild-type HPV16 DNA was 
unable to persist in cells that already expressed the E6 protein. Studies in the 
1980s had looked at the ability of BPV1 genomes to persist in cells that already 
harboured viral genomes (Berg et al., 1986a; Berg et al., 1986b). The results 
were fascinating in that wild-type BPV1 genomes failed to replicate when 
introduced into cells that already harboured mutant BPV1 genomes (with 
mutations in the E6 or E7 ORFs). As a result, the newly-introduced wild-type 
genomes persisted at a very low copy number in these cells. However, when 
the two genomes (wild-type and mutant) were introduced into the cells at the 
same time, they were both able to persist at high copy numbers (Berg et al., 
1986a; Berg et al., 1986b). This suggests that the persistence of viral genomes 
is subjected to a very ordered and well timed expression of viral proteins in 
cells. Similarly, my data show that the expression of E6 prior to HPV DNA entry 
into cells is detrimental to persistence. In my experiments I did not use a cell 
line that harboured mutant viral genomes. Rather, I used a cell line that 
expressed one viral protein alone (E6), which represents aberrant expression of 
the protein.  
 
The notion that pre-existing expression of certain viral proteins prevents re-
infection with new virus is very important, as it implies that an already infected 
cell may be refractive to being successfully infected by other HPVs. In support 
of this is a study from the 1990s, that showed that wild-type and mutant BPV1 
genomes were unable to co-exist in the same cells, even though both were able 
to persist independently (Stewart et al., 1994).  
 
What is interesting about my results is that E6, which is necessary for the 
persistence of HPV16, is also detrimental to it when expressed at the wrong 
time (prior to infection) or at the wrong amount. In line with the older studies 
mentioned above, this suggests that the regulation and timing of viral protein 
expression is very important and complex in the viral life-cycle.  
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We do not yet know which activity of E6 causes the inhibition of persistence in 
the LXSN-E6WT cells. However my experiments suggest a role for p53- 
degradation. This is consistent with a hypothesis proposed by Lepik et al. that 
perhaps p53-mediated inhibition of replication may be necessary at the early 
stages of infection in order to ensure that viral replication is kept under control 
and that the genomes do not replicate uncontrolled and cause harm to the cell 
(Lepik et al., 1998). An alternative explanation might be that cells that express 
E6, or have low-levels of p53 (due to the expression of shRNA against p53) 
may grow too quickly for the viral DNA to establish itself. Although little is know 
about the requirements for establishment, it is perceivable that too rapid cell 
proliferation may not allow time for the build up of viral proteins to the required 
level that is crucial for viral DNA replication and segregation. It has to be noted 
however that the persistence assay in the NIKS-shp53 cell line is lacking the 
proper control, which in this case would be the transfection of 16WT genomes 
in cells that express an unrelated shRNA construct such as shGFP. The ability 
of 16WT to persist in these cells would prove that the lack of persistence in the 
NIKS-shp53 cells was due to the low levels of p53, and not an effect of the 
shRNA expression, such as induction of an interferon response (Bridge et al., 
2003). Such a response could inhibit the persistence of HPV DNA, for example 
by inducing the expression of p56, which in turn down-regulates the replication 
of HPV DNA (Terenzi et al., 2008). 
 
In conclusion, the results presented in this chapter show that the 16E6p53m 
genome is compromised in its ability to replicate in NIKS. This suggests a 
mechanism by which p53-degradation may be important for viral genome 
persistence. As no significant impairment of viral DNA replication was observed 
for the 16E6PDZ mutant genome, I hypothesise that the reason why this 
genome cannot persist is due to a different mechanism.  
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Chapter 5: Stabilisation of E6 by PDZ proteins 
 
5.1. Introduction 
 
In Chapter 4 I showed that the 16E6p53m mutant genomes do not replicate as 
efficiently as the 16WT genomes, and I suggested that this could be the reason 
why the 16E6p53m genomes do not persist in NIKS cells. The same was not 
true for the 16E6PDZ mutant genomes, as these were shown to replicate with a 
similar efficiency as the 16WT genomes. Therefore, I concluded that the role of 
the PDZ-binding motif of E6 in persistence is not related to HPV DNA 
replication, but to another process or processes.   
 
As described in Chapter 1, the PDZ-binding motif is found on most high-risk 
HPV types, and is absent from the low-risk types (Kiyono et al., 1997; Lee et al., 
1997; Nakagawa & Huibregtse, 2000). Previous studies have shown that this 
motif mediates an interaction between the scaffolding PDZ proteins and high-
risk E6 proteins, and E6 has been shown to induce the proteasomal 
degradation of some of these PDZ proteins (Gardiol et al., 1999; Glaunsinger et 
al., 2000; Nakagawa & Huibregtse, 2000; Thomas et al., 2002). Interestingly, 
HPV16 and HPV18 E6 proteins have been shown to target PDZ proteins with 
different affinities, with hScrib being a preferential target of HPV16 E6 and hDlg 
being a preferential target of HPV18 E6 (Thomas et al., 2005). The absence of 
a PDZ-binding motif from low-risk HPV types suggests a potential role for this 
motif in the transformation of cells and the oncogenicity of the high-risk E6 
proteins (Howley & Lowy, 2007). However, the role for this interaction in the 
productive life-cycle of HPVs is not well understood. From the work presented in 
Chapter 3 and from the work of Lee and Laimins on HPV31 (Lee & Laimins, 
2004), it is now clear that the PDZ-binding motif of E6 is necessary for viral 
episomal persistence.   
 
The PDZ proteins are members of multi-protein structures in the cell and many 
of their interactions occur via their multiple PDZ domains. Cellular PDZ-binding 
proteins include the tumour suppressor adenomatous polyposis coli (APC), 
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which is an integral member of the Wnt signalling pathway as part of the 
complex that controls the degradation of β-catenin (Logan & Nusse, 2004). This 
protein interacts with both hScrib and hDlg (Matsumine et al., 1996; Takizawa et 
al., 2006).  
 
Another cellular tumour suppressor protein, PTEN, interacts with the PDZ 
proteins MAGI-1, -2 and -3 (Kotelevets et al., 2005; Wu et al., 2000b; Wu et al., 
2000c). Interaction with MAGI-2 has been shown to stabilise PTEN (Valiente et 
al., 2005; Wu et al., 2000b), which provides evidence that binding to PDZ 
proteins can have an effect on the steady-state levels of the PDZ-binding 
protein. In support of this are also data from a study of the Drosophila PDZ 
protein InaD, which has been shown to stabilise other proteins by way of its 
PDZ domains (Tsunoda et al., 1997).  
 
Interestingly, a recent study identified a novel and important feature of E6’s 
interaction with the cellular ubiquitin ligase E6AP; it demonstrated that by 
associating with E6AP, the E6 protein is stabilised (Tomaic et al., 2009b). Until 
this report, the interaction between E6 and E6AP had been studied primarily 
within the context of p53 protein degradation (Scheffner et al., 1993). This new 
finding suggests that the outcomes of E6-E6AP interaction are not confined to 
the use of E6AP’s ubiquitin ligase activity, but also extend to the stabilisation of 
the E6 protein itself. 
 
These studies prompted me to question whether the interactions of E6 with 
other cellular proteins may also have an impact on E6 stability. Recent 
developments in E6 detection by western blotting in the laboratory allowed me 
to address this question and specifically test whether the E6-PDZ protein 
interactions have any effect on the E6 protein. 
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5.2. Results 
 
5.2.1. Detection of E6 protein after transient transfection of NIKS cells 
As stated in the introduction, the aim of this part of the study was to investigate 
the relationship of E6 with its binding partners, the PDZ proteins, in light of a 
recent report that suggested that E6 can be stabilised by its binding partners 
(Tomaic et al., 2009b). Previous studies have only investigated this relationship 
from the perspective of the degradation of PDZ proteins by E6. I have also done 
this in Chapter 3, where I characterised the wild-type and mutant E6 proteins in 
terms of their ability to degrade hScrib. To do this I co-transfected NIKS cells 
with plasmids that express E6WT, E6p53m or E6PDZ, and a plasmid that 
expresses HA-tagged hScrib, and analysed the levels of HA-hScrib by western 
blotting. One such experiment was presented in Figures 3.4B and C and the 
results were consistent with the published data (Nakagawa & Huibregtse, 2000) 
in that E6WT and E6p53m proteins were able to degrade hScrib, whereas the 
E6PDZ protein, which lacks the PDZ-binding motif, was not. 
 
Whilst carrying out the abovementioned experiments, I came across some 
unexpected and very interesting results with regards to the levels of E6 in the 
transfected cells. The E6PDZ mutant protein was consistently found to be 
present at significantly lower levels than the E6WT and the E6p53m proteins. 
One such example is shown in Figure 5.1. These observations with regards to 
the levels of E6 protein were novel. Previous studies that focused on the levels 
of PDZ proteins in the presence of wild-type and mutant E6 proteins, did not 
determine the levels of E6 in their experiments. This may be partly due to the 
difficulty in detecting the E6 protein by western blotting.  
 
The difference in the levels of the E6WT and E6PDZ proteins was very 
intriguing as it could imply a role for the PDZ-binding motif of E6 in the stability 
of the protein and consequently in the protein’s role in the viral life-cycle. I was 
thus interested to investigate this further. 
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Figure 5.1: Expression of wild-type and mutant E6 proteins in NIKS cells  
NIKS cells were transiently co-transfected with pMV11-E6WT, pMV11-E6p53m, 
pMV11-E6PDZ or control pMV11 plasmid, and the pcDNA-HA-hScrib plasmid 
and extracts were prepared 48 h post-transfection. Western blots show the 
levels of the wild-type or mutant E6 proteins as well as the levels of the HA-
hScrib protein. HSP70 was used as a loading control. 
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5.2.2. The difference in the levels of E6WT and E6PDZ proteins is not due 
to variations in their solubilities or in the transfection efficiencies of the 
plasmids 
We first considered the possibility that the difference in the levels of E6WT and 
E6PDZ proteins may be caused by variations in the solubility of the E6 proteins. 
The lysates analysed in the western blot presented in Figure 5.1 were prepared 
in a RIPA buffer that contained a relatively low concentration of anionic 
detergent. Therefore, these lysates were not whole-cell extracts but were RIPA-
soluble extracts. As mentioned in Chapter 1, E6 has been shown to have 
cytoplasmic binding partners, such as E6AP (Huibregtse et al., 1991), as well 
as nuclear ones, such p53 (Werness et al., 1990). As the solubility of a protein 
can change depending on its localisation in the cell, I hypothesised that there 
may be pools of E6 that are not RIPA-soluble, and may have been excluded 
from the analysis.  
 
To address any potential differences in the solubility of E6WT and E6PDZ, I 
measured the levels of E6 protein in whole-cell extracts (prepared in a RIPA 
buffer containing 6% of SDS). These extracts were of NIKS cells that were co-
transfected with vectors expressing E6 proteins (wild-type or mutant) and HA-
hScrib. Once again the levels of E6WT were found to be significantly higher 
than those of E6PDZ (Fig. 5.2A). The intensities of the three E6WT and three 
E6PDZ bands were measured using ImageJ software and normalised to the 
loading controls (HSP70). An unpaired t-test showed that the levels of the 
E6WT protein were statistically higher than those of the E6PDZ protein 
(p=0.0034), while no significant difference was observed between the levels of 
E6WT and E6p53m proteins (Fig. 5.2B). 
 
To test whether the difference between the levels of E6WT and E6PDZ proteins 
may be caused by variations in the transfection efficiencies of their respective 
plasmids, I repeated the transfections as before but with the inclusion of 
pMV10, a plasmid that expresses β-galactosidase (β-gal) (Forrester et al., 
1992), in the transfection mix. The levels of β-gal protein were analysed by 
western blotting and were found to be similar between the two sets of 
transfections (Fig. 5.2C) indicating that the difference in the levels of the two E6 
proteins was not due to differences in the transfection efficiencies of the 
Chapter 5: Stabilisation of E6 by PDZ proteins 
 169 
plasmids. Furthermore, as in Figure 3.4C, the levels of HA-hScrib were lower in 
the presence of E6WT than E6PDZ, which is consistent with what I would 
expect based on the literature (Nakagawa & Huibregtse, 2000). 
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Figure 5.2: Levels of E6PDZ protein but not E6p53m protein are lower than 
levels of E6WT protein 
NIKS cells were transiently co-transfected with pMV11-E6WT, pMV11-E6p53m, 
pMV11-E6PDZ, or control pMV11 plasmid and pcDNA-HA-hScrib plasmid and 
whole-cell extracts were prepared 48 h post-transfection. Each transfection was 
carried out in triplicate. A) Levels of E6WT and E6PDZ. B) Levels of E6WT and 
E6p53m. The levels of E6 were measured using ImageJ software and 
normalised to the loading controls. The bar charts show the mean levels of E6 
protein (in arbitrary units) and the standard deviation. Unpaired t-tests were 
used to compare the levels of E6 and p values are shown above the graphs. C) 
Levels of E6WT, E6PDZ, HA and β –gal. HSP70 was used as a loading control.  
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5.2.3. The lower levels of the E6PDZ protein are not cell line dependent or 
antibody-dependent 
To ascertain whether my observation with regards to the lower levels of E6PDZ 
mutant protein was specific to NIKS cells, or if it is an intrinsic characteristic of 
the protein, I repeated the transfections in two different cell lines. The cell lines 
used were HT1080 cells, a human fibrosarcoma cell line, and 293T cells, a 
human embryonic kidney cell line, which expresses the SV40 T-antigen. The 
cells were co-transfected with pMV11-E6WT or pMV11-E6PDZ plasmids, and 
pcDNA-HA-hScrib plasmid and the levels of E6 were assessed (Fig. 5.3A). 
Once again, the levels of E6PDZ protein were much lower than those of E6WT 
protein in both HT1080 and 293T cells, in line with the observations in NIKS 
cells. These results confirm that my previous observations were not specific to 
NIKS cells but were likely to be characteristic of a wide variety of cell types, 
possibly including the cells that HPV normally resides in.  
 
To exclude the possibility that the observations made so far were caused by the 
specific antibody I have been using, which recognises an epitope in the C-
terminal half of E6, I repeated the western blot, using a different antibody (Fig. 
5.3B). The 1E-6F4 antibody clone, also from Euromedex, was used. This 
recognises an epitope in the N-terminus of E6. The levels of E6PDZ protein 
were again lower than the levels of E6WT protein. This confirms that my 
previous results were not due to differences in the detection of the two proteins 
by the antibody I have been using.  
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Figure 5.3: The difference in the levels of E6WT and E6PDZ is not cell line 
or antibody dependent 
A) HT1080 and 293T cells or B) NIKS cells were transiently co-transfected with 
pMV11-E6WT, pMV11-E6PDZ or control pMV11 plasmid, and the pcDNA-HA-
hScrib plasmid, and whole-cell extracts were prepared 48 h post-transfection. 
The western blots show the levels of E6WT, E6PDZ and HA-hScrib detected 
with an antibody that recognises an epitope in the A) C-terminus or B) N-
terminus of E6. HSP70 was used as a loading control.  
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5.2.4. The difference in the levels of E6WT and E6PDZ proteins is not due 
to differences in their transcription levels 
One process that can affect the turn-over rate of a protein (and thus its steady-
state levels) is the rate at which it is produced. Therefore, the difference in the 
levels of the wild-type and mutant E6 proteins may be a reflection of a 
difference in their respective mRNA levels. 
 
To address this, NIKS cells were again co-transfected in triplicate with pMV11-
E6WT or pMV11-E6PDZ plasmid, and pcDNA-HA-hScrib plasmid and RNA was 
extracted from the cells 48 hours post-transfection. cDNA was made by reverse 
transcription and used as a template for qPCR. Primers against the E6 ORF 
were used to detect full-length E6 transcripts and primers against β-actin were 
used as a control. The levels of E6 transcripts were normalised to those of β-
actin transcripts for each sample (Fig. 5.4). An unpaired t-test showed that the 
difference in the levels of E6WT and E6PDZ transcripts was not statistically 
significant (p = 0.14) and if anything, the E6PDZ transcript levels appear higher.   
 
I thus conclude that the difference in the levels of E6WT and E6PDZ proteins 
cannot be explained by differences in their respective trascription levels.  
 
 
 
 
 
 
 
 
Chapter 5: Stabilisation of E6 by PDZ proteins 
 174 
 
 
 
 
 
Figure 5.4: E6WT and E6PDZ have similar transcription levels 
NIKS cells were transiently co-transfected with pMV11-E6WT or pMV11-E6PDZ 
plasmid, and pcDNA-HA-hScrib plasmid. RNA was extracted 48 h post-
transfection and analysed by RT-qPCR. The transfections were carried out in 
triplicate and the bar chart shows the mean levels of full-length E6 transcripts 
(normalised to β-actin transcripts) and the standard deviation. An unpaired t-test 
was used to compare the levels of E6 transcripts and the p value is shown 
above the graph. 
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5.2.5. The difference in the levels of E6WT and E6PDZ is due to protein 
stability 
Having established that the difference in the levels of E6WT and E6PDZ protein 
is not due to differences in the transcription levels of the two plasmids, I next 
wanted to assess the relative stability of these two proteins. To investigate this, 
NIKS cells were co-transfected with pMV11-E6WT or pMV11-E6PDZ plasmids, 
and the pcDNA-HA-hScrib plasmid. At 46 hours post-transfection the cells were 
treated with 50 µg/ml of cycloheximide, an inhibitor of protein biosynthesis, for 
60 or 120 minutes, and then harvested for protein analysis. The levels of E6 
were assessed by western blotting, and presented relative to the levels at the “0 
minutes” time-point (Fig. 5.5).The rate of loss of the E6PDZ protein is greater 
than that of the E6WT protein, which demonstrates that the wild-type E6 protein 
is more stable than the mutant one. An unpaired t-test analysis showed that the 
levels of the two proteins were significantly different at time-point 120’ 
(p=0.032). Moreover, from these data, the half-lives of the two proteins were 
calculated to be 113 minutes for E6WT and 47 minutes for E6PDZ.  
 
As previous studies have shown that E6 is degraded by the proteasome 
(Kehmeier et al., 2002; Stewart et al., 2004), I hypothesised that the PDZ-
binding motif of E6WT may protect the protein from proteasomal degradation. 
To investigate this, NIKS cells were co-transfected with pMV11-E6WT or 
pMV11-E6PDZ plasmids, and the pcDNA-HA-hScrib plasmid and at 46 hours 
post-transfection were treated with the proteasome inhibitor MG-132 (final 
concentration 40 µM) or with an equivalent volume of DMSO as a control, for 
two hours. Whole-cell extracts were prepared and the levels of E6 protein were 
analysed by western blotting (Fig. 5.6). A paired t-test showed that the levels of 
E6WT protein did not vary significantly in MG-132- or DMSO-treated cells 
(p=0.62). On the contrary, the levels of E6PDZ protein were significantly 
increased in the MG-132-treated cells, compared to the untreated control cells 
(p=0.0046). The accumulation of E6PDZ protein in the 2-hour treatment with the 
inhibitor indicates that this protein is more susceptible to proteasomal 
degradation than the E6WT protein.  
 
Furthermore, the data presented in Figure 5.6 also appear to show a higher 
degree of degradation of HA-hScrib in the presence of E6WT than in the 
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presence of E6PDZ, consistent with the current understanding of degradation of 
the hScrib protein by E6 (Nakagawa & Huibregtse, 2000).  
 
 
 
 
 
Figure 5.5: E6WT protein is more stable than E6PDZ protein 
NKS cells were transiently co-transfected with pMV11-E6WT or pMV11-E6PDZ 
plasmid, and pcDNA-HA-hScrib plasmid. At 46 h post-transfection, cells were 
treated with 50 µg/ml of cycloheximide for 60 or 120 minutes and whole-cell 
extracts were prepared for each time-point. Extracts were also prepared from 
untreated cells to be used as the “0 minutes” time-point. The levels of E6 were 
analysed by western blotting and measured using ImageJ software. The 
transfections were carried out in duplicate and the bar charts show the mean 
levels of E6, relative to the levels at the “0 minutes” time-point, and the standard 
deviation. HSP70 was used as a loading control. 
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Figure 5.6: E6PDZ is more susceptible to proteasomal degradation than 
E6WT in the presence of HA-hScrib 
NIKS cells were transiently co-transfected with pMV11-E6WT or pMV11-E6PDZ 
plasmid, and pcDNA-HA-hScrib plasmid. At 46 h post-transfection, cells were 
treated with 40 µM of MG-132 or with DMSO as a control, for two hours, and 
whole-cell extracts were prepared. Each transfection was carried out in 
triplicate. The levels of E6 were measured using ImageJ software and the bar 
charts show the mean levels of E6 protein (in arbitrary units) and the standard 
deviation. A paired t-test was used to compare the levels of E6 with and without 
MG-132, and the p values are shown above the graphs. HSP70 was used as a 
loading control.  
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5.2.6. Levels of HPV16 E6WT, but not HPV16 E6PDZ or HPV11 E6WT 
proteins, are higher in the presence of exogenous hScrib.   
The data so far showed that the E6PDZ protein is more unstable than the 
E6WT protein. The only difference in primary structure between these two 
proteins is the absence of the PDZ-binding motif on the C-terminus of E6PDZ 
mutant protein. As described above, this is the motif that interacts with the PDZ 
domains of hScrib (Nakagawa & Huibregtse, 2000). As such, it has been 
presumed that the difference in the stability of these two proteins is owed to 
their ability (or not) to interact with PDZ proteins. Hence, all the experiments 
presented so far had been carried out in the presence of exogenously-
expressed hScrib. To test whether this presumption is erroneous or correct, the 
following experiments were carried out.  
 
NIKS cells were transiently co-transfected in triplicate with pMV11-E6WT (Fig. 
5.7) or pMV11-E6PDZ plasmid (Fig. 5.8), and pcDNA-HA-hScrib or control 
pcDNA plasmid. The levels of E6 proteins were measured and normalised to 
those of the loading control (HSP70). The results were very informative from 
two perspectives; firstly, I observed that the levels of E6WT were very much 
higher in the presence of exogenous hScrib compared to the control cells, in 
which the empty pcDNA vector was co-transfected with the E6-expression 
vector (p=0.0013) (Fig. 5.7). This validated the notion that the stability of the E6 
protein is affected by the presence of exogenous hScrib. Secondly, this hScrib-
dependent augmentation of the E6 protein level did not apply to the E6PDZ 
protein, as the levels of this mutant protein remained unaffected by the 
presence of exogenous hScrib (p=0.79) (Fig. 5.8). 
 
From this section I can conclude that the difference in the stabilities of E6WT 
and E6PDZ proteins is due to stabilisation of E6WT by hScrib. Thus, the PDZ-
binding motif of E6 plays a role in stabilising the E6 protein. If this is correct, it 
would stand to reason that hScrib would have no effect on the levels of the low-
risk HPV11 E6 protein, which lacks a PDZ-binding motif (Kiyono et al., 1997; 
Lee et al., 1997; Nakagawa & Huibregtse, 2000). To test this, NIKS cells were 
co-transfected with pGWI-HA-11E6 (a plasmid that expresses HA-tagged 
HPV11 E6), kindly provided by Dr. Lawrence Banks (Glaunsinger et al., 2000), 
or control pMV11 plasmid, and pcDNA-HA-hScrib or control pcDNA plasmid. 
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The transfections were carried out in triplicate and whole-cell extracts were 
prepared. The protein levels of E6 were measured by western blotting and 
normalised to the HSP70 loading controls (Fig 5.9). As expected, the levels of 
low-risk E6 protein were not altered in the presence of HA-hScrib. This confirms 
my prediction that the absence of a PDZ-binding motif in HPV11 E6 prevents 
hScrib-mediated stabilisation of the E6 protein.  
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Figure 5.7: Levels of E6WT protein are higher in the presence of HA-
hScrib 
NIKS cells were transiently co-transfected with pcDNA-HA-hScrib or control 
pcDNA plasmid, and pMV11-E6WT plasmid and whole-cell extracts were 
prepared 48 h post-transfection. Each transfection was carried out in triplicate. 
The levels of E6 were measured using ImageJ software and normalised to the 
loading control. The bar chart shows the mean levels of E6 protein (in arbitrary 
units) and the standard deviation. An unpaired t-test was used to compare the 
levels of E6 and the p value is shown above the graph. β-gal expression was 
used as a transfection control and HSP70 was used as a loading control.  
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Figure 5.8: Levels of E6PDZ protein are unaffected by the presence of HA-
hScrib 
NIKS cells were transiently co-transfected with pcDNA-HA-hScrib or control 
pcDNA plasmid, and pMV11-E6PDZ plasmid and whole-cell extracts were 
prepared 48 h post-transfection. Each transfection was carried out in triplicate. 
The levels of E6 were measured using ImageJ software and normalised to the 
loading controls. The bar chart shows the mean levels of E6 protein (in arbitrary 
units) and the standard deviation. An unpaired t-test was used to compare the 
levels of E6 and the p value is shown above the graph. β-gal expression was 
used as a transfection control and HSP70 was used as a loading control.  
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Figure 5.9: Levels of low-risk E6 protein are unaffected by the presence of 
HA-hScrib 
NIKS cells were transiently co-transfected with pGW1-HA-11E6 or control 
pMV11 plasmid, and pcDNA-HA-hScrib or control pcDNA plasmid and whole-
cell extracts were prepared 48 h post-transfection. Each transfection was 
carried out in triplicate. The levels of E6 were measured using ImageJ software 
and normalised to the loading controls. The bar chart shows the mean levels of 
E6 protein (in arbitrary units) and the standard deviation. An unpaired t-test was 
used to compare the levels of E6 and the p value is shown above the graph. β-
gal expression was used as a transfection control and HSP70 was used as a 
loading control. 
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5.2.7. The PDZ domains of hScrib are involved in the stabilisation of wild-
type E6 protein 
As E6 has been shown to bind to hScrib via the PDZ domains of the latter 
(Nakagawa & Huibregtse, 2000), I wanted to investigate whether the PDZ 
domains on the hScrib protein are necessary for the stabilisation of E6. To test 
this, I made use of a plasmid that expresses a mutant hScrib protein, pcDNA-
HA-hScrib∆PDZ (Thomas et al., 2005), which was kindly provided by Dr. 
Lawrence Banks. This plasmid encodes an HA-tagged hScrib protein that lacks 
the whole of the PDZ domain region (deleted between amino acids 724 and 
1224) and was shown to not be degraded by HPV16 E6 (Thomas et al., 2005). 
Its localisation was also investigated using a GFP-tagged protein, and the 
mutant protein was found to resemble the wild-type in localising to adherens 
junctions at the basolateral membrane (Thomas et al., 2005).  
 
For my experiments, NIKS cells were co-transfected in triplicate with pcDNA-
HA-hScrib∆PDZ or control pcDNA plasmid, and pMV11-E6WT plasmid. The 
levels of E6WT protein were analysed by western blotting (Fig. 5.10) and were 
found not to increase in the presence of mutant hScrib protein (p=0.28), 
confirming that the PDZ domains of hScrib are necessary for the stabilisation of 
E6WT protein. 
 
5.2.8. Endogenous hScrib cannot stabilise exogenously expressed E6 as 
efficiently 
Having observed that exogenously-expressed hScrib increases the levels of 
wild-type E6 protein in a manner that is dependent on the PDZ-binding motif of 
E6 and the PDZ domains of hScrib, I went on to test whether endogenous 
hScrib protein can do the same to E6. NIKS cells were transiently co-
transfected with pMV11-E6WT or pMV11-E6PDZ plasmid, and control pcDNA 
plasmid. The transfections were carried out in triplicate and whole-cell extracts 
were prepared. The levels of E6 were measured by western blotting and 
normalised to the protein levels of HSP70 in the respective lanes (Fig. 5.11).  
 
Although the levels of E6WT protein appeared to be higher than those of 
E6PDZ protein, the difference was much smaller than that observed in the 
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presence of exogenous HA-hScrib. This result may suggest that the effect of 
the endogenous hScrib protein on the levels of E6WT protein is less significant 
than the effect of the exogenous hScrib protein (compare Figure 5.11 to 5.2C). 
However, it is important to note that in the previous experiments, both hScrib 
and E6 were expressed from CMV promoters. In this experiment however, 
hScrib was expressed solely from its own promoter, and the total levels of 
hScrib protein in transfected cells would therefore be lower. The effect of hScrib 
on E6 may thus be masked by the sheer amount of E6 protein present.  
 
To get around this problem, I decided to knock-down the hScrib protein in 
HPV16-positive episomal cell lines, using a retroviral expression system, and to 
observe whether this would have any effect on the levels of the E6 protein. I  
firstly tested two different shRNA constructs against hScrib (Dow et al., 2007) 
and one shRNA construct with a scrambled sequence (Dow et al., 2008) (kindly 
provided by Dr. Patrick Humbert) in NIKS cells. I found that shScrib 1 (shScrib 6 
in Dow et al., 2007) did not knock down hScrib protein levels in these cells 
(compared to the levels of hScrib observed with shScramble). On the other 
hand, shScrib 2 (shScrib 7 in Dow et al., 2007) did so very efficiently (Fig. 
5.12A). Retroviruses expressing the shScrib 2 and shScramble constructs were 
then used to infect an HPV-positive NIKS cell line (in duplicate). However, the 
shRNA did not work as efficiently in these cells as it did in the NIKS cells (Fig. 
5.12B). This was repeated with similar results.  
 
The reason for the above results is not clear. However, at the same time as this 
work was being carried out, our collaborators in Dr. Lawrence Banks’s 
laboratory (ICGEB, Trieste) successfully knocked down hScrib in HeLa cells 
using siRNA, and observed a reduction in the levels of E6 (Nicolaides et al., 
2011). This demonstrates that the E6 protein in HeLa cells is stabilised by 
endogenous hScrib protein. Furthermore, as HeLa cells contain integrated 
copies of HPV18, these results also suggest that the stability of E6 protein by 
hScrib holds true for other HPV types as well. 
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Figure 5.10: Levels of E6WT protein are unaffected by the presence of 
mutant HA-hScrib 
NIKS cells were transiently co-transfected with pcDNA-HA-hScrib∆PDZ or 
control pcDNA plasmid, and pMV11-E6WT plasmid and whole-cell extracts 
were prepared 48 h post-transfection. Each transfection was carried out in 
triplicate. The levels of E6 were measured using ImageJ software and 
normalised to the loading control. The bar chart shows the mean levels of E6 
protein (in arbitrary units) and the standard deviation. An unpaired t-test was 
used to compare the levels of E6 and the p value is shown above the graph. β-
gal expression was used as a transfection control and Histone H2B (H2B) and 
HSP70 were used as loading controls.  
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Figure 5.11: The difference between the levels of E6WT and E6PDZ 
proteins is marginal in the absence of exogenous hScrib 
NIKS cells were transiently co-transfected with pMV11-E6WT or pMV11-E6PDZ 
plasmid, and pcDNA plasmid and whole-cell extracts were prepared 48 h post-
transfection. Each transfection was carried out in triplicate. The levels of E6 
were measured using ImageJ software and normalised to the loading control. 
The bar chart shows the mean levels of E6 protein (in arbitrary units) and the 
standard deviation. An unpaired t-test was used to compare the levels of E6 
and the p value is shown above the graph. β-gal expression was used as a 
transfection control and HSP70 was used as a loading control.  
 
 
 
 
 
Chapter 5: Stabilisation of E6 by PDZ proteins 
 187 
 
 
Figure 5.12: shRNA against hScrib  
A) NIKS cells or B) a NIKS + HPV16 clonal cell line were infected with 
retroviruses expressing shRNA against hScrib or a scrambled sequence. Two 
different shScrib constructs were used to knock down hScrib in NIKS cells (A), 
whilst only the most efficient one (shScrib 2) was used in the HPV-positive NIKS 
cell line (B). In both A) and B) the infections were carried out in duplicate. 
HSP70 was used as a loading control. 
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5.2.9. E6WT protein is also stabilised by other PDZ proteins 
We were also interested to determine whether other PDZ proteins were able to 
stabilise E6 in the way that hScrib has been shown to do. In addition to hScrib, 
targets of E6 include other MAGUK proteins such as hDlg (Gardiol et al., 1999; 
Kiyono et al., 1997; Lee et al., 1997) and MAGI-1, -2 and -3, (Glaunsinger et al., 
2000; Thomas et al., 2002) as well as the non-MAGUK protein MUPP-1 (Lee et 
al., 2000).  
 
Most of the abovementioned targets of E6 were found to be more efficiently 
targeted by HPV18 than HPV16 E6 (Gardiol et al., 1999; Pim et al., 2000; 
Thomas et al., 2001; Thomas et al., 2002). The reason why I initially chose to 
study the relationship between E6 and hScrib in this study, instead of any of the 
other PDZ proteins, was because hScrib was found to be more efficiently 
targeted for degradation by HPV16 rather than HPV18 E6 (Thomas et al., 
2005). This may indirectly suggest that HPV16 E6 binds more efficiently to 
hScrib than any of the other PDZ proteins.  
 
We decided to look at whether hDlg and MAGI-1, which have also been shown 
in the literature to bind to HPV16 E6 (Glaunsinger et al., 2000; Kiyono et al., 
1997), have the same effect on the steady-state levels of E6 as hScrib does. 
NIKS cells were co-transfected in triplicate with pMV11-E6WT or pMV11-
E6PDZ plasmid, and pGW1-HA-Dlg (Gardiol et al., 1999) or pcDNA-FLAG-
MAGI-1c (Glaunsinger et al., 2000) plasmid, both of which were kindly provided 
by Dr. Lawrence Banks. The levels of E6 protein were assessed by western 
blotting (Fig. 5.13A). The presence of exogenous MAGI-1 had a similar effect as 
hScrib on the levels of E6; that is, the levels of E6WT protein were much higher 
than those of E6PDZ protein. This is not surprising as MAGI-1, like hScrib, has 
been shown to bind strongly to HPV16 E6 (Glaunsinger et al., 2000) and is also 
efficiently targeted for degradation in HPV16-positive cancer cell lines (Kranjec 
& Banks, 2010). In the presence of exogenous HA-Dlg, E6WT protein levels 
were also higher than E6PDZ protein levels; however the difference was not as 
striking as the one observed in the presence of hScrib or MAGI-1. 
 
To verify that these plasmids do indeed express the respective proteins, I 
transfected them into NIKS cells and analysed the lysates by western blotting. I 
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was not able to detect either of these proteins on the blots. A repeat of the 
transfection in 293T cells however demonstrated that these plasmids can 
indeed express the respective PDZ proteins (Figure 5.13B). This apparent 
anomaly is almost certainly due to the poor transfection efficiency of the NIKS 
cells compared to the 293T cells. 
 
These data suggest that the stabilisation of E6 may be a common characteristic 
of several PDZ proteins and not just of hScrib. However, different PDZ proteins 
appear to stabilise E6 to different degrees. This may be simply due to a 
difference in the expression levels of these PDZ proteins from their respective 
plasmids. However, I consider it more likely that this is reflective of the variation 
in the binding affinities of the E6 protein to different PDZ proteins. Whether 
other PDZ proteins have a similar effect on E6 protein levels remains to be 
established. 
 
From the experiments described so far, I can conclude that E6WT protein is 
stabilised by its cellular binding partners, the PDZ proteins. This stabilisation is 
dependent on the PDZ-binding motif of E6 as well as the PDZ domains of the 
PDZ proteins and comes about by the protection of the E6WT protein from 
proteasomal degradation. 
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Figure 5.13: Multiple PDZ proteins can stabilise E6WT  
A) NIKS cells were transiently co-transfected with pMV11-E6WT or pMV11-
E6PDZ plasmid, and pcDNA-FLAG-MAGI-1c or pGW1-HA-Dlg plasmid and 
whole-cell extracts were prepared. Each transfection was carried out in 
triplicate. The levels of E6 were measured using ImageJ software and 
normalised to the loading control. The bar charts show the mean levels of E6 
protein (in arbitrary units) and the standard deviation. Unpaired t-tests were 
used to compare the levels of E6 and the p values are shown above the graphs. 
Histone H2B (H2B) and HSP70 were used as loading controls. B) 293T cells 
were transfected with FLAG-MAGI-1c or pGW1-HA-Dlg plasmid. HSP70 was 
used as a loading control.  
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All of the experiments carried out so far have looked at the levels of E6 protein 
when expressed from the CMV promoter of the pMV11 plasmid. E6 expressed 
from a CMV promoter is expected to be at much higher levels than E6 
expressed from the HPV genomes. Therefore, the levels of E6 in these 
experiments do not accurately reflect the levels present in the cells following an 
infection with the virus. That being said, the use of the over-expression system 
was deemed necessary as the levels of E6 protein expressed from the HPV16 
genomes when transiently transfected into NIKS cells, have proven very difficult 
to detect by western blotting. This difficulty was compounded by the relatively 
low transfection efficiency of NIKS, as well as the fact that it was imperative to 
assess the levels of E6 shortly after transfection, since I have previously shown 
that the 16E6PDZ genomes are unable to persist in NIKS cells. This highly-
restricted time-frame meant that I could not utilise any antibiotic selection 
method to enrich for cells that contain the HPV genomes. Nevertheless, it was 
important to assess whether the stabilisation of E6 by PDZ proteins holds true 
in the endogenous system as well.  
 
5.2.10. The levels of E6 transcripts are significantly lower when expressed 
from the HPV16 genomes than the pMV11 plasmid 
Unsurprisingly, the initial attempts, using western blots, to detect the E6 protein 
expressed from the HPV genomes in a population of transfected NIKS cells, 
were unsuccessful. This was attempted using varying amounts of protein on the 
western blots, but when high amounts were loaded on the gel, the blot had 
significant background that made it difficult to detect individual bands. Different 
anti-E6 antibodies were used with similar results (see Chapter 2). I also co-
transfected the pcDNA-HA-hScrib plasmid with the HPV16 genomes in an 
attempt to augment the levels of E6WT in transfected cells, but to no avail as 
the detection of E6 was still unsuccessful (Fig. 5.14).  
 
I then wanted to ascertain the difference in the levels of E6 transcripts that were 
produced from HPV16 genomes and those produced from pMV11-E6WT 
plasmids. NIKS cells were transfected with wild-type HPV16 genomes (16WT) 
or pMV11-E6WT plasmids. RNA was extracted 48 hours post-transfection and 
cDNA was made and used as a template for qPCR in order to detect the levels 
Chapter 5: Stabilisation of E6 by PDZ proteins 
 192 
of full-length E6 transcripts (Fig. 5.15). For the synthesis of cDNA, I chose to 
use oligo-dT as this primer will only initiate reverse-transcription of mature 
mRNAs and will thus give a more accurate indication of the levels of mRNA that 
are “ready” for translation. β-actin transcript levels were used as a control. As 
expected, the levels of E6 transcripts were much lower when expressed from 
the 16WT genomes, compared to the pMV11-E6WT plasmids. Therefore, in 
order to be able to detect the E6 protein when expressed from the HPV 
genomes, I would need to use very sensitive western blotting detection methods 
or to enrich the population of transfected cells for E6-expressing cells. It should 
be noted however that the above results were obtained by measuring the levels 
of E6 transcripts and may not necessarily accurately reflect the difference in the 
protein levels.  
 
I also wanted to determine the time-point post-transfection at which the levels of 
E6 transcripts were highest, as this could in turn indicate the best time-point for 
E6 protein analysis. NIKS cells were transfected with 16WT genomes and RNA 
was extracted every 24 hours for 4 days post-transfection. cDNA was prepared 
(using oligo-dT) and the levels of full-length E6 transcripts were measured and 
normalised to the levels of β-actin transcripts (Fig. 5.16). The highest levels of 
E6 transcripts were detected at 24 and 48 hours post-transfection. This could 
be because after this time-point, the majority of the HPV genomes may be lost 
from the cells, before their number is stabilised. I therefore decided that 48 
hours post-transfection would be the appropriate time-point to assess the levels 
of E6 protein (as I have been doing thus far), as I considered that the 24-hour 
time-point might be too early for the detection of E6 protein. 
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Figure 5.14: Attempts to detect E6 expressed from HPV16 genomes 
NIKS cells were co-transfected with 16WT genomes and pcDNA-HA-hScrib 
plasmid and 120 µg of protein were loaded on a 15% gel. The blot was probed 
with anti-E6 antibody. The positive control is cell extract from cells transfected 
with pMV11-E6PDZ. 
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Figure 5.15: qPCR analysis of E6 transcripts from HPV16 genomes or 
pMV11 plasmids  
NIKS cells were transiently transfected with 16WT genomes or pMV11-E6WT 
plasmids. RNA was extracted 48 h post-transfection and analysed by RT-qPCR. 
The transfections were carried out in duplicate and the bar chart shows the 
mean levels of full-length E6 transcripts (normalised to β-actin transcripts) and 
the standard deviation. The transfection was not carried out in an equimolar 
ratio. The values from the qPCR were adjusted so that the graph represents the 
values expected from the equimolar ratio.  
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Figure 5.16: qPCR analysis of E6 transcripts from HPV16 genomes at 24-
hour intervals post-transfection 
NIKS cells were transfected with 16WT genomes and RNA was extracted at 24-
hour intervals for 96 hours and analysed by RT-qPCR. The transfections were 
carried out in duplicate and the bar chart shows the mean levels of full-length 
E6 transcripts (normalised to β-actin transcripts) and the standard deviation.  
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5.2.11. Optimising the anti-E6 western blot 
From the experiments described in the previous section, it became clear that in 
order to be able to detect E6 expressed from the HPV16 genomes, I would 
need to optimise the western blot to make it more sensitive in detecting much 
lower levels of E6 protein than had been necessary thus far. Loading higher 
levels of protein and using more sensitive ECL reagents resulted in blots with 
very high background and with multiple unspecific bands, including some in the 
15-20 kDa range, which is where the E6 protein runs. Several things were 
tested in order to increase the sensitivity of the western blots whilst decreasing 
the background of the blots. These are outlined in Table 5.1.  
 
 Table 5.1: Outline of attempts to detect E6 expressed from HPV16 
genomes by western blotting 
Reduce background on the western blots 
More stringent washing of western 
blots; added 0.1% SDS and 0.25 M 
NaCl to washing buffer 
No signal detected on the blot 
Lower anti-E6 antibody concentration; 
tried dilutions of 1:2000 to 1:8000 
Decreased overall background but still 
had unspecific bands in the 15-20 kDa 
region with high sensitivity ECL  
Try to eliminate or shift the location of the unspecific bands 
Used different protein extraction 
buffers; used a urea buffer 
Similar background as with RIPA 6% 
SDS buffer 
Pre-adsorb the antibody with protein 
lysate from NIKS cells; pre-incubated 
the antibody solution with a blot that 
only had NIKS cell lysate on it, or 
added crude NIKS cell lysate together 
with the blot 
Unspecific bands were still visible 
Used gels with different compositions; 
used the 16% Novex® Tricine gels 
from Invitrogen, commonly used to 
separate low-molecular weight proteins 
Unspecific bands were still visible 
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I also considered the possibility that the secondary antibody may be contributing 
to the unspecific bands. Incubating a membrane containing NIKS lysate with the 
GE Heatlhcare anti-mouse secondary antibody alone, I observed that even in 
the absence of primary antibody there is significant background on the blot, 
including in the 15-20 kDa region. To try to eliminate the background 
contributed from the secondary antibody, I repeated the experiment using a 
secondary anti-mouse antibody from Pierce instead. The background was 
similar as with the former secondary antibody.  
 
5.2.12. Enriching the transfected cell population for E6-expressing cells 
From the results presented above, it became clear that in order to be able to 
detect E6 protein that is expressed from the viral genomes after transient 
transfection of NIKS cells, I would need to enrich from the population of cells, 
those that were successfully transfected. To do this, I decided to co-transfect 
the HPV16 genomes with a GFP-expressing plasmid (pCI-EGFP) (Tuting et al., 
1999) and use Fluorescent Activated Cell Sorting (FACS) to sort cells on the 
basis of their GFP-expression. As co-transfected plasmids are thought to enter 
cells together, I reasoned that the GFP-positive cells would be cells that were 
also transfected with the HPV16 genomes. Therefore the sorted population of 
cells would be enriched not only for GFP-positive cells but also for E6-
expresssing cells.  
 
To test this, and to determine if I could indeed detect E6 in these cells by 
western blotting, I first carried out an experiment in which only the expression of 
E6 from the 16WT genomes was assessed. Cells were co-transfected with 
16WT genomes and the pCI-EGFP plasmid. Alternatively, cells were 
transfected with the pMV10 plasmid to be used for setting up the GFP-negative 
gate for the sorting. A subset of the 16WT+pCI-EGFP-transfected cells was 
used to set the GFP-positive gate (Fig. 5.17A). The cells were sorted 48 hours 
post-transfection and the sorting was carried out by Graham Preece at the Flow 
Cytometry Facility at the NIMR. Both GFP-negative and GFP-positive cells were 
collected, pelleted, washed once with PBS, pelleted again and the pellets frozen 
at   -80oC.  
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For the detection of E6 potein, whole-cell extracts were prepared, quantified 
and used for western blotting (Fig. 5.17B). Un-transfected cells were used as a 
negative control for E6 and cells transfected with pMV11-E6WT and pCI-EGFP 
plasmids were used as a positive control. As can be seen, the GFP-positive 
sorted population had very high levels of GFP whereas the GFP-negative 
sorted population had undetectable levels of GFP, thus confirming that the 
sorting enriched the population for GFP-positive cells. More importantly, the E6 
band was detectable in the GFP-positive cells and no bands were detected in 
the un-transfected cells in the 15-20 kDa region of the gel, thereby suggesting 
that the enrichment for GFP-positive cells worked in enriching for E6-expressing 
cells as well.  
 
This result suggests that this type of experiment could be used to compare the 
levels of E6WT and E6PDZ proteins expressed from the HPV16 genomes. In 
order to improve the quality of the blot, in the following experiment the important 
samples to be analysed were loaded with a separating lane in between, to avoid 
any interference between signals from different samples. In addition, the fact 
that the E6 band in the GFP-positive sample was very faint suggested that more 
sample may need to be loaded on the gel. Hence in the following experiment I 
transfected a larger number of cells in order to obtain a higher concentration of 
enriched protein lysate, and consequently load more protein on the gel.    
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Figure 5.17: Sorted cells are enriched for E6-expressing cells  
NIKS cells were transiently co-transfected with 16WT genomes and pCI-EGFP 
plasmid and were subjected to FACS 48 h post-transfection, to sort on the basis 
of GFP-expression. A) The left panel shows the Forward and Side Scatter 
(FSC/SSC) set-up. The right panel shows the FITC set-up. P5 was the GFP-
positive gate and P4 was the GFP-negative gate. B) Whole-cell extracts from 
FACS-sorted GFP-positive and GFP-negative cells were analysed by western 
blot for GFP and E6 expression. HSP70 was used as a loading control. 
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5.2.13. E6WT protein is more stable than E6PDZ protein when these are 
expressed from HPV16 genomes 
Having confirmed that the sorting method was able to enrich the population of 
transfected cells for E6-expressing cells, I wanted to use this method to 
investigate the relative stability of the wild-type and mutant E6 proteins when 
these are expressed from their respective HPV16 genomes. 
 
To do this I co-transfected NIKS cells with re-circularised 16WT or 16E6PDZ 
genomes, and pCI-EGFP plasmid. Thirty-five wells of a 6-well plate were 
transfected with each of the genomes and pCI-EGFP. The sorting procedure 
was carried out as described above. Whole-cell extracts were obtained, 
quantified and used for western blotting (Fig. 5.18A). The sorting procedure was 
again able to enrich for E6-expressing cells, as both E6WT and E6PDZ proteins 
were detectable on this gel, with no interfering background bands in the 
negative controls. Most importantly however, the levels of E6WT protein were 
much higher than those of E6PDZ protein. To ensure that the difference in the 
protein levels was not due to a difference in the expression of E6 transcripts, 
these were assessed by RT-qPCR (Fig. 5.18B) and were found not to be 
significantly different (p=0.33). 
 
As no exogenous PDZ proteins were expressed in this experiment, the data 
suggest that the higher levels of E6WT compared to E6PDZ protein are due to 
the stabilisation of the wild-type protein by endogenous PDZ proteins. This is of 
particular importance as it confirms that the results I have presented so far, 
using an over-expression system, also hold true for the endogenous system, in 
which PDZ proteins and E6 are expressed at more physiological levels.  
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Figure 5.18: The levels of E6WT protein are higher than those of E6PDZ 
protein when expressed from the HPV16 genomes 
NIKS cells were transiently co-transfected with 16WT or 16E6PDZ genomes 
and pCI-EGFP plasmid. A) At 48 h post-transfection the cells were subjected to 
FACS to sort on the basis of GFP-expression. Whole-cell extracts from the 
sorted GFP-positive and GFP-negative cells were analysed by western blotting 
for GFP and E6 expression. HSP70 was used as a loading control. B) RNA was 
extracted from the total cell population at 48 h post-transfection and analysed 
by RT-qPCR. The transfection was carried out in triplicate and the bar chart 
shows the mean levels of full-length E6 transcripts (normalised to β-actin 
transcripts) and the standard deviation. An unpaired t-test was used to compare 
the levels of E6 transcripts and the p value is shown above the graph. 
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5.2.14. Levels of p53 are similarly diminished in NIKS cells transfected 
with 16WT or 16E6PDZ genomes 
I have shown so far that the E6PDZ protein is unstable compared to the E6WT 
protein when these are expressed from heterologous promoters or from the 
HPV promoter. This is important when considered in the context of my earlier 
findings, as it would suggest that the reason why the 16E6PDZ genomes were 
unable to persist (as presented in Chapter 3) may be because the levels of E6 
protein in these cells were insufficient. In Chapter 3 I also presented data that 
suggested that E6-mediated p53-degradation is necessary for viral genome 
persistence. Therefore, I hypothesised that the reason why the 16E6PDZ 
genomes were unable to persist may be because the E6PDZ protein was 
unable to efficiently degrade p53.    
 
I was thus interested to determine whether the levels of p53 were higher in cells 
transfected with 16E6PDZ genomes compared to cells transfected with 
16E6WT genomes. To do this, I transfected cells with 16WT or 16E6PDZ 
genomes or pMV10 plasmid, and the pCI-EGFP plasmid, and FACS-sorted 
them as described above. Whole-cell extracts from GFP-positive cells were 
analysed for the levels of p53 protein (Fig. 5.19A). Cells transfected with 16WT 
genomes had lower levels of p53 protein than cells transfected with pMV10 
plasmid. Interestingly, the levels of p53 protein in cells transfected with 
16E6PDZ genomes were similar to those in cells transfected with 16WT 
genomes. The bar graph in Figure 5.19A shows the intensities of the p53 bands 
(normalised to the loading control). p53 levels were also measured in the 
samples presented in section 5.2.13. The average of the two experiments is 
presented in Figure 5.19B.  
 
I also wanted to determine whether E6 had any effect on endogenous hScrib at 
this early time-point post-transfection. I therefore analysed the levels of hScrib 
in the transfected and FACS-sorted cells (Fig. 5.19C). The levels of hScrib were 
found not to be different between the cells that had been transfected with 
pMV10 plasmid or either of the HPV16 genomes. This suggests that the E6 
protein, even the wild-type, had no effect on the levels of endogenous hScrib 
protein at this early time-point. 
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In conclusion, despite the difference in their stabilities, E6WT and E6PDZ 
proteins are able to degrade p53 protein with similar efficiencies. Neither 
however seems to have had an effect on endogenous hScrib protein in the 
time-frame in which the testing was carried out. 
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Figure 5.19: p53 and hScrib levels in transfected and FACS-sorted cells 
NIKS cells were transiently co-transfected with 16WT or 16E6PDZ genomes or 
pMV10 plasmid, and pCI-EGFP plasmid, and subjected to FACS 48 h post-
transfection, to sort on the basis of GFP-expression. Whole-cell extracts from 
the sorted GFP-positive cells were analysed by western blotting for A) p53 and 
C) hScrib. The levels of p53 and hScrib were measured using ImageJ software 
and normalised to the loading controls and are shown in the bar charts (in 
arbitrary units). HSP70 was used as a loading control. B) The levels of p53 in 
cells transfected with 16WT or 16E6PDZ genomes were measured in two 
experiments. The bar chart shows the mean levels of p53 in cells transfected 
with 16E6PDZ genomes (in arbitrary units), normalised to the levels of p53 in 
cells transfected with16WT genomes, and the range.  
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5.3. Discussion 
 
The experiments presented in this chapter have conclusively shown that the 
HPV16 E6 protein is stabilised by way of its interaction with the PDZ protein 
hScrib. This stabilisation was found to be dependent on the PDZ-binding motif 
of the E6 protein as well as the PDZ domains on the hScrib protein. The 
resulting stabilisation of the E6 protein is brought about by the protection of the 
E6 protein from proteasomal degradation. My data also show that this 
stabilisation of the E6 protein can be afforded not only by hScrib but also by 
other PDZ proteins, namely hDlg and MAGI. Only hDlg and MAGI were 
investigated in this study and it would be interesting to determine if other PDZ 
proteins have a similar effect, as well as whether this effect is true for E6 
proteins from other high-risk types. Different levels of E6 protein stabilisation 
were observed with the different PDZ proteins. This supports previous studies 
that showed that E6 proteins from different HPV types target PDZ proteins with 
varying efficiencies (Thomas et al., 2005).  
 
Importantly, in this study I was able to demonstrate that the stabilisation of E6, 
observed when E6 and PDZ proteins are over-expressed from heterologous 
promoters, also holds true when E6 is expressed from the HPV16 promoter and 
the PDZ proteins from their endogenous promoters. This is significant as it 
shows that E6 is stabilised by PDZ proteins under physiological conditions. The 
difficulty in carrying out these experiments has been highlighted in this chapter 
and is also reflected by the fact that previous studies have used tags and over-
expression systems in order to study the E6 protein. To the best of my 
knowledge, this is the first time that the levels of un-tagged E6 protein have 
been analysed by western blotting following the transient transfection of 
keratinocytes and prior to any antibiotic selection processes or prolonged cell 
growth. This is important, as I have already shown in Chapter 3 that prolonged 
growth of cells transfected with mutant HPV genomes may result in loss of the 
genomes, which would inevitably influence the results. Furthermore, prolonged 
cell growth may inadvertently select for cells that express higher levels of E6 
protein, as these are expected to have a growth advantage over other cells in 
the population. This selection may mask the differences in the levels of wild-
type and mutant E6 protein.  
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The finding that PDZ proteins stabilise wild-type E6 suggests a way in which the 
PDZ-binding motif of E6 may be involved in viral episomal persistence. Its role 
may be to stabilise enough E6 protein, to facilitate the E6 activities that are 
necessary for persistence. One obvious activity is p53-degradation, the need for 
which in persistence was shown in Chapter 3. The lack of a PDZ-binding motif 
may mean that insufficient E6 protein is present to efficiently degrade p53. If 
this were the case, the levels of p53 would be expected to be higher in E6PDZ-
expressing cells than in E6WT-expressing cells. However, my experiments 
suggest that this is not the case, as the levels of p53 were found to be similarly 
reduced in cells transfected with 16WT or 16E6PDZ genomes. This had also 
been suggested in a previous study, in which an E6 mutant that is deficient for 
PDZ-binding (6 amino acid deletion) was able to induce efficient degradation of 
p53 (Foster et al., 1994). A more recent study also showed that a similar E6 
mutant affected the cellular response to DNA damage in a comparable way as 
the wild-type protein, thus again implying similar reduction in p53 levels in cells 
expressing wild-type or mutant E6 (Nguyen et al., 2003).  However, in both of 
these studies the E6 protein was over-expressed in cells in the absence of 
exogenous expression of hScrib (or other PDZ proteins) and the levels of the 
E6 protein were not assessed. Therefore the levels of wild-type and mutant E6 
proteins in these studies may not actually have been different. My results on the 
other hand show that the efficiency of p53-degradation is similar when E6 is 
expressed from the wild-type or mutant HPV16 genomes, even when the 
steady-state levels of E6WT protein are clearly higher than those of E6PDZ 
protein.  
 
As insufficient p53-degradation does not appear to be the reason why the 
16E6PDZ genomes do not persist, this suggests that other activities of E6, 
apart from p53-degradation must also be necessary. These activities may be 
compromised by the instability of the E6PDZ protein, consequently resulting in 
the lack of viral episomal persistence seen with the 16E6PDZ mutant genomes. 
One such activity which has recently been shown to be necessary for 
persistence is the ability of E6 to bind to and degrade E6TP1 (Lee et al., 2007). 
It is therefore possible that the E6PDZ mutant protein is unable to degrade 
E6TP1 efficiently, due to its lower levels. Moreover, the Lee et al. study 
suggested that the localisation of E6 to the nucleus may also be important for 
Chapter 5: Stabilisation of E6 by PDZ proteins 
 207 
viral episomal persistence (Lee et al., 2007). An earlier study identified three 
nuclear localisation signals on the HPV16 E6 protein, none of which overlapped 
with the PDZ-binding motif (Tao et al., 2003). However, it is possible that 
deletion of the PDZ-binding motif disrupts an as yet unidentified nuclear 
localisation signal of E6 or induces a conformational change in E6 that prevents 
its localisation to the nucleus, thereby inhibiting episomal persistence. More 
ways in which the levels of E6 protein may impact persistence will be discussed 
later. It is important to note however, that my results on the instability of the 
E6PDZ protein do not preclude the possibility that the degradation of PDZ 
proteins is also necessary for viral episomal persistence, in addition to the 
stability of E6.  
 
It is also of interest that hScrib, which has previously been shown to be 
degraded by E6 (Nakagawa & Huibregtse, 2000), is also able to stabilise it. This 
apparent paradox will be further discussed later. As mentioned earlier, this is 
not a novel concept as previous studies have also shown a similar relationship 
between E6 and E6AP. The E6AP protein, which is targeted by E6 for 
degradation (Kao et al., 2000) also stabilises the E6 protein (Tomaic et al., 
2009b). These observations raise interesting questions as to whether E6AP is 
directly necessary for certain activities of E6 (such as for p53-degradation) or 
whether it is needed primarily to stabilise sufficient amounts of E6. Similarly, my 
data indicate that care must be taken when working with E6 mutants that lack 
the PDZ-binding motif, as results could potentially be affected by the lower 
levels of E6 protein instead of by changes in the levels of PDZ proteins. This 
could also be true when looking retrospectively at studies in which such E6 
mutants were used. For example, the binding of E6 to PDZ proteins has been 
attributed roles in cell growth as well as in tissue hyperproliferation (Lee & 
Laimins, 2004). It is possible however that these effects were not due to the 
impact of E6 on PDZ proteins but rather due to the impact of the PDZ proteins 
on the stability of E6. Similarly, the reduced hyperplasia observed in mice that 
express PDZ-binding mutant E6 protein compared to ones that express wild-
type E6 protein, might also be explained by the instability of the mutant E6 
protein (Nguyen et al., 2003). Future studies using such mutants would benefit 
from a thorough investigation of the levels of E6 prior to attributing any effects to 
the degradation of PDZ proteins.    
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6.1. Two regions of the E6 ORF are necessary for episomal persistence of 
HPVs 
Previous studies have suggested a role for E6 in the persistence of HPV 
episomes (Thomas et al., 1999; and Ken Raj, unpublished data). In this study 
my aim was to build on these observations and investigate what the role of 
HPV16 E6 is in this function. My results show that two regions of the E6 protein 
are necessary for the episomal persistence of HPV16 DNA. The first region has 
been associated with the degradation of p53 (Kiyono et al., 1998; Klingelhutz et 
al., 1996), whereas the second region is the PDZ-binding motif of the E6 
protein, which is found at the C-terminus of the protein (Kiyono et al., 1997; Lee 
et al., 1997; Nakagawa & Huibregtse, 2000). I show that HPV16 genomes that 
harbour mutations in these regions are unable to persist in NIKS cells.  
 
Previous studies have also investigated the ability of mutant genomes (with 
mutations in the E6 ORF) to persist in cells (Lee & Laimins, 2004; Park & 
Androphy, 2002; Thomas et al., 1999). These had various unresolved issues, 
which I took care to address in my study. Firstly, whereas the previous studies 
only used Southern blotting to assess persistence, I also assessed it by qPCR, 
by measuring the number of HPV copies per cell in successive passages. I 
believe that the qPCR analysis provides higher resolution, as it allows me to 
determine smaller and quantitative differences between samples, and to 
analyse earlier time-points post-transfection as it requires significantly lower 
amounts of sample than Southern blotting. 
 
Secondly, I took care to prevent other factors from interfering with the results. 
One such factor is the potential growth competition that may exist in a 
population of cells that was transfected with mutant HPV16 genomes. As 
discussed in Chapter 3, I considered the possibility that cells harbouring the 
16E6p53m or 16E6PDZ mutant genomes may have a growth disadvantage 
compared to cells that do not contain any viral genomes, and may be outgrown. 
This would result in an apparent loss of mutant viral genomes from cells.The 
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experimental approach was designed in a way that would minimise this 
possibility, in that I isolated individual cells soon after transfection (thereby 
removing them from the growth competition), and analysed the resulting clones 
for the presence of HPV DNA. Moreover, I directly assessed potential growth 
differences between cells that express mutant E6 protein (together with E7 
protein) compared to control cells. All of the above led me to conclude that the 
reason why the mutant genomes are unable to persist in NIKS cells is not due 
to a growth disadvantage of the cells that harbour them.  
 
Thirdly, unlike the previous studies, I carried out the persistence assays in an 
immortalised cell line (NIKS) (Allen-Hoffmann et al., 2000), which supports the 
HPV life-cycle (Flores et al., 1999). The decision to use immortalised cells 
instead of primary cells was made because some mutant genomes may be 
unable to immortalise keratinocytes upon transfection (as discussed in Thomas 
et al., 1999). The limited life-span of primary cells would thus prevent long-term 
persistence of the viral DNA and may even interfere with short-term 
persistence. By using the NIKS cells, I hoped to study factors that solely affect 
episomal persistence, without interference from other factors that may be 
required for cellular immortalisation. A further advantage of NIKS cells over 
primary cells is that they provide an isogenic background for all the 
experiments.  
 
In conclusion, I have shown that two regions of the E6 protein are necessary for 
the episomal persistence of HPV16 DNA. As discussed in Chapter 3 however, I 
have not conclusively shown that the activities of E6 that have been associated 
with these regions of the protein (i.e. p53-degradation and binding/degradation 
of PDZ proteins) are necessary for persistence. An experiment aimed at 
determining whether p53-degradation was indeed necessary for viral DNA 
persistence was presented in Chapter 4 (using shRNA against p53). While this 
experiment yielded unexpected and interesting results, it did not prove to be 
suitable for answering the original question. More experiments to this end will 
be discussed in section 6.7.1. 
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6.2. 16E6p53m and 16E6PDZ genomes: two different persistence-defective 
phenotypes   
The aims of this study were not only to investigate which activities of E6 are 
necessary for viral persistence, but also to determine why they are so. To this 
end, I set out to investigate what persistence mechanisms may be affected by 
the mutations I introduced into the HPV16 genome. 
 
My experiments show that the replication efficiency of the 16E6p53m genomes 
is significantly lower than that of the 16WT genomes. Although this result does 
not conclusively show that inefficient replication is the reason why the 
16E6p53m genomes are unable to persist, it suggests that this may be a 
contributing factor. This was not found to be the case for the 16E6PDZ 
genomes, which replicate at a similar efficiency to the 16WT genomes. 
 
My results also show that the E6PDZ mutant protein is unstable, being more 
susceptible to proteasomal degradation than the E6WT protein. Consequently 
its steady-state levels are significantly lower than those of the E6WT protein. 
This is not the case for the E6p53m protein. This suggests that the mechanism 
by which the PDZ-binding motif of E6 is involved in persistence may be through 
stabilisation of the E6 protein, rather than through regulation of the levels of the 
PDZ proteins.  
 
In observing the lower levels of the E6PDZ protein, compared to the E6WT 
protein, my initial hypothesis was that degradation of p53 by the E6PDZ protein 
may be inefficient. This could explain the lack of persistence of the 16E6PDZ 
mutant genomes. However, my results show that, in fact, p53 is degraded at 
similar efficiencies in cells expressing E6WT and E6PDZ proteins, despite the 
much reduced levels of the E6PDZ protein, suggesting that this is not the 
reason why the 16E6PDZ genomes cannot persist. This was in support of the 
observation that the two genomes behave differently in the transient replication 
assay.  
 
Moreover, close analysis of the results from Chapter 3 hint at the existence of 
two different persistence-defective phenotypes. Cells containing 16E6p53m 
genomes exhibit gradual loss of the viral genomes. Cells containing 16E6PDZ 
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genomes exhibit either complete loss of the viral DNA, or loss of the viral 
episomes and integration of the viral DNA into the cellular DNA at high copies. 
All of the above suggest that the E6 protein is involved in at least two processes 
that function in permitting the extrachromosomal persistence of the viral DNA 
during successive cell divisions.  
 
6.3. E6PDZ protein is less stable than E6WT protein in the endogenous 
system 
A significant aspect of this study was that I was able to demonstrate the 
instability of the E6PDZ protein compared to the E6WT protein, both in an over-
expression system, but more importantly in the endogenous system, when 
these proteins are expressed from the HPV genome. These results suggest that 
endogenous PDZ proteins can stabilise the E6WT protein during a productive 
infection and emphasise the fact that future studies should take care to assess 
the levels of E6 in their experiments, when using mutants of the E6 protein. For 
example, phenotypes that have so far been attributed to the 
binding/degradation of PDZ proteins by E6 may in fact be due to the instability 
of the E6PDZ protein. The importance of these results is also highlighted by the 
difficulty in obtaining them, as described in Chapter 5.  
 
In addition to the importance of studying the stability of E6 in the endogenous 
system, an interesting observation was also made with regards to the detection 
of different E6 species. Although not discussed in the results chapters, several 
of the E6 western blots shown in this study suggest the existence of different E6 
species, as determined by the detection of more than one specific band by the 
anti-E6 antibody. The antibody used in this study is unable to detect the known 
E6* splice variants, as it recognises an epitope in the C-terminus of E6. We thus 
speculate that the alternative E6 species detected in these blots could either be 
as-yet-unidentified splice variants, or full-length E6 protein that has undergone 
post-translational modification (for example, phosphorylation). Post-translational 
modifications of E6 have not been well studied. It would thus be interesting to 
address the presence of these E6 variants in future studies and attempt to 
characterise them and to determine whether they are differentially stabilised by 
interaction with PDZ proteins. 
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6.4. What other activities of E6 may be necessary for persistence?   
The lower steady-state levels of the E6PDZ protein may have implications on 
the ability of this mutant protein to carry out its activities. In Chapter 5 I 
discussed an activity of E6, that of binding to and degrading E6TP1 (Gao et al., 
1999), that has already been linked to viral DNA persistence (Lee et al., 2007). 
This activity may be compromised by the lower levels of E6PDZ protein. 
However, there may be other activities of E6 that are also important but have 
not yet been identified as being necessary for persistence. These may also be 
compromised by the low levels of E6PDZ protein. Some of these are highlighted 
below. 
 
6.4.1. Interaction of E6 with E2    
A recent study has shown interplay between the E6 protein and the viral 
replication and transcription protein E2 (Grm et al., 2005). The two proteins 
were shown to affect each other’s cellular distribution and activities. For 
example E6 augments E2-mediated viral gene transcription and inhibits E2-
mediated viral DNA replication (Grm et al., 2005). Lower levels of the E6PDZ 
protein may interfere with the regulation of these pathways, potentially leading 
to lower transcription of other viral proteins, and/or uncontrolled replication 
which may consequently result in loss of episomes or integration.  
 
E2 has also been shown to interact with topoisomerase II-binding protein 1 
(TopBP1) (Boner et al., 2002). Topoisomerase II (Topo II) is involved in 
decatenation of DNA following replication, including viral DNA (Snapka et al., 
1988), and it is possible that Topo II is also required for the decatenation of 
HPV episomes. This may be mediated by an interaction between Topo II, 
TopBP1 and E2, and E6 may also play a role by way of its interaction with E2. If 
the above is true, then lower levels of E6PDZ protein may fail to elicit the 
decatenation of HPV episomes. This could affect the equal segregation of the 
genomes into the two daughter cells or result in the integration of multiple 
copies of HPV DNA (as concatamers) in the cellular chromosomes.    
 
Moreover, E2 is the only HPV protein that has so far been attributed a role in 
episomal segregation (Abbate et al., 2006; Bastien & McBride, 2000; Ilves et al., 
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1999; Lehman & Botchan, 1998; Oliveira et al., 2006; Skiadopoulos & McBride, 
1998; Van Tine et al., 2004). It is conceivable that the interaction between E6 
and E2 may facilitate this process, suggesting that lower levels of E6PDZ may 
fail to elicit proper segregation of viral episomes, thus preventing their 
persistence. Moreover, several cellular proteins have been implicated in 
episomal segregation, such as Brd4 (Abbate et al., 2006; Baxter et al., 2005; 
You et al., 2004; You et al., 2005), Chlr1 (Parish et al., 2006a) and TopBP1 
(Donaldson et al., 2007). It is plausible that E6 may affect the expression of 
these proteins (as it does with many other cellular proteins). Alternatively, E6 
may mediate their interaction with the cellular chromosomes and with the 
episome-bound E2. For example, E6 may be a co-factor of segregation by 
facilitating the already demonstrated interaction between E2 and TopBP1 
(Boner et al., 2002). It is worth noting however, that most work on episomal 
segregation has been carried out using BPV1 and studies suggest that 
variations exist between the different PVs (McPhillips et al., 2006; Oliveira et al., 
2006). The mechanism employed by HPV16 has not yet been elucidated.  
     
6.4.2. E6 and replication 
In the transient replication assay the 16E6PDZ mutant genomes were not found 
to replicate significantly less efficiently than the 16WT genomes. However, the 
possibility still exists that even minor or statistically insignificant differences in 
replication efficiency may have a biological effect on the ability of the mutant 
genomes to persist. Moreover, the transient replication assay was a short-term 
assay, carried out over the course of 4 days. It is therefore possible that subtle 
differences in the replication efficiencies of the 16WT and 16E6PDZ genomes 
do exist but were not identified by this assay. Hence, possible ways in which the 
levels of E6 may impact viral DNA replication, and consequently persistence, 
should be considered.   
 
One cellular pathway that has been shown to inhibit viral DNA replication is the 
IFN- signalling pathway, which inhibits the replication of both HBV (Hayashi & 
Koike, 1989) and HPV (Terenzi et al., 2008). HPVs down-regulate the 
expression of IFN-inducible genes, such as Stat-1 (Chang & Laimins, 2000), 
and this is at least in part due to the activities of E6 (Li et al., 1999; Nees et al., 
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2001). It is therefore plausible that E6 functions to reduce the IFN-mediated 
inhibition of viral DNA replication. If the levels of E6 protein are lower, as is the 
case with the E6PDZ mutant protein, the levels of IFN-inducible proteins may 
increase, thereby impeding viral DNA replication, and resulting in the loss of 
viral episomes, as seen with the transfection of 16E6PDZ mutant genomes. 
Interestingly, several studies have looked at the effect of IFN-treatment on BPV- 
and HPV-positive cells (Chang et al., 2002; Herdman et al., 2006; Turek et al., 
1982).  In all studies, treatment with IFN resulted in loss of viral episomes. 
Importantly, Herdman et al. also reported an increase in HPV integrants 
following IFN-treatment of HPV16-positive cells (Herdman et al., 2006).  
 
Another replication-related protein that is regulated by E6 is minichromosome 
maintenance 7 (MCM7), which has a role in ensuring that DNA only replicates 
once per cell-cycle (reviewed in Chong et al., 1996). It has been suggested that 
E6 degrades MCM7 by interaction with E6AP (Kuhne & Banks, 1998). HPVs 
rely on cellular replication machinery to replicate their DNA and it is likely that 
the activities of MCM7 will have an effect on HPV DNA replication as well. It is 
therefore reasonable to consider that E6-mediated degradation of MCM7 may 
be necessary to allow amplificational/establishment replication to take place. 
The lower levels of E6PDZ protein may impinge on this.    
 
6.4.3. E6 and DNA damage 
A recent report identified an interaction between the tight junction protein Par3 
(partitioning-defective 3) and two of the subunits of the DNA-PK complex 
(involved in double-strand break repair), Ku70 and Ku80, and demonstrated a 
role for Par3 in this pathway (Fang et al., 2007). Par3 is a PDZ protein and has 
been shown to interact with the HPV18 E6 protein, as well as the Rhesus 
papillomavirus type 1 E7 protein, which also has a PDZ-binding motif (Tomaic 
et al., 2009a). Interestingly, Ku80 has been suggested to play a role in the 
persistence of extrachromosomal DNA in cells, as transfected plasmids are 
rapidly lost in cells that lack the Ku80 protein (Liang & Jasin, 1996). Moreover, 
depletion of Ku70 in episomal HPV16-positive cells was shown to promote 
episome loss and generation of integrants (Winder et al., 2007). The interaction 
of E6 with Par3, and Par3’s interaction with Ku70 and Ku80 may therefore play 
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a role in Ku70/80-mediated stabilisation of extrachromosomal DNA, thereby 
also supporting the persistence of viral episomal DNA. 
 
 
6.4.4. E6 and the immune response 
In addition to down-regulating IFN-inducible genes (see section 6.4.2.), E6 also 
interferes with the immune system by down-regulating the expression of E-
cadherin (Matthews et al., 2003). Potential consequences of this would be 
reduced recognition of HPV-positive cells by the immune system, lack of 
clearance, and consequent persistence of HPV DNA in cells. Although this 
would be relevant in the persistence of HPV DNA in infected tissues, where an 
immune system is present, it cannot explain the loss of episomes in cultured 
cells in the absence of an immune system, as have been used in this study. 
 
6.4.5. E6* splice variants 
As mentioned earlier, high-risk E6 ORFs contain an intron, the excision of which 
has been shown to generate several alternatively spliced E6 transcripts (Zheng 
& Baker, 2006) collectively referred to as E6*. In addition to the alternatively 
spliced transcripts, an E6* protein product has also been identified, the function 
of which remains unclear. In the study presented here, the role of individual E6 
protein species (full-length or spliced) in persistence was not assessed. It would 
thus be important to determine whether the full-length and splice variants of the 
E6 protein have different roles in persistence, as this could potentially identify a 
role for E6* in the viral life-cycle. Such studies would however involve the 
mutation of the splice donor and acceptor sites within the E6 ORF, which could 
interfere with the splicing of other transcripts and therefore the expression of 
other viral proteins. In fact, one study did try to investigate the role of the E6 
intron in the persistence of HPV31 genomes (Thomas et al., 1999). The authors 
reported that HPV31 splice-donor or splice-acceptor mutant genomes were 
replication-defective, and demonstrated that this was due to disruption of the 
expression of E1 and E2 replication proteins.  
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6.5. E6 cannot be expressed prior to entry of HPV DNA into cells 
One of the more unexpected results obtained from this study is that the E6 
protein, although necessary for persistence, is detrimental to it if expressed 
prior to the entry of HPV DNA into cells, or at abnormally high levels. The 
experiments using cell lines that constitutively express E6 (LXSN-E6WT cells) 
were carried out in order to establish if a cis- or trans-acting factor may 
contribute to the inability of the 16E6p53m and 16E6PDZ mutant genomes to 
persist. However, the results from the experiments show that not even the wild-
type genomes can persist in LXSN-E6WT cells, and suggest an inhibitory role 
for E6 in persistence when it is expressed at this early stage.  
 
The reason for this inhibitory effect is unknown. p53 has been shown to inhibit 
amplificational/establishment replication (Ilves et al., 2003; Lepik et al., 1998). 
We could thus speculate that the levels of p53 need to be kept above a certain 
threshold, so as to prevent uncontrolled replication. This control on replication 
would be beneficial to the virus, as it would ensure that the virus does not harm 
the cell, causing cell death and ending the viral life-cycle. The involvement of 
p53 in the inhibition of viral DNA persistence is supported by the observation 
that 16WT genomes cannot persist in NIKS-shp53 cells either. Importantly, 
these results could have significant implications when considering whether HPV 
virions can infect cells that already harbour HPV DNA (“super-infection”).  
 
Moreover, if very low levels of p53 are detrimental to episomal persistence, this 
may also be true in high-grade lesions. As the lesions become more severe, the 
levels of p53 decrease (Kurvinen et al., 1996). This could lead to an 
environment that is not conducive to episomal persistence, and could promote 
integration of the viral DNA into cellular chromosomes, as is often seen in 
cancers.  
 
6.6. E6 and PDZ proteins: Degradation or stabilisation? 
An interesting question that arises from my results is how PDZ proteins, which 
are degraded by wild-type E6 protein (Gardiol et al., 1999; Glaunsinger et al., 
2000; Nakagawa & Huibregtse, 2000; Thomas et al., 2002), are also able to 
stabilise it. As discussed in Chapter 5, this apparent paradox is not a novel 
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concept, as a similar relationship has already been shown for E6 and E6AP 
(Kao et al., 2000; Tomaic et al., 2009b). Although, the mechanism of how this 
degradation and stabilisation is regulated remains unknown, the results imply 
that the relationship of E6 and its binding partners is complex.  
 
One aspect of this question that should be addressed is how does the PDZ-
binding motif of E6 confer stability on the E6 protein? As mentioned in Chapter 
5, the stabilisation of PDZ-binding proteins via interaction with PDZ proteins has 
been shown before, with MAGI-2 stabilising PTEN (Valiente et al., 2005; Wu et 
al., 2000b) and the Drosophila PDZ protein InaD stabilising some of its binding 
partners (Tsunoda et al., 1997). This suggests that a common mechanism may 
exist.  
 
As the mechanism is not known we are free to speculate as to how this is 
brought about. PDZ proteins are generally large proteins (hScrib is >200 kDa) 
that are often found as part of even larger, multi-protein complexes (Thomas et 
al., 2008). The E6 protein on the other hand is small (~15 kDa). It is therefore 
possible that by binding to PDZ proteins, E6 finds itself stabilised as part of a 
large structure. Moreover, the complexes that the PDZ proteins are often found 
in form the adherens or tight junctions (Thomas et al., 2008) at the cell 
membrane. Re-localisation of E6 to these sites, upon binding to PDZ proteins, 
may make it less accessible to the proteasome. Binding to PDZ proteins could 
also change the structure of the E6 protein, making it more stable. In addition to 
interacting with cellular proteins, E6 has been shown to form stable oligomers 
(Garcia-Alai et al., 2007). It may be that oligomerisation is somehow mediated 
by binding to PDZ proteins.  
 
In its discussion, the Tomaic et al. report suggested that the binding of E6AP to 
E6 may conceal the ubiquitination sites of E6 (Tomaic et al., 2009b), thereby 
making E6 refractive to proteasomal degradation. This could also be true for the 
interaction of PDZ proteins with E6. Other possibilities include mediating the 
binding of E6 to the deubiquitylating enzyme USP15, which was recently shown 
to augment the levels of E6 protein (Vos et al., 2009), or preventing the binding 
of E6 to the as-yet-unknown ubiquitin ligase that regulates its levels. 
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What determines whether PDZ proteins are degraded by E6 or whether they 
stabilise E6 remains unclear. We hypothesise that many factors can affect the 
outcome of the interaction of E6 with PDZ proteins and these include the levels 
and localisation of the proteins in the cells. Interestingly, the degradation of PDZ 
proteins by E6 has so far only been shown in cancer cell lines (Kranjec & 
Banks, 2010; Massimi et al., 2004) or using over-expression systems (Gardiol 
et al., 1999; Nakagawa & Huibregtse, 2000 and Chapter 3). In these cases, the 
levels of E6 protein are higher than those found during productive infections. In 
fact, no difference was observed in the levels of PDZ proteins between cells 
harbouring HPV31 episomes and control cells (Lee & Laimins, 2004). Moreover, 
in my experiments I did not observe a difference in the levels of hScrib in cells 
that had been transfected with 16WT genomes or control plasmid (Chapter 5). It 
is therefore possible that during a productive infection, when the levels of E6 
are not high, the interaction of E6 with PDZ proteins leads to stabilisation of the 
E6 protein. This dynamic may change during neoplasia, when the levels of E6 
increase. It is important to note however, that stabilisation of E6 by hScrib was 
also observed in HeLa cells, (Nicolaides et al., 2011), suggesting that the two 
processes may not be mutually exclusive.  
 
Furthermore, it has been shown that PDZ proteins exist in different cellular 
pools (Garcia-Mata et al., 2007; Massimi et al., 2004; McLaughlin et al., 2002) 
and the same appears to be true for E6, as the protein has been reported to be 
nuclear, cytoplasmic and membrane-associated (Grossman et al., 1989; Tosi et 
al., 1993). Interestingly, the cellular localisation of E6 has been shown to affect 
its stability (Grossman et al., 1989). Moreover, the targeting of PDZ proteins by 
E6 is dependent on the cellular localisation of the PDZ proteins, as well as on 
their phosphorylation state (Massimi et al., 2004; Massimi et al., 2006; Narayan 
et al., 2009a). Therefore, the outcome of the interaction between E6 and PDZ 
proteins may depend on the different cellular pools of the proteins that are 
interacting. This hypothesis is supported by the observations that the pool of E6 
that is stabilised by PDZ proteins is not the same as the one involved in p53-
degradation (Chapter 5). Whether the PDZ-bound E6 protein is still able to 
interact with its other binding partners, and perform its known activities, remains 
of interest. 
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6.7. Future experiments 
 
6.7.1. To determine whether p53-degradation is indeed necessary for 
persistence 
It remains important to conclusively determine whether p53-degradation is 
indeed necessary for persistence. My initial plan of using NIKS-shp53 cells to 
answer this question proved to be unsuitable. Therefore alternative means 
would need to be employed in order to address this. One option would be to use 
chemicals to inhibit p53 in NIKS cells (such as the p53-inhibitor Pifithrin-α 
(Komarov et al., 1999)) and to establish whether 16E6p53m genomes are able 
to persist in treated cells. The inhibitor will need to be applied to the cells after 
transfection with HPV DNA, as my results so far suggest that low levels of p53 
at the time of HPV entry into cells are detrimental for persistence. Before using 
this chemical for such an assay, preliminary experiments to determine whether 
the drug confers inhibitory effects on the persistence of the wild-type genomes 
will be required.  
 
Alternatively we could co-transfect the 16E6p53m genomes with a plasmid that 
expresses a dominant negative form of p53. A similar experiment was 
discussed in a previous study (Thomas et al., 1999). The authors mentioned 
that they co-transfected an HPV31 E6null genome with a plasmid that 
expresses a dominant negative form of p53, to determine whether degradation 
of p53 is sufficient for persistence (Thomas et al., 1999). The E6null genomes 
were unable to persist in this experiment. It is now clear from the work 
presented here (Chapter 3) and that of others (Lee & Laimins, 2004; Lee et al., 
2007), that p53-degradation is not sufficient for persistence. Therefore, the 
experiment proposed here, using 16E6p53m mutant genomes instead of 
16E6null genomes, would be a refined version of the experiment in the Thomas 
et al. study (Thomas et al., 1999), in trying to conclusively determine whether 
p53-degradation is in fact necessary for persistence.  
 
To further elucidate the requirement for E6 in persistence, we could co-transfect 
the two mutant genomes, 16E6p53m and 16E6PDZ, to determine whether they 
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can complement each other. This experiment would determine whether the two 
mutations disrupt a common function of E6 that is necessary for persistence. 
 
6.7.2. What other activities of E6 are necessary for persistence? 
The finding that the E6PDZ protein is less stable has opened doors for the 
exploration of other activities of E6 that may be necessary for persistence, and 
which may be compromised by the lower steady-state levels of the E6PDZ 
protein. Several possible activities of E6 were discussed in section 6.4. and 
experiments to address some of these are discussed here. 
 
The ability of E6 to target E6TP1 for degradation has already been shown to be 
necessary for persistence (Lee et al., 2007). It would thus be important to 
determine whether the levels of E6TP1 are different in cells that harbour 16WT 
or 16E6PDZ genomes (using FACS-sorted cells from experiments similar to the 
ones described in Chapter 5). Alternatively, we could assess whether the 
16E6PDZ mutant genomes can persist in cells that have low levels of E6TP1 
(generated using shRNA against E6TP1).  
 
The localisation of E6 to the nucleus, has also been implicated in persistence 
(Lee et al., 2007), and it would therefore be important to determine whether this 
localisation is compromised by the deletion of the PDZ-binding motif. This could 
be addressed by immunocytochemistry, or cell-fractionation followed by western 
blotting, in order to determine whether the localisation of E6PDZ protein is 
different to that of E6WT protein. Aberrant localisation of the E6PDZ protein 
would more likely be due to the deletion of the PDZ-binding motif, rather than to 
the lower steady-state levels of the protein itself. Therefore these experiments 
could be carried out in cells that stably express the wild-type and mutant E6 
proteins (for example the LXSN-E6WT and LXSN-E6PDZ cells), rather than in 
FACS-sorted cells, as the former are easier to obtain. As both the degradation 
of E6TP1 and the nuclear localisation of E6 have been attributed roles in 
persistence (Lee et al., 2007), disruption of either process due to the deletion of 
the PDZ-binding motif would suggest the pathway by which this mutation 
disrupts persistence.  
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The abovementioned activities or properties of E6 have already been linked to 
persistence (Lee et al., 2007), and are therefore important to address. However, 
as discussed earlier, other activities may potentially have a role in persistence 
One such activity that may be significant is interference with the IFN-signalling 
pathway (Nees et al., 2001), as IFN-signalling has been shown to down-
regulate HPV replication (Terenzi et al., 2008) Therefore, looking at the 
expression levels of different IFN-inducible genes, such as Stat-1 or p56, in the 
16E6WT- and 16E6PDZ-positive FACS-sorted cells, could help us identify any 
potential differences that may suggest an interferon-mediated inhibition of viral 
DNA replication.  
 
Moreover, assessing the levels of MCM7 in the FACS-sorted cells could also 
give an indication of whether the degradation of this protein is compromised by 
the lower levels of E6PDZ protein, and suggest a potential pathway for 
persistence. 
 
I have also discussed a potential role for E6 in the segregation of viral 
episomes, although the segregation pathway of HPV16 episomes is not well 
understood. This could be addressed using fluorescence in situ hybridisation to 
look at the segregation of viral episomes in cells that have been transfected with 
16WT or 16E6PDZ genomes. This would allow the detection of differences in 
the localisation of the viral DNA during cell division, and consequently 
potentially identify a role for E6 in viral genome segregation. 
 
6.7.3. Can HPV infections be established in cells that already harbour HPV 
episomes? 
My results have also suggested a role for E6 in inhibiting “super-infection” which 
could have potential implications when considering treatments of HPV-induced 
lesions. It would be interesting to investigate whether HPV-positive cells are 
indeed refractive to the establishment of a new infection by a different HPV 
type. To do this we could transfect episomal HPV-positive cell lines with 
genomes of different HPV types and assess the ability of the newly-introduced 
genomes to persist. These experiments would determine whether certain HPV 
types would not be able to persist together in the same cells. 
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6.7.4. Is degradation of PDZ proteins also necessary for episomal 
persistence? 
Our results suggest that the reason why the 16E6PDZ mutant genomes cannot 
persist may be due to the lower stability of the E6PDZ protein. However, they 
do not preclude a role for the degradation of PDZ proteins in persistence. PDZ 
proteins are signalling proteins involved in the control of cell polarity and cell 
proliferation (Thomas et al., 2008) and may have a role in establishing and 
maintaining a cellular environment that is conducive to the persistence of HPV 
episomes.  
 
PDZ proteins are a large group of proteins and it is not currently know which of 
these may be involved in HPV persistence. To address this, we could 
systematically knock-down individual PDZ proteins, or combinations of proteins, 
that have been identified as targets of E6. We could assess the persistence of 
the 16E6PDZ genomes in stable NIKS cell lines in which these proteins have 
been knocked-down, to identify which, if any, are inhibitory to persistence.  
 
Similarly, we could individually knock-down PDZ proteins in HPV-positive cells, 
to identify which ones are able to stabilise E6 (in addition to hScrib, hDlg and 
MAGI-1, which were identified in this study). In this way, we could also look for 
any variations in the stabilisation of E6 proteins from different HPV types, 
thereby contributing to the current understanding of the different affinities of E6 
proteins for PDZ proteins.      
 
6.7.5. Is there a balance between the stabilisation of E6 by PDZ proteins 
and the E6-mediated degradation of PDZ proteins 
We hypothesised earlier that the levels and localisation of E6 and PDZ proteins 
in the cell may determine whether PDZ proteins stabilise E6 or are targeted by it 
for degradation. For example, at low levels of E6 (such as in productive 
infections), E6 may be stabilised by PDZ proteins, whereas as at high-levels 
(such as during neoplasia) PDZ proteins may be degraded by E6. Investigation 
of this is important, as it could contribute to the current understanding of the 
molecular events that promote the development of neoplasia. 
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In the laboratory we have NIKS-based cell lines that stably harbour HPV16 
episomes. These could be used in combination with the control NIKS cells in 
order to study the effect of episomally-expressed E6 on PDZ proteins and vice 
versa. In addition, we have an integrated HPV16-positive cell line that was 
made by growing one of the episomal HPV16-positive cell lines without feeder 
cells for multiple passages (made by Dr. Deborah Jackson). This line could 
provide an important tool in this study, as it is isogenic to the NIKS cells and the 
episomal HPV16-positive cell line. As the levels of E6 in the integrated cell line 
are expected to be much higher than those in the episomal cell line, the two 
could be used to compare the effects of low- versus high-levels of E6 on PDZ 
proteins and vice-versa.  
 
Furthermore, to determine whether only some cellular pools of E6 are stabilised 
by PDZ proteins, we could carry out cell fractionation experiments, and assess 
the levels of E6 in the different fractions. Alternatively, it would be interesting to 
use immunofluorescence to visualise the localisation of E6 and PDZ proteins, 
and to determine whether these change when the two proteins are expressed 
together or individually.  
 
6.8. Final remarks  
This study has shed light on the regulation of episomal persistence by the viral 
protein E6. Importantly, I have not only looked at regions of E6 that are 
necessary for the episomal persistence of HPV DNA, but also highlighted that 
regulation of timing and/or amount of E6 expression is critical for persistence. 
 
Most of the current knowledge of the E6 protein has been derived from studies 
of cellular cancer lines, or other systems in which the viral life-cycle is not 
supported. Results from such studies are useful for identifying the oncogenic 
activities of E6. It is however important to recognise that the functions of the E6 
protein are unlikely to have evolved to promote its oncogenicity, as this would 
imply that E6 is fundamentally detrimental to the virus. Rather, E6 has essential 
roles in the viral life-cycle, one of which being episomal persistence. The 
oncogenic effects of E6 are therefore likely to be unfortunate consequences of 
its essential life-cycle functions. 
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Interestingly, low-risk HPVs, whose E6 proteins cannot degrade p53 (Foster et 
al., 1994; Scheffner et al., 1990) and do not have a PDZ-binding motif (Kiyono 
et al., 1997; Lee et al., 1997; Nakagawa & Huibregtse, 2000), do not persist 
very well in cell culture (Oh et al., 2004, and observations of others in the 
laboratory). This suggests that the activities of high-risk E6 proteins may have 
evolved to enable the persistence of viral genomes under certain conditions, 
such as in proliferating basal cells, often seen in high-risk HPV-induced lesions 
(Middleton et al., 2003).   
 
Insights gained from my study also have implications for future studies using 
mutants of the E6 ORF, as I have shown that mutant proteins may have lower 
stability than the wild-type protein. Therefore, interesting phenotypes which may 
be wrongly attributed to the mutated region of E6 may in fact be due to the 
lower steady-state levels of the protein itself. Detailed protein analysis of E6 has 
so far been hindered by the low-levels of the protein and the lack of sensitive 
detection methods. As shown in this study, current methods allow a more 
thorough analyses and this should be taken into consideration in future studies.  
 
Lastly, it would be tempting to propose the inhibition of E6 activities as a 
therapeutic means to rid cells of their HPV episomes. However, care must be 
taken when such methods are put forward. As seen by my results, although 
inhibiting the activities of E6, or causing mutations in the E6 ORF, can indeed 
have the desired effect of eliminating viral episomes, in some cases this could 
result in the integration of viral genomes into the cellular chromosomes. Such 
an event can be even more detrimental to the cell and to the organism as a 
whole.  
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